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Abstract 
Biotin is an essential vitamin that is required for growth and pathogenicity of bacteria. Biotin 
protein ligase (BPL) catalyses the ordered reaction of biotin and ATP to give biotinyl-5-
AMP, which then activates a number of biotin dependent enzymes that are critical to cell 
survival. Dethiobiotin synthase (DTBS) is the sole enzyme responsible for catalysing a key 
step in biotin biosynthesis, namely the carboxylation of 7,8-diaminopelargonic acid (DAPA), 
closing the ureido ring to form dethiobiotin in a reaction requiring a nucleotide triphosphate. 
Research undertaken in this thesis highlights strategies to selectively inhibit Staphylococcus 
aureus biotin protein ligase (SaBPL) using 1,2,3-triazole and sulfonamide isosteres to 
replace the phosphoroanhydride linker found in biotinyl-5-AMP. In addition, this thesis 
discusses the design and development of inhibitors targeting Mycobacterium tuberculosis 
dethiobiotin synthase (MtbDTBS). 
Chapter one describes the structure and catalytic mechanism of the target enzymes SaBPL 
and MtbDTBS. Preliminary studies on the utility of 1,2,3-triazole and sulfonamide as 
bioisosteres of the phosphoroanhydride linker of biotinyl-5-AMP are also discussed.  
Chapter two elaborates on the potent inhibitors with chemical modifications carried out at 
the C5 position of the triazole ring to generate 1,4,5-trisubstituted 1,2,3-triazoles. A class of 
5-iodo 1,2,3-triazoles was synthesised from biotin acetylene 8 and azides using CuAAC. 
Subsequent halogen exchange reaction allowed conversion of iodide to fluoride. The 
halogenated triazoles exhibited significantly improved antibacterial activity against S. 
aureus over nonhalogenated counterparts. 
 
Chapter three describes the design, synthesis, and biological assay of sulfonamide analogues 
targeting SaBPL assisted by computational chemistry. Acylsulfamide 6 and amino 
sulfonylurea 7 showed potent in vitro inhibitory activities (Ki = 0.007  0.003 and 0.065  
0.03 µM respectively) and also antibacterial activity against S. aureus ATCC49775 with a 
minimum inhibitory concentration (MIC) of 0.25 and 4 µg/ml respectively. Compound 7 
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displayed a vastly improved pharmacokinetic profile compared to 6 presumably due to the 
enhanced metabolic stability of the sulfonamide linker moiety. 
 
Chapter four focuses on the structure-guided chemical optimization of a hit compound 
targeting the DAPA binding site of MtbDTBS using X-ray crystallography screening and 
docking experiments. Analogues 4.03 and 4.05 were shown to be potent toward MtbDTBS 
(KD = 19 ± 5 and 17 ± 1 µM respectively). The crystal structures of 4.03 and 4.05 bound to 
MtbDTBS reveals that carboxylic acid groups attached to benzene ring form hydrogen bonds 
with residues Leu146 and Asn147 in the binding site as observed in DAPA carbamate 1.16. 
 
Chapter five describes the linking between the optimized DAPA pocket binder (discovered 
in Chapter four) and 2-deoxycytidine 5.01 to create potent bi-substrate ligands for 
MtbDTBS. Linked compounds 5.03 and 5.05 showed binding affinities toward MtbDTBS 
(KD = 0.6 ± 0.2 and 0.7 ± 0.2 mM respectively). The linker moieties of 5.03 and 5.05 do not 
bind to the P-loop of the enzyme, with the crystallographic precipitant (sulfate or citrate) 
occupying this site. 
 
Chapter six details the experimental procedures for compounds described in chapter 2 – 5.  
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1.1 The need for new antibiotics  
There is an urgent need for novel classes of antimicrobials due to rapidly escalating incidence 
of bacterial resistance and the associated threat to human health. The Centers for Disease 
Control and Prevention (CDC) at the US Department of Health and Human Services has 
predicted over 2 million illnesses and 23,000 mortalities due to antibiotic resistance every 
year in the USA alone.1 However, current antibacterial drug development pipelines have 
‘dried up’ mainly due to the exit of major pharmaceutical companies from antibiotic 
research.2 In addition, only five of 30 new antibiotics introduced worldwide between 2000 
and 2015 were first-in-class.3 Large pharmaceutical companies remain reluctant to initiate 
or continue their antibiotic research programmes due to a low return on investment. Thus 
academic-led research on antimicrobial agents is crucial to overcome the rapid emergence 
of new drug-resistant strains and the declining rate of new antibiotic development. 
Staphylococcus aureus (S. aureus) is responsible for numerous diseases in humans from 
mild skin infection to fatal sepsis.4 In particular, methicillin-resistant S. aureus (MRSA) 
has become a major cause of life threatening infections. It is estimated that MRSA causes 
more than 80,000 invasive infections and 11,000 deaths each year in the United States.5 
Mycobacterium tuberculosis (M. tuberculosis) is the principal pathogen for tuberculosis, one 
of the top ten causes of human mortality worldwide.6 There has been a significant rise in 
cases of multidrug-resistant tuberculosis (MDR-TB), with an estimated 458,000 new cases 
of MDR-TB in 2017 alone.6 One logical strategy to combat resistance is to discover new 
chemical classes affecting novel drug targets that are not subject to pre-existing resistance 
mechanisms. This thesis presents work on S. aureus biotin protein ligase (SaBPL) and M. 
tuberculosis dethiobiotin synthase (MtbDTBS) as novel targets for antibiotic research and 
the design of small molecule inhibitors thereof. These proteins play key roles in biotin 
biology and biosynthesis. 
1.2 Biotin biology and biosynthesis 
Biotin (also known as vitamin B7 or vitamin H) is an essential vitamin that is required for 
growth and pathogenicity of bacteria. Biotin serves as an indispensable cofactor for biotin-
dependent enzymes that are involved in membrane lipid synthesis, gluconeogenesis and 
amino acid metabolism.7-11 Two representative biotin-dependent enzymes, namely acetyl 
CoA carboxylase (ACC)12 and pyruvate carboxylase (PC)13, play critical roles in bacteria. 
These enzymes are activated when ligated to biotin by biotin protein ligase (BPL). ACC 
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catalyses the carboxylation of acetyl-CoA to malonyl-CoA in fatty acid biosynthesis, which 
is essential for cell membrane biogenesis and maintenance.14 PC is a critical enzyme for the 
conversion of pyruvate to oxaloacetate in the TCA cycle which then plays a pivotal role in 
a number of key metabolic pathways including gluconeogenesis and amino acid 
biosynthesis.15 Even though biotin is essential for all living cells, only microbes, plants and 
some fungi are able to synthesise biotin de novo.16 Humans and other mammals, lack this 
biosynthetic pathway and thus must obtain biotin through exogenous sources, i.e. diet and/or 
from intestinal microflora.17  
The biotin biosynthetic pathway can be readily divided into two stages, synthesis of a 
pimeloyl thioester precursor and assembly of the bicyclic rings. Scheme 1.1 shows the 
second stage of biotin biosynthetic pathway and the chemical structures of the synthetic 
intermediates involved.18 The steps leading to the synthesis of a pimeloyl thioester precursor 
1.01 are variable among different biotin-producing organisms. Unlike the formation of the 
pimeloyl thioester precursor 1.01, the final four reaction steps in the pathway that assemble 
the bicyclic rings of biotin 1.05, are conserved in all biotin-producing organisms. The 
pimeloyl thioester 1.01 is a dedicated precursor of the second stage of the biosynthetic 
pathway and provides the majority of the biotin backbone carbon atoms. In a four-step 
pathway, a pimelate thioester 1.01 is firstly converted to 7-keto-7-aminopelargonic acid 
(KAPA) 1.02 and the pathway then proceeds through two more intermediates, 7,8-
diaminopelargonic acid (DAPA) 1.03 and dethiobiotin (DTB) 1.04, to form biotin 1.05 
(Scheme 1.1). The enzymes of 7-keto-7-aminopelargonic acid synthase (KAPAS), 7,8-
diaminopelargonic acid synthase (DAPAS), dethiobiotin synthase (DTBS) and biotin 
synthase (BS) are encoded by bioF, bioA, bioD, and bioB respectively.10 
1.3 Biotin protein ligase (BPL) 
BPL, a ubiquitous enzyme found in all organisms, is responsible for the post-translational 
attachment of biotin 1.05 onto the biotin domain of biotin-dependent enzymes (ACC and 
PC).19-20 ACC and PC are highly related to bacteria survival and virulence, and as such BPL 
presents as a potential new antibacterial drug target. Moreover, genetic knockout studies 
using S. aureus deficient in the bpl gene prevent cell growth, indicating that there is no 
alternative pathway for the biotinylation of biotin-dependent proteins in bacteria.21-22  
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Scheme 1.1. The second stage of biotin biosynthesis, the assembly of the bicyclic rings, 
consists of four reactions catalysed by KAPAS, DAPAS, DTBS and BS. The R group 
indicates either CoA or acyl carrier protein (ACP). Abbreviations: SAM, S-adenosyl-L-
methionine; AMTOD, S-adenosyl-2-oxo-4-thiomethylbutyrate; 5-DOA, 5-deoxyadenosine. 
The figure is modified from Lin & Cronan.18 
S. aureus BPL (SaBPL) utilises biotin and also controls the uptake and biosynthesis of biotin 
in response to cellular demand.23-25 Without activated biotin-dependent enzymes, SaBPL 
produces a homodimer that is responsive to DNA binding. The SaBPL homodimer serves as 
a transcriptional repressor that regulates biotin biosynthesis and transport by binding specific 
DNA sequences present in the operator site of the biotin biosynthesis operon. Therefore, 
SaBPL not only activates biotin-dependent enzymes including ACC and PC, but also 
functions as a transcriptional repressor of the biotin biosynthesis operon. SaBPL is a 
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promising drug target due to its bifunctionality as it is less likely for S. aureus to develop 
target based resistance by reason of  the intimate involvement with multiple metabolic 
pathways.25  
1.3.1 Mechanism of BPL 
Protein biotinylation is achieved through a two-step ordered reaction that is catalysed by 
BPL in all organisms as shown in Scheme 1.2.20, 26 In the first step, biotin 1.05 reacts with 
ATP to form biotinyl-5-AMP 1.06, with the release of pyrophosphate (PPi). During this 
stage, biotin 1.05 binds to the biotin binding pocket in BPL and stimulates ordering of a 
biotin binding loop (BBL) within the enzyme (Figure 1.1). This conformational change in 
BPL generates the ATP binding pocket that allows subsequent binding of ATP. A 
condensation reaction between biotin and the α-phosphate of ATP then produces the reaction 
intermediate biotinyl-5-AMP 1.06 to complete the first step. When the cellular demand for 
biotin 1.05 is low, the complex of BPL with biotinyl-5-AMP 1.06 can dimerize and bind 
DNA without the second step of biotinylation. This then results in the concomitant 
repression of biotin biosynthesis. In the presence of a biotin-dependent enzyme (e.g. ACC 
or PC) requiring biotinylation, the BPL/1.06 complex recognises and binds to a biotin 
carboxyl carrier protein (BCCP) domain present in the unliganded biotin-dependent enzyme 
(see Step 2 in Scheme 1.2). During this step, the ɛ-amino group of the target lysine residue 
present in BCCP domain reacts with the carbonyl group of 1.06, resulting in the transfer of 
the biotin moiety onto the biotin domain to give biotinylated ACC or PC, with the release of 
AMP.  
 
Scheme 1.2. The catalytic two-step reaction of biotinylation. 
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1.3.2 Structural classes of BPL 
BPL can be divided into three divergent structural classes (Figure 1.2).  Class I BPLs are 
composed solely of the conserved catalytic domain, which is required for protein 
biotinylation, and C-terminal domain. X-ray crystal structures of class I BPLs have been 
reported for M. tuberculosis27, Aquifex aeolicus28, and Pyrococcus horikoshii20. Class II 
BPLs contain an additional N-terminal DNA binding domain, suggesting these class 
enzymes have both biotin ligase and transcriptional repressor activities. The X-ray crystal 
structures of bifunctional class II BPLs from S. aureus29 and Escherichia coli (E. coli)26 have 




Figure 1.1. 3D depiction of SaBPL in complex with biotinyl-5-AMP 1.06 (PDB: 3V8L). 
The β sheets are shown in green, α helices in red, biotin binding loop (BBL) in orange, 
ATP binding loop (ABL) in purple and biotinyl-5-AMP 1.06 in blue.  
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a large N-terminal extension that bears no similarity to the DNA binding domain of class II 
BPLs.30-33 According to recent mutagenic and genetic studies, this extension contains a 
‘proof reading’ activity to ensure that the correct enzymes are chosen for protein 
biotinylation.30 All BPLs contain a conserved catalytic core through a disordered to ordered 
conformational change within the enzyme.34 Comparison of the catalytic domains of 
liganded and unliganded SaBPL shows two disordered binding loops, a biotin binding loop 
(BBL; highlighted in orange in Figure 1.1) and an ATP binding loop (ABL; highlighted in 
purple in Figure 1.1).35 A closer examination of the active site is described below.  
 
Figure 1.2. Schematic diagram of the three classes of BPL. The conserved catalytic region 
is depicted in blue, the DNA binding domain of class II enzymes in red and the proof reading 
domain in human BPL is boxed black. The figure is adapted from Satiaputra et al.36 
1.3.3 BPL active site 
The active site of BPL is located in the catalytic domain, where synthesis of biotinyl-5-AMP 
1.06 and biotin transfer occur. The BPL active site consists of two major pockets including 
biotin binding pocket and ATP binding pocket. In the biotin pocket of SaBPL, the oxygen 
on the ureido ring of biotin 1.05 forms multiple hydrogen bonds with the side chain of Ser93 
and a backbone amide at Arg120, as depicted in Figure 1.3. The ureido NH also form 
hydrogen bonds with the backbone oxygen of Arg120 and the side chain of Gln116, 
respectively (Figure 1.3). These residues are highly conserved in BPLs across most species.37 
The valeric tail of biotin on the other hand is encased in a hydrophobic tunnel defined by 
induced fit binding of biotin in the first catalytic step of BPL.38-39 The hydrophobic tunnel is 
composed of Gly119, Gly210, Gly189, Leu192 and Ile209. Structural analysis with co-
crystal structures of biotin 1.05 and biotinyl-5-AMP 1.06  bound to BPLs reveals a high 
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degree of conservation in the biotin binding pocket of SaBPL29, EcBPL (E. coli)26, MtbBPL 
(M. tuberculosis)40, AaBPL (Aquifex aeolicus)28 and PhBPL (Pyrococcus horikoshii)39.   
 
Figure 1.3. 3D depiction of reaction intermediate biotinyl-5-AMP 1.06 bound to SaBPL 
(PDB: 3V8L) (left). 2D interaction diagram of reaction intermediate biotinyl-5-AMP 1.06 
bound to SaBPL (right). 
The induced fit ordering of BBL orientates the side chain of Trp127 of SaBPL such that it 
generates a binding surface for nucleotide binding in the ATP binding pocket. This binding 
is stabilised by a π-π stacking interaction between the adenine moiety of ATP and the indole 
ring of Trp127.37, 41 In the absence of biotin, Trp127 is not appropriately oriented, without 
π-π stacking interaction between the adenine moiety and the indole ring.20 The adenine ring 
of ATP also forms hydrogen bonding interactions with Ser128 at the base of the ATP binding 
pocket. After ATP binding, the previously mentioned reaction (step 1 in Scheme 1.2) occurs 
to afford biotinyl-5-AMP 1.06.42 ATP binding loop (ABL) then turns to the ordered 
conformation to stabilise the reaction intermediate 1.06 by forming hydrophobic interactions 
with 1.06 through Ile224, and Ala228. Here, ABL is proposed to encapsulate the adenine 
moiety of 1.06. 
The phosphate binding domain of SaBPL is situated between the ATP pocket and biotin 
pocket. The phosphoanhydride linker of biotinyl-5-AMP 1.06 forms a number of hydrogen 
bonding interactions with the backbone of Arg122 and the side chains of Lys187 and 
Arg125.42 A defined feature on BBL is a highly conserved ‘Gly-Arg-Gly-Arg-X’ motif 
present in all BPLs. Of particular note is Arg122 (i.e. Gly-Arg-Gly-Arg122-X) that plays a 
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central role in stabilising the active binding site via a complex network with water-mediated 
hydrogen bonds with the side chain of Asp180.37, 42 
1.4 SaBPL inhibitors - preliminary data 
SaBPL is an attractive novel target for antibiotic development. Firstly, SaBPL is a sole 
enzyme that regulates biotinylation of ACC and PC of S. aureus.43 Targeting SaBPL will 
consequently target metabolic pathways critical for survival and virulence as ACC and PC 
are responsible for these metabolic pathways including fatty acid biosynthesis. Secondly, 
SaBPL is the only enzyme in S. aureus that is involved in the biosynthesis and uptake of 
biotin in response to cellular demand. Thus, targeting SaBPL will target not only biotin 
utilisation but also the source of biotin.23-24 Thirdly, SaBPL is not the target of antibiotics 
currently in clinical use. Novel classes of antibiotics are critically needed to develop as 
bacterial resistance to one antibiotic often leads to resistance to similar types of antibiotics.  
1.4.1 1,2,3-Triazole based analogues 
Our group previously identified 1,2,3-triazole as an alternative bioisostere for the labile 
phosphoanhydride linker in biotinyl-5-AMP 1.06.44 Importantly, most 1,2,3-triazole BPL 
inhibitors were highly selective for SaBPL over Homo sapiens BPL (HsBPL). There are a 
number of advantages in a triazole moiety over the natural phosphate linker of 1.06. The 
1,2,3-triazole moiety has two potential hydrogen bond acceptor sites and an ability to 
participate in π-π stacking interactions as shown in Figure 1.4. This motif is stable under 
acid/base hydrolysis, reductive and oxidative conditions, as well as typical physiological 
Figure 1.4. The assignment of 1,2,3-triazole with the potential intermolecular interaction 
sites.  
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conditions, and therefore resistant to metabolic degradation.45 In addition, 1,2,3-triazole can 
be readily synthesised by copper(I)-catalysed azide alkyne cycloaddition (CuAAC).  
A series of 1,4-disubstituted-1,2,3-triazole based analogues of 1.07 – 1.13 (see Figure 1.5) 
was synthesised and tested for inhibitory activity against SaBPL.44, 46-48 The triazole 1.07 
was found to be active against SaBPL (Ki = 1.17 µM) but was effectively inactive against 
HsBPL (Ki > 33 µM) in vitro, thereby providing the first example of a BPL inhibitor with 
high selectivity for SaBPL over HsBPL. In addition, the triazole 1.07 was not toxic against 
mammalian HepG2 cells in culture. The triazole analogue 1.08, lacking the ribose group, 
proved to be more potent than 1.07 against SaBPL with Ki of 0.66 µM.
44, 48 X-ray 
crystallography of SaBPL in complex with 1.08 revealed that the triazole ring acts as an 
isostere of the phosphoanhydride group of biotinyl-5-AMP 1.06 and adopts hydrogen bonds 
with Arg122 and Arg125.44 Furthermore, the triazole 1.09, with a 2-benzoxazolone moiety, 
was identified to be more potent than 1.08 against SaBPL with a Ki = 0.23 ± 0.01 µM while 
exhibiting >1100 fold selectivity for SaBPL compare to the human homolgue.44 This was an 
important finding as a 2-benzoxazolone group was identified as a isostere of the adenine 
moiety of 1.08 to target the ATP binding pocket. While this biotin triazole class exhibits in 
vitro potency and selectivity over the human homologue, it displays poor whole cell 
activity.44 For example, 1.09 inhibited S. aureus growth by 60% at 8 μg/mL, but did not 
completely reduce cell growth at the highest assayed concentration (64 μg/mL).44, 49 There 
were attempts to shorten and simplify the 1,4-disubstituted-1,2,3-triazole pharmacophore 
(1.10 – 1.13) to enhance antibacterial potency.47 The 1-benzyl substituted 1,2,3-triazoles 
1.10, 1.11, 1.12, and 1.13 that lack the adenine group, or analogue thereof, had Ki values of 
0.28, 0.39, 0.56, and 0.53 µM, respectively. These derivatives inhibited the growth of S. 
Figure 1.5. Representative 1,4-disubstituted-1,2,3-triazole BPL inhibitors. 
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aureus ATCC 49775 and displayed low cytotoxicity against mammalian HepG2 cells. The 
compounds 1.10 – 1.13 provide important new scaffolds for further chemical modification 
and activity optimization, specifically to interact with the adjacent adenyl-binding site in the 
enzyme. Since these triazole BPL inhibitors did not show appropriate antibacterial profile to 
be preclinical candidates, an approach for improving the whole call activity is required. 
1.4.2 Sulfonamide based analogues 
Brown and coworkers described a N-acyl sulfamate analogue 1.14 as a structure mimic of 
biotinyl-5-AMP 1.06 (Figure 1.6).50-51 This analogue is however reported to lack potency 
toward EcBPL due to its structural instability and rapid decomposition.27, 50 Duckworth et al 
reported a bisubstrate inhibitor of MtbBPL termed Bio-AMS 1.15 which binds with a KD of 
approximately 0.5 nM, more than 1700-fold more tightly than biotin.27 This compound 
possesses potent and selective antimicrobial activity against the virulent M. tuberculosis 
strain H37Rv as well as a number of multi-drug resistant M. tuberculosis strains with 
minimum inhibitory concentrations (MICs) ranging from 0.16 to 0.625 μM.27 Interestingly, 
Bio-AMS 1.15 proved to be inactive against a panel of gram-positive bacteria (E. faecalis 
and S. aureus), gram-negative bacteria (A. baumannii, E. coli, K. pneumoniae and P. 
aeruginosa), and fungi (C. neoformans, and C. albicans). The X-ray crystal structure of Bio-
AMS 1.15 bound to MtbBPL revealed key hydrogen bonding interactions between the 
sulfamide oxygens of 1.15 and amino acid residues Arg69, Arg72, and Asn130 (as numbered 
in MtbBPL). It is thought to be critical that the terminal amine of Lys138 interacts with the 
amide oxygen of the acylsulfamide linker of 1.15 through an electrostatic interaction because 
of the low pKa of the central nitrogen atom of the linker. A sulfonamide linkage is a good 
candidate to achieve improved potency, solubility and drug-like property of SaBPL 
inhibitors. 
Figure 1.6. Reported sulfonamide BPL inhibitors 1.14 and 1.15. 
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1.5 Dethiobiotin synthase (DTBS) 
DTBS is the sole enzyme responsible for catalysing a key step in biotin biosynthesis, namely 
the carboxylation of 7,8-diaminopelargonic acid (DAPA) 1.03, closing the ureido ring to 
form dethiobiotin 1.04 in a reaction requiring a nucleotide triphosphate (Scheme 1.1).  
 
Scheme 1.3. The reaction scheme of DTBS, which catalyses the ATP-dependent insertion 
of CO2 between the N7 and N8 nitrogen atoms of DAPA 1.03 to form the ureido ring, is 
modified from Huang et al.52 
1.5.1 Mechanism of DTBS  
The carboxylation reaction catalysed by DTBS proceeds through three distinct steps 
(Scheme 1.3). In the first step, DAPA 1.03 reacts with CO2 to form N7-DAPA carbamate 
1.16. This reaction is the regiospecific with formation of carbamate at N7 of DAPA 1.03, a 
highly coordinated event at the enzyme active site.52-53 During this stage, the N7 nitrogen is 
deprotonated and CO2 is polarised by DTBS, facilitating a nucleophilic attack of the N7 
nitrogen. The resulting carbamate intermediate 1.16 is partially buried in the enzyme 
shielding it from solvent and is further stabilised by a complex network with water-mediated 
hydrogen bonding and ionic interactions particularly involving the terminal amine groups of 
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Lys15 and Lys37 (Scheme 1.3).52 In the second step, DAPA carbamate 1.16 is converted to 
carbamic-phosphoric anhydride 1.17 by nucleophilic attack at the ATP γ-phosphate by the 
carbamate oxygen atom of the reaction intermediate 1.16.54 This event is thought to be 
facilitated by Lys37 which stabilises the resulting negatively charged carbonyl oxygen. In 
the final step, carbamic-phosphoric anhydride 1.17 is converted to dethiobiotin 1.04 by the 
closure of the ureido ring, with the release of inorganic phosphate. The proposed mechanism 
begins with nucleophilic attack at the carbamate carbon by N8 to form a tetrahedral 
intermediate 1.18 (Scheme 1.3).52 The carbon – oxygen bond is then cleaved to complete 
formation of the ureido ring and a proton from the N8 nitrogen is abstracted by possibly a 
Glu12 residue or a phosphate oxygen atom (Scheme 1.3).52 
1.5.2 DTBS structure 
The structure of DTBS has been reported from M. tuberculosis, E. coli, H. pylori and F. 
tularensis either with or without ligands such as DAPA or ATP.52, 54-59 The active DTBS is 
a homodimer with a molecular mass of ~46 kDa and contains two active sites which are 
placed at the interface between the two subunits in anti-parallel directions 25 Å apart (Figure 
1.7).57 Each subunit folds into a single globular domain containing seven parallel β-sheets 
interconnected with α-helices. Each active site includes adjacent binding pockets for DAPA 
Figure 1.7. 3D depiction of MtbDTBS with DAPA carbamate 1.16 bound (PDB: 3FMF). 
The chain A is shown in red, chain B in green, and DAPA carbamate 1.16 in blue. 
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and nucleotide substrates. The DAPA pocket is formed by amino acids from the two 
subunits. In particular, four amino acids, including Lys37, Thr41 from the first subunit and 
Leu146, Asn147 form the partner subunit (numbering in M. tuberculosis DTBS 
(MtbDTBS)), are involved in DAPA binding.57 In contrast, the nucleotide pocket is situated 
exclusively in one subunit. Binding of ATP to E. coli DTBS is known to induce 
conformation changes of active site loop regions including the phosphate binding loop (P-
loop).52 MtbDTBS includes the classical P-loop motif, Gly8-X-Gly10-X-Gly12-Val13-
Gly14-Lys15-Thr16, which is crucial for binding to the α, β and γ phosphate groups of 
ATP.58 While the overall fold is similar, the nucleotide binding pocket in MtbDTBS is 
different from that in DTBS from other species. 
1.5.3 DTBS active site 
The DTBS active site can be divided into three distinct pockets: the DAPA pocket, 
phosphate-binding loop (P-loop), and nucleoside pocket (Figure 1.8). The catalytically 
competent unit for DTBS is a dimer and amino acids from both subunits contribute to the 
tunnel-like DAPA binding site placed at the dimer interface. The DAPA alkyl chain extends 
along this tunnel, whereas the amine and carboxyl groups form hydrogen bonds with DTBS 
at either end. The P-loop accommodates the phosphate groups of nucleoside triphosphate 
(NTP) via electrostatic interactions. The nucleoside base is stabilised by hydrogen bonding 
interactions in the nucleoside pocket.60 The DAPA and nucleotide binding sites are discrete 
Figure 1.8. An overlay of DAPA carbamate 1.16 (blue) and CTP (yellow with phosphates 
in orange/red) bound to MtbDTBS (PDB: 3FMF and 4WOP, respectively). 
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and  binding of one substrate is not required for binding of the other.60 MtbDTBS is not 
restricted to using ATP to generate dethiobiotin, with a range of different nucleotides 
allowing the reaction to proceed with similar rates.60 In particular, DTBS has a significantly 
greater affinity for CTP (KD = 0.16 μM) than ATP (KD = 75 μM).
61  
In the DAPA pocket of MtbDTBS, the carboxyl group of the carbamate in DAPA carbamate 
1.16 occupies the position of the water molecule (W11) at the active site of the apo structure 
and the carboxy oxygen atoms are within hydrogen bond distance to the ε-amino groups of 
residues Lys37 (2.91 Å) and to the backbone amide nitrogen of Thr41 main-chain (2.84 Å) 
(Figure 1.9). The N7 atom of DAPA carbamate 1.16 forms a hydrogen bond with the 
hydroxyl group of Thr41 (2.86 Å). The long aliphatic chain of DAPA carbamate 1.16 spans 
the two subunits, making hydrophobic interactions with Ala73, Pro74, Gly111, and Val115. 
One of the C1-carboxy oxygen atoms coordinates with the backbone amide nitrogen of 
Leu146 (2.87 Å) and a neighbouring water molecule (2.31 Å), while the other of the C1-
carboxy oxygen atoms interacts with the main-chain amide of Asn147 (2.81 Å) and with an 
ordered water molecule (2.99 Å).  
    
Figure 1.9. 3D depiction of reaction intermediate DAPA carbamate 1.16 bound to MtbDTBS 
(PDB: 3FMF) (left). 2D interaction diagram of reaction intermediate DAPA carbamate 1.16 
bound to MtbDTBS (right). 
The crystal structure of MtbDTBS in complex with CTP reveals that hydrogen bonding 
interactions with the pyrimidine heterocycle occur exclusively through the peptide backbone 
of the enzyme, and not via side chains (Figure 1.10). Hydrogen bonding interactions are 
observed between the cytosine amine group and the backbone amide oxygens of Pro197 
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(2.94 Å) and Gly169 (2.85 Å), as well as between the cytosine N3 and the backbone amide 
NH of Ala200 (2.95 Å) (Figure 1.10). The pyrimidine heterocycle of CTP also forms a 
hydrophobic interaction with the side chains of Val17. The cytosine O2 coordinates with a 
neighbouring water molecule (2.94 Å). 
The triphosphate moiety of CTP forms a network of intermolecular interactions with water 
molecules and amino acid residues of the P-loop. The backbone amides of Gly12, Val13, 
Gly14, Lys15, Thr16, and Val17 are involved in polar interactions with the triphosphate 
group. In particular, the β-phosphate of CTP coordinates with the P-loop through a network 
of hydrogen bonding interactions including the ε-amino groups of Lys15 and the hydroxyl 
group of Thr16 in addition to the backbone amides of Gly12, Val13, Gly14, Lys15, and 
Thr16. The α- and γ-phosphate moieties form comparatively fewer hydrogen bonding 
interactions with the P-loop than the β-phosphate. 
  
Figure 1.10. 3D depiction of CTP bound to MtbDTBS (PDB: 4WOP) (left). 2D interaction 
diagram of CTP bound to MtbDTBS (right). 
1.5.4 MtbDTBS as an antituberculosis drug target 
MtbDTBS appears to be a promising, untested target for antituberculosis drug development. 
Genetic knockout studies have demonstrated MtbDTBS is an essential enzyme for the 
growth and virulence of M. tuberculosis.62 Several structures of DTBS are available from 
many species such as M. tuberculosis, E. coli, H. pylori, and F. tularensis.52, 59 These crystal 
structures are powerful tools for the development of molecules that bind specifically to 
MtbDTBS and only inhibit M. tuberculosis. In addition, there are no human homologues to 
MtbDTBS, indicating that it is less likely that the inhibitor will have unintended side effects. 
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Despite the previous structural characterisation of MtbDTBS, there are no published 
examples of inhibitors developed against this enzyme. 
1.6 Research described in this thesis 
This thesis describes the design of new classes of SaBPL inhibitors that have improved 
antimicrobial activity and metabolic stability. This thesis also reports the design of novel 
MtbDTBS binders based on the X-ray crystal structure of MtbDTBS in complex with 
ligands. 
Chapter 2 elaborates on the potent inhibitors 1.10 - 1.13 with chemical modifications carried 
out at the C5 position on the 1,2,3-triazole ring to increase antimicrobial activities towards 
S. aureus. Chapter 3 describes the design, synthesis, and biological assay of sulfonamide 
analogues targeting SaBPL to improve metabolic stability, assisted by computational 
chemistry. Chapter 4 focuses on the structure guided chemical optimization of a hit 
compound targeting the DAPA binding site of MtbDTBS using X-ray crystallography 
screening and docking experiments. Finally, chapter 5 describes the linking between the 
optimized DAPA pocket binder (discovered in Chapter 4) and 2-deoxycytidine to produce 
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2.1 Introduction  
As discussed in chapter one, biotin protein ligase (BPL) is the sole enzyme responsible for 
the activation of biotin-dependent enzymes (ACC and PC) through protein biotinylation. 
BPL catalyses protein biotinylation using a two-step ordered reaction requiring biotin 1.05 
and ATP to produce an adenylated reaction intermediate, biotinyl-5-AMP 1.06. The BPL 
active site consists of two major pockets including biotin binding pocket and ATP binding 
pocket. The reaction intermediate 1.06 adopts a tight V shape geometry to allow binding to 
the biotin and ATP pockets. 
Replacement of the labile phosphoanhydride linker in biotinyl-5-AMP 1.06 with a non-
hydrolysable 1,4-disubstituted-1,2,3-triazole heterocycle has led to the development of 
potent BPL inhibitors with excellent selectivity over the human isozyme. However, 
antibacterial activity is not sufficient to determine a minimal inhibitory concentration (MIC).  
This chapter discusses chemical modifications carried out of at the C5 position on the 1,2,3-
triazole linker to increase antimicrobial activities against S. aureus. 
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ABSTRACT: We report the synthesis and evaluation of 5-
halogenated-1,2,3-triazoles as inhibitors of biotin protein ligase
from Staphylococcus aureus. The halogenated compounds exhibit
significantly improved antibacterial activity over their nonhalo-
genated counterparts. Importantly, the 5-fluoro-1,2,3-triazole
compound 4c displays antibacterial activity against S. aureus
ATCC49775 with a minimum inhibitory concentration (MIC) of
8 μg/mL.
KEYWORDS: antibiotic, Staphylococcus aureus, enzyme inhibitor, biotin protein ligase
There is an urgent need for new therapeutics to combatantibiotic resistant bacteria.1 Target based approaches to
antibiotic discovery have been somewhat limited by poor
translation of compounds with potent in vitro activity into
bioactives with whole cell antibacterial activity.2−4 This is often
due to an inability of compounds to permeate into the cell and
access intracellular drug targets. One approach to improve
whole cell activity is through halogenation of compounds that
are otherwise cell impermeable.5,6 For example, fluoroquino-
lones display ∼100-fold improved whole cell potency compared
to their protoanalogues.7,8 Other clinically relevant antibiotics
that possess a halogen include chloramphenicol, chlortetracy-
cline, and the glycopeptides vancomycin and teicoplanin.
Fluorination presents as a particularly attractive modification
to improve binding affinity, membrane permeability, and
metabolic stability,9 with 20% of available drugs being
fluorinated.10
Biotin protein ligase (BPL) is a promising drug target that
has been the subject of antibiotic drug discovery programs by
several groups.2,11−19 BPL serves as the sole enzyme
responsible for the biotinylation, and subsequent activation,
of biotin-dependent enzymes. The clinically important bacterial
pathogen Staphylococcus aureus possesses two such biotin-
dependent enzymes, namely, acetyl-CoA carboxylase and
pyruvate carboxylase, which catalyze key reactions in the
important metabolic pathways of fatty acid biosynthesis and
gluconeogenesis, respectively.20 BPL catalyzes protein bio-
tinylation through ligation of biotin 1 and ATP to form
biotinyl-5′-AMP, 2 (see Figure 1). Replacement of the labile
phosphoanhydride linker in 2 with more stable bioisosteres has
produced inhibitors of BPL from bacterial pathogens such as
S. aureus,16,17 Mycobacterium tuberculosis,18,19 and Escherichia
coli.21 This work has recently been reviewed.20,22 However,
there are precious few examples of BPL inhibitors with whole
cell antistaphylococcal activity. The archetypal BPL inhibitor
biotinol-5′-AMP (see 3, Figure 2) is known to reduce the
growth of S. aureus and M. tuberculosis with minimal inhibitory
concentrations (MICs) of 2 and 2.5 μg/mL, respectively,17
thereby providing in vitro proof of concept that pharmaco-
logical inhibition of BPL is a strategy for new antibacterials.
Recently, we reported 1,4-disubstituted-1,2,3-triazoles as novel
BPL inhibitors that selectively target BPL from S. aureus over
the human homologue.11,12,15 While this biotin triazole class
exhibits in vitro potency and selectivity over the human
homologue, it displays poor whole cell activity.11 For example,
4a (see Figure 3) only reduces the growth of S. aureus ATCC
49775 by 60% of nontreated controls at 8 μg/mL,11 a level
significantly below that required in a preclinical candidate.
Attempts to improve antibacterial potency by shortening and
simplifying the 1,4-disubstituted-1,2,3-triazole pharmacophore
(see 5a−k, 5m, 5o, Figure 3)12 have had modest success. Here,
we present halogenation of C5 on the 1,2,3-triazole of 4a and
5a−o as a route toward improved antistaphylococcal activity.
The mechanism of action for the most potent antibacterials was
demonstrated to be consistent with the inhibition of BPL
through microbiological, biochemical, and structural studies.
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■ RESULTS AND DISCUSSION
Series 1: Compounds 4a−d (Figure 3A). The synthesis
of the 1,4-disubstituted-1,2,3-triazole 4a11 and the 1,4,5-
trisubstituted-1,2,3-triazoles 4b−d was carried out as summar-
ized in Scheme 1. Biotin acetylene 811 was first reacted with
CuI and N-iodomorpholine to give biotin 1-iodoacetylene 10.
Biotin 1-iodoacetylene 10 was then reacted with azide 911 in
the presence of CuI as a catalyst and TEA as an amine ligand to
afford 5-iodo-1,2,3-triazole 4b in 36% yield.23 Iodinated 4b was
subsequently converted to fluorinated 4c and chlorinated 4d by
halogen exchange reaction based on optimized conditions
reported by Worrell et al.24 In particular, iodide 4b was treated
with 5 equiv of either potassium fluoride or potassium chloride
in a MeCN/H2O (1:1) mixture in a microwave reactor, at 180
°C, to give 5-fluoro-1,2,3-triazole 4c and 5-chloro-1,2,3-triazole
4d in 89% and 80% yields, respectively.
Fluorination of Compound 4a Improved Whole Cell
Activity without Cytotoxic Effects. The antibacterial
potency of 4a−d was determined against S. aureus clinical
isolate ATCC 49775 (Figure 4A).14 The optical density of
bacterial cultures treated for 24 h with varying concentrations
of 4a−d was measured spectrophotometrically at 620 nm. As
previously reported,11 parent compound 4a only reduced the
optical density of the culture by ∼40% of the nontreated
control. This low level of activity is below the response required
to determine an MIC (i.e., >90% inhibited growth). In contrast,
5-fluoro analogue 4c was bioactive against S. aureus and
inhibited growth of the bacteria with an MIC of 8 μg/mL (16
μM). This represents the first example of a 1,2,3-triazole with
potent antibacterial activity. Interestingly, the selection of
halogen is critical with 5-iodo (4b) and the 5-chloro (4d)
analogues having the same poor antistaphyloccal activity as
parent derivative 4a. The mechanism of antibacterial action for
4c was determined to be due to the inhibition of BPL by
performing antibacterial susceptibility assays with S. aureus
RN4220 engineered to recombinantly overproduce the BPL
target.12 A concomitant decrease in whole cell activity is
expected upon overexpression of a drug target, should the
mechanism of action be directly through that target.12,18 This
was first verified using the archetypical BPL inhibitor biotinol-
5′-AMP 3, where an 8-fold increase in the MIC was observed as
a result of BPL overexpression in S. aureus RN4220 (Figure
S1). Consistent with 4c binding directly to the BPL target,
overexpression of the enzyme significantly reduced the
antibacterial potency of the compound (Figure 4B). Finally,
cytotoxicity assays were performed with HepG2 liver cells on
inhibitors 4b−d. No cytotoxicity was measured at the highest
concentration tested (approximately 80 μM) (Table 1)
demonstrating that inhibitors 4a−d have the same high
therapeutic index of other reported biotin substituted 1,2,3-
triazoles.11,12 Together, these results support the hypothesis
that halogenation of BPL inhibitors can improve whole cell
bioactivity against S. aureus without adverse in vitro cytotoxicity.
Antibacterial Activity Was Not a Result of Increased
Inhibitory Activity in Compound 4c. The improved whole
cell activity observed for 5-fluoro 4c over the nonhalogenated
protoanalogue 4a was not the result of strengthened
interactions between the inhibitor and BPL. This was
established through in vitro binding and enzyme assays
(Table 1). Surface plasmon resonance (SPR) studies on 4a−
d with SaBPL immobilized onto a sensor chip11,14 revealed
rapid association and dissociation rates that were unable to be
quantified (Figure S2). Accordingly, the equilibrium dissocia-
Figure 1. Reaction mechanism of biotin protein ligase.
Figure 2. Chemical structure of biotinol-5′-AMP.
Figure 3. Chemical structure of BPL inhibitors. (A) Benzoxazolone
triazole series. (B) Benzyl triazole series.
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tion constants (KD) were measured using a steady state affinity
model. No significant differences in affinity were measured
between 4a (KD = 8.4 μM) and the halogenated analogues 4b−
d (Table 1). The indistinguishable and fast dissociation rates
observed for all inhibitors also ruled out increased occupancy of
4c on the BPL target (a function of slow dissociation kinetics)
as a possible mechanism for increased whole cell potency.
Similarly, biochemical analysis using an in vitro protein
biotinylation assay demonstrated 4a−d were equipotent as
BPL inhibitors. The enzymatic incorporation of radiolabeled
biotin onto an acceptor protein (the 90 amino acid biotin-
acceptor domain from pyruvate carboxylase (SaPC90)) was
assayed using recombinant BPLs from S. aureus and Homo
sapiens. Inhibition of BPL activity was then measured in the
presence of varying concentrations of inhibitors 4a−d. The
biochemical assays demonstrated similar activities for parent 4a
(Ki = 0.23 μM) and the halogenated derivatives 4b−d against
SaBPL (Table 1). All compounds tested were inactive against
human BPL (Ki > 10 μM) highlighting that halogenation does
not adversely affect selective binding to the bacterial enzyme
over the human homologue. Together, the SPR binding and
biochemical assays demonstrate that the fluorination, as in 4c,
plays no additional role in the inhibitor binding to BPL.
A crystal structure of 4c in complex with SaBPL was
determined to define its mechanism of binding (Figure 5). The
resulting data was compared to the published structures of
SaBPL in complex with biotin 1, biotinyl-5′-AMP 2, and the
parent compound 4a (PDB 3 V7S)11 (Figure 5A). Both 4a and
Scheme 1. Synthesis of Benzoxazolone Triazole Series
Figure 4. Inhibition of S. aureus growth in vitro. (A) Compounds 3 (orange), 4a (brown), 4b (blue), 4c (red), and 4d (green) were tested against
S. aureus strain ATCC 49775. (B) Compound 4c was tested for antibacterial susceptibility against S. aureus RN4220 in the presence and absence of
overexpressed SaBPL. S. aureus RN4220 harboring the SaBPL expression plasmid pCN51-BPL (solid line), the parent vector pCN51 (dashed line),
or no plasmid (dotted line) are shown.
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4c adopted similar binding modes with the biotinyl and
benzoxazolone moieties occupying the biotin and nucleotide
pockets, as expected. Consistent with our earlier in vitro assay
results, the fluorine of 4c does not directly contribute any new
bonding interactions with SaBPL compared with 4a. Previous
crystallography studies on SaBPL in complex with 1 and 2 have
established that conformational changes accompany ligand
binding and these are necessary for inhibitor binding. The same
conformational changes were observed for both 4a and 4c. In
particular, residues T177-K131 undergo a disordered to
ordered transition when in complex with biotin.11,26 This
feature, known as the biotin-binding loop, encases the active
site to prevent ligand dissociation and positions the side chain
of W127 in the active site such that it can participate in a π−π
stacking interaction with the adenyl group of ATP. Both 4a and
4c induced these same disordered-to-ordered conformational
changes resulting in ordering of the biotin-binding loop.
Hydrogen bonding between the triazole heterocycle and amino
acids in the biotin-binding loop are apparent in both structures,
namely, between triazole N2 and the side chain of R125 and
triazole N3 with R122 (Figure 5B,C). Further interactions were
observed between the triazole and side chains of D180 and
K187. The main differences between the 4a and 4c structures
were apparent with the side chain of W127. For SaBPL in
complex with 4a, the indole ring of W127 adopted the same
conformation as observed in the costructure with biotin 1 and
biotinyl-5′-AMP 2 that facilitates ATP binding. In the
cocomplex with 4a, the conformation of the indole side chain
defines a T-shaped π interaction with the triazole heterocycle.
However, for 4c, the side chain of W127 was tilted, thereby
disrupting the protein−triazole interaction. This was offset by a
new T-shaped π interaction between W127 and the
benzoxazolone group (Figure S3). The volume and area of
the binding pocket of SaBPL were also increased as 5-fluoro
triazole 4c was bound into the binding site of the enzyme
(Table S1). These data suggest an induced fit model of ligand
binding occurs involving the biotin-binding loop, and the BPL
active site has enough flexibility to accommodate the C5
halogen-substituted biotinyl 1,2,3-triazole inhibitors.
Series 2: Compounds 5a−o, 6a−o, and 7a−o (Figure
3B). A second series (6a−o, 7a−o) was investigated to
determine if the improved whole cell activity of 5-fluoro triazole
4c could be replicated in the truncated benzyl-biotin triazole
BPL inhibitors.12 The synthesis of 1-benzyl-5-proto-1,2,3-
triazoles 5a−o,12 1-benzyl-5-iodo-1,2,3-triazoles 6a−o, and 1-
benzyl-5-fluoro-1,2,3-triazoles 7a−o was accomplished as
outlined in Schemes 2 and 3. Biotin 1-iodoacetylene 10 was
reacted with benzyl azides 11a−l and 11n to yield 5-iodo-1,2,3-
triazoles 6a−l according to the procedure described for the
synthesis of compound 4b (Scheme 2). This two-step reaction
required preformation and isolation of 1-iodoacetylene 10, and
in some instances, the 5-proto triazole was obtained as a side
product. For example, 5-proto triazole compound 5l was
isolated as a side product along with 5-iodo triazole compound
6l after the two-step reaction (Scheme 3). Acetylene 811 was
treated with LiI, Cu(ClO4)2, and TEA in THF to give 1-iodo
acetylene 10 in situ to which 4-trifluoromethylbenzyl azide was
added to give 5-iodo-1,2,3-triazole 6m to improve the synthetic
method (Scheme 3). The 5-fluoro-1,2,3-triazoles 7a−n were
prepared as per 4c (Scheme 1). MeCN/H2O (1:1) was added
to a mixture of potassium fluoride and 5-iodo-1,2,3-triazoles
6a−n, and the solution was reacted in a microwave for 5 min to
give the corresponding 5-fluoro-triazoles 7a−n in 64−81%
yields. Carboxylic acids 6o and 7o were prepared by hydrolysis
using LiOH from the corresponding methyl esters 6n and 7n
(Scheme 2).
Table 1. Binding Affinities Derived from SPR Analysis, Inhibition, and Cytotoxic Data for Compounds 4a−d
ID X KD SaBPL (μM) Ki SaBPL (μM)
a Ki HsBPL (μM) MIC ATCC49775 (μM) Cytotox HepG2 (μg/mL)
4a H 8.4 ± 1.0 0.23 ± 0.01 >10 >100 >80
4b I 3.8 ± 1.5 0.41 ± 0.02 >10 >100 >80
4c F 7.1 ± 3.4 0.42 ± 0.05 >10 16 >80
4d Cl 10.1 ± 1.8 0.9 ± 0.11 >10 >100 >80
aInhibition constants (Ki) for the competitive inhibitors of biotin were derived from IC50 values using the KM for biotin, as previously described.
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Figure 5. Comparison of cocrystal structures. (A) 4a (green) and 4c
(magenta) were superimposed to reveal the different binding pose of
the benzoxazolone ring. (B) Binding pocket of SaBPL in complex with
4a (PDB 3V7S). (C) Binding pocket of SaBPL in complex with 4c.
Amino acids that encompass the triazole-binding site are shown.
Dashed lines represent hydrogen bonds.
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X-ray Structure of 5o in Complex with SaBPL. The
truncated benzyl-biotin triazole BPL inhibitors 5a−o were
designed for improved bioactivity with simpler structures than
4a−d. In silico docking experiments supported a model where
the functionalized benzyl groups 11a−o, appended onto the
biotin-triazole pharmacophore (Figure 2B), bound within the
ribose-binding site of SaBPL.12 The ribose-binding pocket
provides multiple sites for hydrogen bonding interactions,
specifically through the side chains of K187 and R227 as well as
the peptide backbone atoms from R122, H126, and S125
(Figure 6A).26 A crystal structure of SaBPL in complex with 5o
was solved to define its mechanism of binding of the inhibitor
(Figure 6B). Electron density was observed for amino acids
T177-K131 in the biotin-binding loop, consistent with the
inhibitor inducing the same disordered to ordered transition
described earlier. The biotinyl moiety of 5o occupied the biotin
pocket of SaBPL as expected, thus placing the inhibitor in the
active site of the enzyme. Hydrogen bonding interactions
between the N2 and N3 of the triazole and the side chains of
R125 and R122, respectively, in the biotin-binding loop further
stabilized the interaction. A comparison between the crystal
structures of SaBPL in complex with biotinyl-5′-AMP 226 and
5o clearly demonstrated a common binding site for the ribosyl
of 2 and the benzoic acid of 5o. Noteworthy was the absence of
hydrogen bonds between the carboxylate of 5o and BPL target,
implying that the affinity for the enzyme−ligand interaction is
driven primarily by the biotinyl and 1,2,3-triazole moieties.
Together, the X-ray and docking studies suggest that the
functionalized benzyl moieties for 5a−o, 6a−o, and 7a−o can
be accommodated in the ribose pocket of SaBPL.
Bioassays of 5a−o, 6a−o, and 7a−o. The antistaphylo-
coccal potency of 5a−o, 6a−o, and 7a−o was measured using
antibacterial susceptibility assays upon S. aureus RN4220.
S. aureus RN4220 was employed for microbiological analysis as
our earlier experiments with 4a−d revealed this strain to be
more sensitive to BPL inhibitors than S. aureus ATCC 49775.
This was exemplified with the archetypical BPL inhibitor
biotinol-5-AMP 3 that was 32-fold more active against RN4220
than ATCC 49775. In this series, 15 analogues halogenated at
Scheme 2. Synthesis of Benzyl Triazole Series
Scheme 3. Synthesis of Compounds 5l, 6l, 6m, and 7m
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C5 on the 1,2,3-triazole were more potent antistaphylococcal
agents than their nonhalogenated counterparts (Table 2).
There was no clear preference for the selection of 5-halogen,
with nine iodo (6a, 6b, 6f−h, 6j−m) and six fluoro (7a, 7e, 7f,
7h, 7j, 7m) compounds having improved whole cell activity
over their prototypical parent. The most potent antibacterials
(MIC of 4 μg/mL) in the series were all appended with a
halogenated benzyl moiety. Both 5-iodo 6h and 5-fluoro 7h
contain a 3-iodo benzyl, with 5-iodo 6f and 5-iodo 6m having
3-chloro and 4-CF3 substitutions, respectively.
The MIC values obtained from the microbiological analysis
were then compared with inhibition constants (Ki) obtained
from in vitro protein biotinylation assays to investigate
correlations between whole cell activity and in vitro inhibition
of SaBPL (Table 2, Figure S4). For 6a−o and 7a−o, a modified
BPL enzyme assay was developed as radiolabeled biotin could
not be sourced commercially. Protein biotinylation was
performed essentially as previously described except a GST
tagged biotin domain (GST-SaPC90) was employed as the
biotin acceptor protein. Biotinylated protein was captured on
white 96-well plates coated with anti-GST antibody and
quantitated using Europium-conjugated streptavidin and time-
resolved fluorescence. This eliminated the need for costly
radiolabeled biotin, while retaining the ability to accurately
characterize inhibitory potency. In support, both assays gave
comparable Ki values for the archetypical BPL inhibitor 3
(Table S2). Concomitant improvements of both in vitro
inhibition and whole cell bioactivity due to halogenation of
C5 on the 1,2,3-triazole were observed with five examples in
this series, namely, 6/7b, 6/7e, 6/7h, 6/7l, and 6m. In each
case, the nonhalogenated parent compounds were inactive in
both the biochemical (Ki > 10 μM) and microbiological (MIC
> 64 μg/mL) testing but halogenation greatly improved
potency in both assays. Three of the most potent
antistaphylococcal compounds described above (6h, 7h, and
6m) belong in this category, where improved biochemical
activity translated to increased microbiological potency. In
contrast, 5-iodo analogues 6f, 6g, 6j, and 6k showed increased
whole cell activity despite only modest changes in biochemical
potency due to 5-halogenation. This was exemplified by the
potent antibacterial 6g (Ki 0.65 μM, MIC 16 μg/mL), where 5-
iodonation reduced the Ki by only 1.7-fold (5g 1.1 μM) but
greatly improved antistaphylococci activity (5g inactive vs
S. aureus RN4220). Importantly, all compounds in this series
with antibacterial activity also inhibited BPL in vitro, and there
were no examples where reduced whole cell activity was
observed as a result of halogenation. This was consistent with
their antibacterial mechanism of action being through the
inhibition of BPL. Furthermore, we confirmed that the
antimicrobial activity was indeed due to the inhibition of
SaBPL. Inhibitors 6f, 7h, and 7f were reassayed for
antistaphylococcal activity using the BPL overexpression strain
of S. aureus described earlier. The growth of bacteria in culture
media containing 32 μg/mL of inhibitor was monitored over 20
h. Growth was observed for those bacteria harboring the SaBPL
overexpression plasmid pCN51-BPL, consistent with these
compounds engaging the BPL target inside the bacteria (Figure
7). In contrast, S. aureus devoid of the plasmid was highly
sensitive to all three compounds and failed to grow. Together,
these data demonstrate that C5-halogenation of a 1,2,3-triazole
is a valid approach for improving whole cell antibacterial
activity of biotin-triazole BPL inhibitors.
■ CONCLUSION
Here, we employed halogenation as an approach for improving
the whole call activity of two series of BPL inhibitors. Both
series contain a common biotin 1,2,3-triazole pharmacophore
prepared by Hüisgen cycloaddition using biotin triazole 8 and
an appropriate azide functionalized partner. Our previous work
has identified 1,2,3-triazole benzoxalone 4a and the benzyl
substituted 1,2,3-triazoles 5a−o as inhibitors of BPL from the
clinically important bacteria S. aureus but with poor
antibacterial activity. The first proof of concept data
demonstrating that halogenation of C5 of the 1,2,3-triazole
could improve whole cell potency was obtained with the 5-
fluoro analogue 4c upon the clinical isolate S. aureus ATCC
49775 (MIC 8 μg/mL). Biochemical assays and biophysical
binding analysis with SPR demonstrated that fluorinated
triazole 4c had no effect upon the interaction between enzyme
and inhibitor compared with the nonhalogenated parent 4a.
The SPR data also argued against a role for the fluorine for
increasing the occupancy of the inhibitor on the BPL target (a
function of a slow dissociation rate) as indistinguishable fast on
and off rates were observed for 4a−d. We extended the
halogenation study to the benzyl biotin-triazoles series of BPL
inhibitors and identified 6f, 7h, and 7f as potent antibacterials
with confirmed mechanism of action through the inhibition of
SaBPL. We propose increased cellular uptake leading to higher
intracellular concentrations of inhibitor as the most likely
mechanism for the observed improvements in whole cell
activity observed here. In support, fluorination of drugs has
been shown to enhance free energy of partitioning and improve
passive diffusion across lipid membranes.5,6 As understanding
compound entry into bacteria is one of the more challenging
aspects for antibiotic discovery,2−4 a better understanding of
Figure 6. Comparison of crystal structures. Crystal structures of SaBPL in complex with (Figure 6A) the reaction intermediate biotinyl-5′-AMP 2
[PDB 3RIR]26 and (Figure 6B) benzyl biotin triazole inhibitor 5o. Amino acids that encompass the ribosyl moiety of 2 are shown. The ribosyl group
of 2 and benzoic acid of 5o both occupy a common binding site.
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the mechanisms of membrane permeation can drive the
development of new antibiotics. Structure activity relationship
studies that specifically address compound uptake into bacteria,
such as those as detailed here, are required to achieve this
objective.
■ METHODS
Recombinant Protein Production and Assay. The
cloning and purification of recombinant BPL from Staph-
ylococcus aureus and Homo sapiens have been previously
described.13,27 The inhibitory activity of compounds 4a−d
and 5a−o was determined by measuring BPL activity in the
presence of varying concentrations of compound. Quantifica-
tion of BPL catalyzed 3H-biotin incorporation into the biotin
domain substrate was performed as previously described.12
Briefly, a reaction mixture was prepared containing 50 mM Tris
HCl, pH 8.0, 3 mM ATP, 4.94 μM biotin, 0.06 μM 3H-biotin
(American Radiolabeled Chemicals), 5.5 mM MgCl2, 100 mM
KCl, 0.1 μM DTT, and 10 μM biotin domain of S. aureus
pyruvate carboxylase (SaPC90). All compounds were dissolved
in DMSO and then diluted into the reaction buffer to give a
final concentration of 4% DMSO. BPL reaction was initiated by
the addition of enzyme to give final concentrations of 6.25 nM
for SaBPL and 140 nM for HsBPL. After 10 min at 37 °C, 90
μL of stop buffer (110 mM EDTA and 50 mM Tris HCl, pH
8.0) was added to terminate the reaction and a 100 μL aliquot
of the reaction mixture was added to the wells of 96-well HTS
multiscreen plate containing an Immobilon-P (Merck Milli-
pore) membrane that had been pretreated with 50 μL of 70%
ethanol and 400 μL of Milli-Q H2O, followed by 200 μL of
Table 2. Biochemical and Antistaphylococcal Properties of




MIC S. aureus RN4220 μg/mL
(μM)
5a H H N/D >64 (>172)
6a I 2.86 ± 0.13 16 (32)
7a F 2.50 ± 0.13 64 (164)
5b 2-F H >10 >64 (>164)
6b I 0.67 ± 0.09 16 (31)
7b F 1.32 ± 0.26 >64 (>157)
5c 3-F H 0.28 ± 0.02 >64 (>164)
6c I 0.54 ± 0.08 >64 (>124)
7c F 1.77 ± 0.15 >64 (>157)
5d 4-F H 0.6 ± 0.1 >64 (>164)
6d I 3.86 ± 0.17 >64 (>124)
7d F 4.16 ± 0.29 >64 (>157)
5e 2-Cl H >10 >64 (>157)
6e I 0.39 ± 0.03 >64 (>120)
7e F 1.15 ± 0.07 8 (18)
5f 3-Cl H 0.39 ± 0.04 16 (39)
6f I 0.48 ± 0.03 4 (7)
7f F 1.40 ± 0.05 8 (18)
5g 4-Cl H 1.1 ± 0.07 >64 (>144)
6g I 0.65 ± 0.06 16 (30)
7g F 3.26 ± 0.13 >64 (>150)
5h 3-I H >10 >64 (128)
6h I 0.38 ± 0.01 4 (6)
7h F 0.86 ± 0.06 4 (7)
5i 4-I H 0.56 ± 0.06 >64 (>128)
6i I 0.43 ± 0.07 >64 (>102)
7i F 1.02 ± 0.25 >64 (>124)
5j 2-OMe H 0.53 ± 0.05 >64 (>159)
6j I 0.80 ± 0.03 16 (30)
7j F 0.55 ± 0.04 32 (76)
5k 4-tBu H 1.22 ± 0.07 >64 (>149)
6k I 0.66 ± 0.11 8 (14)
7k F 0.73 ± 0.05 >64 (>143)
5l 2-NO2 H >10 >64 (>153)
6l I 0.80 ± 0.06 8 (14)
7l F 0.78 ± 0.07 >64 (>147)
5m 4-CF3 H >10 >64 (>145)
6m I 2.75 ± 0.20 4 (7)
7m F N/D 8 (17)
5n 4-COOMe H N/D >64 (>149)
6n I 1.54 ± 0.08 >64 (>113)
7n F >10 >64 (>140)
5o 4-COOH H 0.67 ± 0.06 >64 (>154)
6o I 0.23 ± 0.07 >64 (>118)
7o F >10 >64 (>148)
Figure 7. Mechanism of action studies. Growth curves for S. aureus
RN4220 harboring the plasmid pCN51 (open circles, negative
control) or pCN51-BPL (solid boxes, for recombinant BPL over-
expression) are shown. Growth media contained 32 μg/mL of (A) 6f,
(B) 7h, or (C) 7f.
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TBS. Quantitation of protein-bound radiolabeled biotin was
determined by liquid scintillation counting. Compounds 6a−o
and 7a−o were assayed essentially as described above with the
following modifications. The assay medium contained 5 μM
biotin (i.e., no 3H biotin), and the SaPC90 was replaced with
25 μM SaPC90 fused to GST. The reaction was terminated
with 80 μL of stop buffer, and three 20 μL aliquots were added
to each well of a white Lumitrac-600 96-well plate (Greiner)
that had been precoated with a polyclonal anti-GST antibody
(Sigma-Aldrich, 50 μL per well, 1:40 000 dilution) at 4 °C
overnight, followed by blocking for 2 h (200 μL per well) with
1% BSA in TBS at 37 °C and incubated at 37 °C for 1 h. The
plate was then washed 5 times (200 μL per well) with TBS
containing 0.1% Tween-20. Europium labeled streptavidin
(PerkinElmer) was diluted to 0.1 μg/mL in TBS containing
0.1% Tween-20. The streptavidin probe (50 μL per well) was
incubated for 30 min at 37 °C followed by washing 5 times with
TBS containing 0.1% Tween-20 followed by another 5 washes
in sterile water. Enhancement solution (PerkinElmer, 50 μL)
was added to each well and incubated for 10 min before reading
the plate using a PerkinElmer Victor X5 multilabel reader
(time-resolved fluorescence settings, 340 nm excitation, and
612 nm emission).28
The IC50 value of each compound was determined from a
dose−response curve by varying the concentration of inhibitor
under the same enzyme concentration. The data was analyzed
with GraphPad prism (version 6) using a nonlinear fit of log10
[inhibitor] vs normalized response. The Ki, the absolute












where [S] is the substrate concentration ([biotin] = 5 μM) and
KM is the affinity of the enzyme for biotin (S. aureus BPL = 1
μM11 and H. sapiens BPL = 1 μM29).
Surface Plasmon Resonance. SPR was performed using a
Biacore S200 instrument (GE healthcare).11,14 S. aureus BPL
was immobilized on a CM5 sensor chip by standard amine
coupling chemistry. The carboxymethyl groups on the chip
were activated by the addition N-ethyl-N-(3-diethylamino-
propyl) carbodiimide and N-hydroxysuccinimide. BPL (120
μg/mL) in 10 mM sodium acetate buffer (pH 5.8) was coupled
onto the surface, and 50 mM Tris, pH 8.0, was injected to block
any unreacted sites. Typically, 7000 resonance units of BPL
were immobilized on the sensor chip. One channel was left
blank which was subtracted from the sample channel to allow
analysis methods to distinguish between actual and nonspecific
binding. Experiments were conducted at 25 °C with a running
buffer containing 10 mM HEPES, pH 7.4, 150 mM NaCl,
0.005% surfactant P20, and 5% (v/v) DMSO. For compounds
that were poorly water-soluble, samples were initially dissolved
in DMSO and diluted in running buffer so that the final
concentration of DMSO was 5%. To correct for variations in
DMSO concentration during the preparation of these
compounds, a solvent correction curve was included in the
analysis by preparing a series of test solutions between 4.5%
and 5.8% DMSO. Binding experiments were performed by
injecting the analyte solutions into the instrument across the
sensor surface of all flow cells at a flow rate of 30 μL/min with a
contact time of 120 s followed by a dissociation time of 300 s.
Zero concentration samples were used as blanks. The time-
dependent binding curves of all flow cells were monitored
simultaneously. The results of compounds 4a−d showed fast
on and off rates outside the range of kinetic quantification, so
KD values were determined by transforming time-dependent
binding curves into an affinity-steady state 1:1 model using
Biacore S200 evaluation software (GE healthcare).
Antibacterial Activity Evaluation. Antibacterial activity
was determined by a microdilution broth method as
recommended by the CLSI (Clinical and Laboratory Standards
Institute, Document M07-A8, 2009, Wayne, PA) using cation-
adjusted Mueller-Hinton broth (Trek Diagnostics Systems,
U.K.). Compounds were dissolved in DMSO. Serial 2-fold
dilutions of each compound were made using DMSO as the
diluent. Trays were inoculated with 5 × 104 CFU of each strain
in a volume of 100 μL (final concentration of DMSO was 3.2%
(v/v)) and incubated at 35 °C for 16−20 h. Growth of the
bacterium was quantified by measuring the absorbance at 620
nm.
X-ray Crystallography. To prepare SaBPL-4c and SaBPL-
5o crystals, 1 mg/mL apo SaBPL, 790 μM of the respective
inhibitor, 4% (v/v) DMSO, 50 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 1 mM DTT, and 5% (v/v) glycerol were incubated
overnight at 4 °C. The incubation was filtered through a 0.2 μm
Nanosep MF centrifugal device (Pall Corp.), and protein was
concentrated to 5 mg/mL. Crystals were prepared at 4 °C using
the hanging drop vapor diffusion method, with a 500 μL
reservoir comprised of 12% (w/v) PEG 8000, 100 mM Tris-
HCl, pH 7.5, and 10% (v/v) glycerol.11 To prepare the hanging
drop, 0.8 μL of reservoir solution was mixed with 1 μL of
protein solution and 0.2 μL of microseeds of SaBPL in complex
with a known inhibitor. A single crystal was looped and
cryoprotected with reservoir solution containing saturated
sucrose, prior to flash freezing with liquid nitrogen. X-ray
diffraction data were collected at the Australian Synchrotron
MX2Micro Crystallography beamline, using an ADSC
Quantum 315r Detector for SaBPL-4c and an Eiger 16 M
Detector for SaBPL-5o The diffraction data were integrated
using XDS,30 and the intensities were merged and scaled using
Aimless31 in the CCP4 program suite.32 MOLREP33 was used
to perform molecular replacement, using a single protein chain
from PDB 3 V7R11 as a search model. PDB and cif files for 4c
and 5o were generated using eLBOW34 in PHENIX.35
Refinement was performed in PHENIX35 and REFMAC,36
and manual model building was undertaken in COOT.37
Statistics for the data and refinement are reported in Table S3.
All structures were deposited in the Protein Databank
(accession codes 6AQQ for SaBPL-4c and 6APW for SaBPL-
5o).
Docking Studies. Docking experiments were performed
using ICM software version 3.8−5 (Molsoft L.L.C., San Diego,
CA, USA). Proteins for docking were retrieved from RCSB
protein data bank 3V7S11 and SaBPL-4c. Then, formal charges
were assigned; protonation states of histidines were adjusted,
and hydrogens, histidine, glutamine, and aspargine were
optimized using the protein preparation procedure imple-
mented in ICM.38 The original bound ligand and all water
molecules were removed from the binding site before docking.
The binding site was defined as the cavity delimited by residues
with at least one nonhydrogen atom within a 4.0 Å cutoff radius
from the ligand 4a or 4c. The pocket was represented by 0.5 Å
grid maps accounting for hydrogen bonding, hydrophobic, van
der Waals, and electrostatic interactions. The molecules were
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flexibly docked into the rigid binding site and scored based on
the ICM scoring function.
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Figure S1.  
Mechanism of action studies. S. aureus RN4220 + pCN51-NcoI control (dashed line) and 
pCN51-BPL overexpression (solid line) vectors susceptibility to (A) archetypical BPL 
inhibitor biotinol-5′-AMP 3 and (B) non BPL targeting antibiotic amoxicillin. Assays were 






Figure S2.  
SPR sensograms (left) and binding isotherms for compounds 4a-d binding to SaBPL. SPR 
sensogram and concentration vs response plots are shown for (A) 4a, (B) 4b, (C) 4c and 
(D) 4d. Concentrations of compounds used were: 0.2 μM (red), 0.4 μM (green), 0.8 μM 
(blue), 1.6 μM (magenta), 3.1 μM (cyan), 6.3 μM (yellow), 12.5 μM (purple), 25 μM 
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Figure S3.  
(A) 2D interaction diagram of 4a and SaBPL. (B) 2D interaction diagram of 4c and 
SaBPL. 2D interaction diagrams were viewed using Discovery Studio Visualizer 
(Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 4.5, San 
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Figure S4.  
Biological activities of benzyl-biotin 1,2,3 triazole series. Graphically demonstrated are 
the (A) MIC against S. aureus RN4220 and (B) Ki for S. aureus BPL for the benzyl-biotin 
1,2,3 triazole series (5a-o) and halogenated analogues 5-iodo (6a-o) and 5-fluoro (7a-o). 
Benzyl substitutions shown are H a (×), 2-F b (●), 3-F c (■), 4-F d (▲), 2-Cl e (●), 3-Cl f 
(■), 4-Cl g (▲), 3-I h (■), 4I i (▲), 2-OMe j (●), 4-tBu k (▲), 2-NO2 l (●), 4-CF3 m (▲), 
































Table S1.  
Comparison of binding pockets. The volume and area of binding pocket of 4c-SaBPL was 
increased in order to accommodate 5-fluoro triazole 4c. The icmPocketFinder macro was 
used to measure the properties of the binding site at SaPBL. 
ID Volume (Å3) Area(Å2) Hydrophobicity Buriedness 
SaBPL-4a (PBD 3V7S) 679.9 635.2 0.5932 0.8844 




Table S2.  
Comparison of Ki values as determined by enzyme assay with radiolabelled biotin 
compared to assay utilising GST fusion of SaPC90 for antibody capture and detection with 
Eu-streptavidin conjugate. 
Compound Ki radiolabelled biotin (μM) Ki GST-fusion (μM) 








Data collection and Refinement Statistics for SaBPL in complex with inhibitors 
Data collectiona SaBPL-4c SaBPL-5o 
Wavelength (Å) 0.9537 0.95374 
 Resolution range (Å) 39.67 - 2.397 (2.482 - 2.397) 46.76  - 2.614 (2.708  - 2.614) 
Space group P 42 21 2 P 42 21 2 
Unit cell a, b, c (Å) 94.241, 94.241, 131.192 94.454 94.454 130.978  
α, β, γ (°) 90, 90, 90 90,90,90 
Total reflections 84981 (8264) 488740 (46053) 
Unique reflections 22814 (2233) 18559 (1788) 
Multiplicity 3.7 (3.7) 26.3 (25.8) 
Completeness (%) 95.52 (95.26) 99.79 (98.51) 
Mean I/sigma(I) 13.86 (1.07) 38.43 (4.37) 
Wilson B-factor 57.05 67.66 
R-merge  0.06603 (1.2) 0.06458 (0.849) 
R-pim 0.038 (0.79) 0.01277 (0.1675) 
CC1/2 0.999 (0.454) 1 (0.948) 
CC* 1 (0.79) 1 (0.987) 
R-work (%) 20.77 (37.00) 0.1937 (0.2859) 
R-free (%) 25.40 (42.72) 0.2280 (0.3401) 
Number of non-hydrogen 
atoms 
2680 2649 
  macromolecules 2613 2613 
  ligands 35 29 
  water 32 7 
Protein residues 322 322 
RMS(bonds) 0.007 0.003 
RMS(angles) 0.94 0.60 
Ramachandran favored (%) 98 96.56 
Ramachandran allowed (%) 2.7 3.44 




Rotamer outliers (%) 0.0 0.00 
Clashscore 8.42 5.18 
Average B-factor 66.60 75.17 
  macromolecules 66.500 75.24 
  ligands 78.00 70.70 
  solvent 64.80 68.64 
aDiffraction data were collected from one crystal 
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3.1 Introduction  
Chapter 2 described the design and development of 5-halogenated-1,2,3-triazoles that target 
SaBPL with improved antimicrobial activity. An investigation of diverse sulfonamide 
moieties is considered in this chapter to develop potent BPL inhibitors, given limitations of 
1,2,3-triazoles (e.g. lack of antimicrobial activity and solubility). This chapter describes the 
design, synthesis, and biological assay of sulfonamide analogues targeting SaBPL to 
improve inhibitory activity, antimicrobial activity, and metabolic stability. 
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ABSTRACT 
Here we report the design, synthesis, and evaluation of a series of sulfonamide-based inhibitors with 
activity against SaBPL. Compounds 6 and 7 showed potent in vitro inhibitory activities (Ki = 0.007  
0.003 and 0.065  0.03 µM respectively) and also antibacterial activity against S. aureus ATCC49775 
with a minimum inhibitory concentration (MIC) of 0.25 and 4 µg/ml respectively. Additionally, the 
bimolecular interactions between the BPL and the inhibitors 6 and 7 were defined by X-ray 
crystallography and molecular dynamics (MD) simulations. The high acidity of sulfonamide linker of 6 
and 7 likely contributes to the enhanced in vitro inhibitory activities compared to 8–10 via strong 
interactions with Lys187 in the active site of SaBPL. Binding free energy estimation using 
computational methods suggest deprotonated 6 and 7 to be the best binders, which is consistent with 
enzyme assay results. Compound 6 was unstable in whole blood leading to poor pharmacokinetics. 
Importantly, 7 has a vastly improved pharmacokinetic profile compared to 6 presumably due to the 




Biotin protein ligase (BPL) is a promising target for antibiotic development, with inhibitors showing 
efficacy against clinically important bacterial pathogens such as Staphylococcus aureus (S. aureus)1 
and Mycobacterium tuberculosis (M. tuberculosis).2, 3 It plays a key role in the viability of bacteria 
catalyzing reaction of biotin and ATP to give biotinyl-5’-AMP 1, which then biotinylates and activates 
key biotin-dependent enzymes.4, 5 S. aureus expresses two such biotin-dependent enzymes, namely 
acetyl CoA carboxylase (ACC) and pyruvate carboxylase (PC), that play critical roles in the important 
metabolic pathways of fatty acid biosynthesis and gluconeogenesis respectively.6 S. aureus BPL (SaBPL) 
also functions as a transcriptional repressor that controls the uptake and biosynthesis of biotin.7-9 All 
this presents BPL as an attractive target for the generation of new antibiotics.  
Inhibitors of BPL are typically generated by replacing the labile phosphoanhydride of biotinyl-5’-AMP 
1 with more stable bioisosteres, see Table 1. For example, biotinol-5-AMP 2, which lacks the labile 
carbonyl group of biotinyl-5-AMP 1, is a potent inhibitor of SaBPL (Ki = 0.03 µM) with whole cell 
activity against S. aureus, including methicillin resistant S. aureus (MRSA).10, 11 However, 2 also inhibits 
the human BPL homologue and hence lacks the 
selectivity necessary for antibiotic development.  
The molecular basis of inhibitor binding has 
been defined by structural studies to assist 
chemical optimization of preclinical candidates 
with enhanced binding potency and selectivity. 
In particular, the crystal structure of SaBPL in 
complex with biotinol-5-AMP 2 reveals an 
extended water mediated network of hydrogen 
bonds between the phosphodiester linkage of 2 
and amino acid residues Arg122, Arg125 and 
Lys187.10 The binding interaction with Lys187 is 
particularly important as this amino acid plays 
an essential role in the synthesis of the reaction 
intermediate 1 and, consequently, protein 
biotinylation.12, 13 This hydrogen bonding 
network is central to binding and likely 
contributes to the high affinity of 2 toward 
SaBPL. Our group has also reported biotin 
triazoles as potent inhibitors of SaBPL, for example 3 (Ki = 1.17 µM) and 4 (Ki = 0.66 µM) as direct 
analogues of 2.10, 14 The triazole ring of these derivatives acts as an isostere of the phosphodiester 
group of 2 and adopts hydrogen bonds with Arg122 and Arg125 based on its X-ray structure in complex 
Table 1. Biotinyl-5’-AMP 1 and reported BPL 
inhibitors 2 – 5. 
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with SaBPL.10 Mutagenesis studies confirm a key hydrogen-bonding interaction between the triazole 
heterocycle and Arg125 (an asparagine in the human homologue) that defines selective binding.10 The 
biotin triazole structure is an important pharmacophore for the development of improved BPL 
inhibitors with enhanced whole cell activity against S. aureus.10, 15, 16 
Duckworth et al reported a series of acylsulfamide analogues of biotinyl-5’-AMP 1 (e.g. Bio-AMS 5) 
that target M. tuberculosis BPL (MtbBPL) with a KD of approximately 0.5 nM, more than 1700-fold 
more tightly than biotin.17, 18 This compound possesses potent and selective antimicrobial activity 
against M. tuberculosis including multi-drug resistant and extensively drug resistant strains, with a 
minimum inhibitory concentration (MIC) ranging from 0.16 to 0.625 μM. Interestingly, Bio-AMS 5 
proved to be inactive against a panel of gram-positive (E. faecalis and S. aureus) and gram-negative 
bacteria (A. baumannii, E. coli, K. pneumoniae and P. aeruginosa), as well as fungi (C. neoformans, and 
C. albicans). 17  An X-ray structure of Bio-AMS 5 bound to MtbBPL reveals key hydrogen bonds between 
the sulfamide oxygens of 5 and amino acid residues Arg69, Arg72, and Asn130 (the equivalent of 
Arg122, Arg125 and Asn179 in SaBPL, respectively).17 Critically, the side chain aminium ion of Lys138 
(the equivalent of Lys187 in SaBPL) also interacts with the carbonyl oxygen of the acylsulfamide 
through an electrostatic interaction, where the acidic central NH of the acylsulfamide linker would be 
expected to be deprotonated to enhance delocalization and hence interaction.17 We propose that this 
strong electrostatic interaction contributes to the potent inhibition of BPL given the important role 
Lys138 in catalysis.13 
Clinical development of bio-AMS 5 has been limited by instability of its acylsulfamide linkage, which 
degrades to biotin and sulfamoylamino adenosine in vivo through the mechanism depicted in Figure 
S1.19, 20 This results in rapid elimination of Bio-AMS 5 from mice and, hence, limited bioavailability.19, 
20 M. tuberculosis has also been shown to develop spontaneous resistance to Bio-AMS 5 through the 
overexpression of Rv3406, a type II alkylsulfatase capable of sulfate scavenging for metabolic and 
biosynthetic purposes.20 Some work has been reported to circumvent this Rv3406-mediated chemical 
inactivation by modifying the component nucleoside.19 Interestingly, S. aureus does not possess an 
equivalent sulfatase so is likely to be highly susceptible to inhibition by sulfonamide-based BPL 
inhibitors. Triazole-based inhibitors offer an advantage of improved stability, but to date they 
somewhat lack the antimicrobial potency and solubility required for further development as 
antibiotics. 
Here we describe the synthesis and evaluation of a panel of novel BPL inhibitors, acylsulfamide 6, 
amino sulfonylurea 7 and related isosteres 8 – 10 as shown Figure 1. These compounds were designed 
to improve metabolic stability relative to 5 and also to target SaBPL with enhanced potency, selectivity 
and/or drug-like properties compared to biotinol-5-AMP 2 and the biotin-triazoles. The acylsulfamide 
4 
 
6 is based on earlier 1,2,3-triazole analogues 3 and 4, where the 1,2,3-triazole is replaced with an 
acylsulfamide as found in 5. We anticipated that removal of the ribose moiety of Bio-AMS 5 would 
increase potency against SaBPL, where this group is known in the triazole series to be superfluous for 
binding to the enzyme.10, 14 Amino sulfonylurea 7 (and also 8 – 10) were specifically designed to 
improve the metabolic stability of the problematic acylsulfamide linker of Bio-AMS 5 and also 
acylsulfamide 6 (see above for discussion), while maintaining key interactions with the BPL active site. 
In addition, while Lys187 of SaBPL is believed to be critical for protein biotinylation, it does not interact 
with the 1,2,3-triazole ring of biotin triazole 4.14 Compounds 6 – 10 thus allow the relative importance 
of this key residue to SaBPL binding to be elucidated with an ensuing opportunity for the ongoing 
development of more potent inhibitors of SaBPL.   
 
Figure 1. Proposed sulfonamide analogues 6 – 10 
 
RESULTS AND DISCUSSION 
Inhibitory and antimicrobial activities  
Derivatives 6 – 10, prepared as described in supporting information, were evaluated for inhibitory 
activity and selectivity against BPLs from S. aureus and Homo sapiens using an in vitro protein 
biotinylation assay,16 with results summarized in Table 2. Acylsulfamide 6, which lacks the ribose of 5, 
was the most potent inhibitor of SaBPL (Ki = 0.007 ± 0.003 µM) and is devoid of activity against Homo 
sapiens BPL (HsBPL) at the highest concentrations tested (Ki > 5 µM). This compound is in fact the 
most potent inhibitor of SaBPL reported to date and confirms our earlier observation in the triazole 
series10, 14 that activity does not require the ribose group of biotinol-5-AMP 2. Importantly, the 
acylsulfamide 6 also demonstrated whole cell activity against S. aureus (discussed further below). 
Amino sulfonylurea 7 was also a potent inhibitor of SaBPL (Ki of 0.065  0.03 µM) and only 9-fold less 
potent than acylsulfamide 6. However, removal of the acylsulfamide carbonyl group of 6, as in 
alkylsulfamide 8, results in approximately 300-fold decrease in potency against SaBPL with Ki = 2.34  
0.19 µM. Interestingly, β-ketosulfonamide 9 and β-hydroxysulfonamide 10 were inactive against 
SaBPL (Ki > 5 µM). The acidity of the central NH of derivatives 6 and 7 likely contributes to binding and 
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hence potency towards SaBPL, where the less acidic analogues 8, 9, and 10 all show poor or no 
inhibitory activities. The resulting increased anion character of the linkers of 6 and 7 would be 
expected to enhance electrostatic interaction with Lys187. This is supported by pKa values of these 
linkers, with 6 and 7 having calculated values of 4.15 and 4.26 respectively (Figure S2). Derivatives 8, 
9, and 10 were all significantly less active and have higher predicted pKa’s > 9.6 (Figure S2). 
Antimicrobial activity of sulfonamide analogues 6 – 10 was measured against the S. aureus clinical 
isolate ATCC 49775 and also the well characterised strain RN4220, using a broth microdilution assay 
and the results are shown in Table 2. Acylsulfamide 6 proved to be a particularly potent antibacterial 
against both S. aureus strains, with MIC values of 0.125 and 0.25 µg/mL respectively. This compares 
to the most potent reported biotin-1,2,3 triazole, which only inhibits growth of S. aureus ATCC 49775 
by 80% with a MIC of 8 µg/mL.16 The antibacterial activity of 6 was particularly noteworthy, with 
ribose-containing bio-AMS 5 reported to be inactive against S. aureus.17 This finding suggests that 
replacement of the ribose moiety of 5 with an alkyl linker (6) significantly improves whole cell activity 
against S. aureus. The alkylsulfamide 8 showed antibacterial activity against S. aureus RN4220 with a 
MIC of 16 µg/mL, but it was inactive against the clinical isolate (ATCC 49775, MIC > 64 µg/mL). Amino 
sulfonylurea 7 was also active against S. aureus RN4220 (MIC 1 µg/mL) and ATCC 49775 (4 µg/mL), 
albeit with reduced potency compared with 6. As expected, SaBPL inactive β-ketosulfonamide 9 and 
β-hydroxysulfonamide 10 were inactive against S. aureus RN4220. Together the biochemical and 
microbiological data demonstrates a clear and strong correlation between antimicrobial activity and 
inhibitory activity against SaBPL.  
 
Table 2. Ki (µM) values of sulfonamide analogues 6 – 10 against SaBPL and HsBPL and antimicrobial 
activity against S. aureus strains MIC ATCC 49775 and MIC RN4220. 
Compound Ki SaBPL (µM) Ki HsBPL (µM) 




6 0.007  0.003 >5 0.25 0.125 
7 0.065  0.03 N/D 4 1 
8 2.34  0.19 N/D >64 16 
9 >5 N/D N/D >64 






    A                                                                                               B 
      
Figure 2. (A) A 3D depiction of acylsulfamide 6 bound to SaBPL with hydrogen bonds shown in 
purple. (B) 2D depiction of acylsulfamide 6 bound to SaBPL with interactions shown in dashes. 
Crystal structures of SaBPL in complex with acylsulfamide 6 and amino sulfonylurea 7 were solved (at 
2.39 and 2.00 Å, respectively) in order to define and compare the molecular details of binding (see 
Table S1 for data collection and refinement statistics). Acylsulfamide 6 adopts a ‘U-shape’ 
conformation when bound to SaBPL, with the biotinyl and adenine groups occupying the biotin and 
nucleoside pockets respectively as per biotinyl-5-AMP 2 and 1,2,3-triazole 421  (shown in Figure 2). 
The adenine group of 6 forms hydrogen bonds with Asn212 and Ser128, while the biotin urea forms 
hydrogen bonds with Arg120, Ser93 and Gln116. The same hydrogen bonding interactions are 
apparent in the reported crystal structures of biotinyl-5-AMP 2 and 1,2,3-triazole 4 bound to SaBPL.21 
The acylsulfamide isostere of 6 interacts with amino acid residues in the phosphate binding domain 
of SaBPL, specifically Arg122, Arg125, and Lys187. N3 of the acylsulfamide linker of 6 is likely 
deprotonated, where this isostere has a calculated pKa of 4.15 (Figure S2). The resulting anion is 
delocalized over N3 and O2 of the acylsulfamide linker, to facilitate interaction with the side chain 
amine of Lys187. The backbone nitrogen atom of Arg122 forms a hydrogen bond with one sulfamide 
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Figure 3. (A) A multiconformer model of amino sulfonylurea 7 bound to SaBPL with a major conformer 
shown in green sticks (coloured by element) and a minor conformer shown in yellow sticks (coloured 
by element). Displayed in blue mesh is a 2Fo-Fc composite omit map contoured at 2σ. Image is depicted 
in wall eye stereo. (B) 3D depiction of a major conformer of amino sulfonylurea 7 (green) looking down 
into the phosphate binding pocket of SaBPL. (C) 3D depiction of a minor conformer of amino 
sulfonylurea 7 (yellow) looking down into the phosphate binding pocket of SaBPL. Hydrogen bonds 
are depicted by blue dashes with distances shown therein. 
 
Interestingly, the electron density observed in the structure of amino sulfonylurea 7 bound to SaBPL 
suggests a multiple conformer model, see Figure 3A. Both conformers adopt the hydrogen bonds 
observed between the biotin heterocycle/adenine ring of 6 and amino acid residues of SaBPL. A single 
conformation of Arg125 was apparent, but the two ligand conformations show distinct hydrogen 
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bonding patterns. The two conformers differ in positioning of the central isostere in the active site. 
The central nitrogen atom of the linker of the major conformer of amino sulfonylurea 7 forms a 
hydrogen bond with the carboxylate of Asp180 (Figure 3B). The side chain amine of Lys187 then forms 
a hydrogen bonding network with one sulfamide oxygen and the carboxylate of Asp180. The backbone 
nitrogen atom of Arg122 forms hydrogen bonds with the urea oxygen of the amino sulfonylurea linker, 
while the guanidium group of Arg125 forms hydrogen bonds with one of the sulfamide oxygens of 7. 
The amino sulfonylurea carbonyl groups of both conformers point in opposite directions. As a 
consequence, one of the sulfamide oxygens in the minor conformer forms a hydrogen bond with the 
backbone nitrogen atom of Arg122 (Figure 3C). The side chain amine of Lys187 forms a hydrogen bond 
with one sulfamide oxygen in the linker of the major conformer of 7, but not for the minor conformer. 
Interaction between Lys187 and the linker moiety likely contributes to the potent inhibition of BPL, as 
Lys187 of SaBPL is believed to be critical for protein biotinylation. The acylsulfamide linker of 6 
interacts with Ly187, while only the major binding conformer of 7 forms a hydrogen bond with Lys187. 
This limited interaction with Lys178 in 7 supports the reduced potency of 7 (Ki = 0.065  0.03 µM) 
compared to 6 (Ki = 0.007 ± 0.003 µM). 
Molecular dynamics (MD) simulations of acylsulfamide 6 and amino sulfonylurea 7 in the binding 
pocket of SaBPL were carried out using the Sander algorithm as implemented in Amber 16 package as 
described in supporting information, in order to gain further insight into the binding of both 
protonated and deprotonated forms to SaBPL. Although the acylsulfamide linker of 6 is likely 
deprotonated as discussed above, both protonated and deprotonated forms were considered to 
define how this feature might influence the binding conformation. The co-crystal structure of 
acylsulfamide 6 bound to SaBPL was first superimposed with the time-averaged conformations of both 
deprotonated and protonated 6 obtained by MD simulations (Figure S3).  Deprotonated 6 is clearly a 
better binder, with the time-averaged conformation of deprotonated and protonated 6 giving root-
mean-square deviation (RMSD) values of 0.62 and 1.13 Å, respectively. The early crystal structure, 
shown in Figure 2, thus likely contains deprotonated 6. The major and minor conformers of amino 
sulfonylurea 7, found in the X-ray structure SaBPL, were superimposed with time-averaged 
conformation of deprotonated and protonated 7 similarly obtained by MD simulations (Figure S4). 
The major binding conformer gave RMSD values of 1.02 and 0.86 Å for time-averaged conformations 
of deprotonated and protonated 7, respectively. In comparison, the minor binding conformer gave 
RMSD values of 0.78 and 0.98 Å, respectively.  This suggests that the major and minor conformers in 




MD simulations of inactive analogues 8 – 10 bound to SaBPL were also conducted to gain some insight 
into the binding affinity of the extended series of sulfonamide analogues. Binding free energies of 6 – 
10 were estimated from MD simulation results, as summarized in Table S2, using quantum 
mechanics/molecular mechanics generalized Born surface area (QM/MM-GBSA) methods. 
Deprotonated 6 and 7 were predicted to have enhanced binding affinities compared to protonated 6 
and 7 as well as 8 – 10. In support, free energies for deprotonated 6 and 7 were calculated to be -
73.75 and -81.27 kcal/mol respectively, while values for protonated 6 and 7, and 8 –10 were all 
estimated to be higher than -71.28 kcal/mol. The relatively low estimated binding energies for 
deprotonated 6 and 7 are consistent with their enhanced potency, see Table 2.  
 
Pharmacokinetic studies  
The acylsulfamide 6 was administered into mice in order to define its pharmacokinetic profile. In 
particular, thirty mice were administered an intravenous bolus dose of 6 and samples of blood 
collected at regular intervals post administration and blood concentrations were measured by LC-MS, 
see Figure 4. Pharmacokinetic parameters were then calculated after fitting a two-compartmental 
model of disposition to the profile of concentrations versus time. Values for the areas under 
concentrations in blood-time curves (AUC) and clearance were determined to be 17300 (± 1740, S.E.) 
ngmin/mL and 1210 (± 154, S.E.) mL/minkg, respectively. The latter value reflects the efficiency with 
which the compound is cleared irreversibly from circulating blood and this far exceeds the summed 
flow of blood to the two major eliminating organs, i.e. the liver (blood flow of 90 mL/minkg) and 
kidney (blood flow of 65 mL/minkg).22 Thus, hepatic and renal mechanisms do not account for the 
high clearance of acylsulfamide 6, suggesting an additional route of the irreversible elimination of 6 





Figure 4. Concentrations of acylsulfamide 6 in blood after administration of an intravenous dose (16.6 
mg/kg) to mice. 
 
The fate of acylsulfamide 6 in blood was thus investigated in vitro by incubating 6 in drug-free rat 
whole blood and the resulting peak response ratios are shown in Figure S5. It is clear that 
acylsulfamide 6 decomposes rapidly in blood, with approximately 50% lost after 3 h of incubation. This 
rapid degradation likely accounts for the high clearance observed after an intravenous dose of 
acylsulfamide 6 in mice. Full mass scans of samples taken at 0, 3 and 71 h identified a m/z of 512.1863 
at 0 h and 3 h (Figure S6A), which corresponds to acylsulfamide 6 (Figure 5). Interestingly, a potential 
decomposition product was also observed at 3 h and 71 h (m/z = 286.1081) (Figure S6B), the mass of 
which is consistent with adenine sulfamide (Figure 5). This suggests that acylsulfamide 6 is quickly 
eliminated in rodent whole blood partially by the hydrolysis event (Figure 5). 
 
 




The stability study in blood was repeated with amino sulfonylurea 7, with comparative data for 6 and 
7 shown in Figure 6A. Importantly, amino sulfonylurea 7 was dramatically more stable in whole blood, 
with most of the compound remaining at 21.5 h (Figure 6A). This contrast acylsulfamide 6 which 
rapidly degrades after a few hours, with complete degradation over the same 21.5 h timeframe 
(Figure 6A). The amino sulfonylurea linker of 7 is clearly more stable than the acylsulfamide linker of 
6 in blood resulting in a significantly longer residence time. Given the evidence of enhanced metabolic 
stability, amino sulfonylurea 7 was administered into mice in order to determine its pharmacokinetic 
profile. Nine mice were administered an intravenous bolus dose of 7 and three samples of blood were 
collected from each mouse. Concentrations of 7 in plasma were measured by LC-MS and a two-
compartmental model was fitted over time (Figure 6B). Clearance of 7 in plasma was estimated at 
91.7 (± 7.9) mL/minkg. Considering a hematocrit value of 0.4, blood clearance is equal to about 1.66 
 plasma clearance.23 Clearance of 7 in plasma thus equates to an approximate value of 152 mL/minkg 
in blood. The estimated clearance of 7 in blood is much lower than the value for 6 (1210 mL/minkg), 
and commensurates with its greater residence in plasma.  
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Figure 6. (A) Comparison of the stability of acylsulfamide 6 and amino sulfonylurea 7 in drug-free rat 
blood. The mass spectrometer responses were converted to a percentage of the response at 0 h. (B) 
Concentrations of amino sulfonylurea 7 in plasma after administration of an intravenous dose (10 
mg/kg) to mice.   
 
Conclusion 
Acylsulfonamide 6 was synthesized and shown to be highly potent against SaBPL (Ki = 0.007  0.003 
µM) and, critically, it displays excellent antibacterial activity against S. aureus with MIC = 0.25 µg/ml. 
Crystallographic analysis and computational studies on the acylsulfamide 6 reveal the importance of 
the central nitrogen, with the associated NH being deprotonated. The anion then binds to the side 
chain of Lys187 in the active site of SaBPL, to account for the high inhibitory activity of 6 towards the 
enzyme. However, acylsulfonamide 6 was unstable in whole blood leading to rapid clearance. The 
poor pharmacokinetics observed for 6 is likely to impact its clinical utility with agents that show slower 
clearance rates more likely to demonstrate efficacy in treating bacterial infections. Sulfonamide 
analogues 7-10 were also prepared and assayed against SaBPL with a view to improving metabolic 
stability over acylsulfamide 6. Whilst sulfonamide analogues 8–10 were devoid of biochemical and 
microbiological activity, amino sulfonylurea 7 showed potent in vitro inhibitory activity (Ki = 0.065  
0.03 µM) and also antibacterial activity against S. aureus (MIC = 4 µg/ml). Critically, amino sulfonylurea 
7 had a vastly improved pharmacokinetic profile compared to acylsulfamide 6, presumably due to the 
enhanced stability of the amino sulfonylurea linker in blood. These combined studies validate the 





Enzyme inhibition assays 
The inhibitory activity of compounds was determined by measuring S. aureus BPL activity in the 
presence of varying concentrations of compound as previously described.16 The inhibition constant (Ki) 
was analysed with GraphPad prism (version 6) by fitting the data to the Morrison equation.  
Antibacterial susceptibility assays 
Antimicrobial activity of the compounds was determined by a broth microdilution method as 
recommended by the Clinical and Laboratory Standards Institute (Document M07-A8, 2009, Wayne, 
PA) with cation-adjusted Mueller-Hinton broth (Trek Diagnostics Systems). Compounds were 
dissolved using DMSO. Serial 2-fold dilutions of each compound were made using DMSO as the diluent. 
Trays were inoculated with 5 x 104 colony-forming units of S. aureus ATCC 49775 in a volume of 100 
μL (final concentration of DMSO was 3.2% (v/v)) and incubated at 35 °C for 16 –20 h. Growth of the 
bacterium was quantitated by measuring the absorbance at 620 nm.  
X-Ray Crystallography 
Crystallization of SaBPL with 6 and 7. SaBPL was prepared for co-crystallization with 6 and 7 using the 
method described by Paparella et al.24 Crystals were grown by hanging drop vapour diffusion with 2 
µL drops composed of equal volumes of protein sample and reservoir solution. Crystals grew as square 
rods to a maximum size of 400 × 200 × 200 µm in approximately 2 weeks at 4°C with 14% PEG 8000, 
0.1 M Tris pH 8.5, 10% glycerol as the reservoir solution.  
Data collection. A single crystal was flash frozen in liquid nitrogen using reservoir solution 
supplemented with 16% glycerol as cryoprotectant. X-ray diffraction data were collected at 100 K 
using an energy of 13000 eV on the MX1 beamline at the Australian Synchrotron25. 360 frames were 
collected with 1° oscillations.  
Data processing and refinement. Data were integrated using XDS26 and scaled and merged using 
Aimless27. Molecular replacement using phaserMR 28 with 6APW as the search model was used to 
derive initial phases. Two conformations of the compound 7 were visible in initial electron Fo-Fc density 
maps as well as composite omit maps generated later in refinement. Each conformation of ligand 7 
was occupancy refined. Model refinement was performed by iterations of manual rebuilding in Coot29 
and automated refinement using phenix.refine30, where anisotropic B-factor refinement was 
restricted to automatically defined translation-liberation-screw (TLS) groups31. Statistics for the data 
and refinement are reported in Table S1. All structures were deposited in the Protein Databank 
(accession codes 6ORU for SaBPL-6 and 6NDL for SaBPL-7). 
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Pharmacokinetic study of acylsulfamide 6  
Thirty swiss mice, weighing 20-30g, were administered an intravenous bolus dose of acylsulfamide 6 
(16.6 mg/kg, as a dispersion of 5.3 mg/mL in PEG400). Samples of blood (approximately 1 mL) 
collected from the mice while under anaesthesia via cardiac puncture at 2, 5, 10, 15 and 30 min, and 
1, 2, 4, 7 and 24 h after the dose and transferred to heparinised 1.5 mL polypropylene tubes; they 
were stored at -20°C. The next day, the samples were thawed and the concentrations of acylsulfamide 
6 in blood measured by liquid chromatography-mass spectrometry. 
To 10 µL of blood, 10 µL of either acylsulfamide 6 working solution (drug-free blood for the calibration 
standards) or water (unknown samples of blood) was added, followed by 50 μL internal standard 
solution (100 ng/mL a biotin analogue in water) and 50 μL 2.8% (w/v) ZnSO4 solution The mixture was 
vortexed briefly, and 50 μL cold methanol added, vortex-mixed for 10 s and centrifuged at high speed 
for 10 min. Ten µL was injected into the LC-MS system. 
A Shimadzu Nexera HPLC system (Shimazdu Oceania, Rydalmere, NSW) was used to pump the mobile 
phase through a Kinetex column (C18 2.6µm 50 x 3.0 mm; Phenomenex Australia, Lane Cove, NSW) 
at a flow of 0.4 mL/min. Mobile phase A (MPA) was 5% acetonitrile and 0.1% formic acid in water and 
mobile phase B (MPB) was 95% acetonitrile and 0.1% formic acid. The mobile phase was run as a 
gradient using the following timetable: 0.2-5.0 min 0-25% MPB; 5.0-6.0 min 25-100% MPB; 6.0-7.0 
min 100% MPB. Acylsulfamide 6 and the internal standard were detected using a Triple-TOF 5600 
(Sciex, Mt.Waverley, Vic) following the mass transitions m/z 512.2  269.1 (acylsulfamide 6) and 
427.2  227.1 (internal standard). Peak ratios were obtained from known concentrations of 
acylsulfamide 6 and internal standard and were used to construct a seven-point calibration curve 
spanning from 3.5 ng/mL to 3500 ng/mL. Two-compartmental model was fitted over time (Phoenix 
64 WinNonLin 6.4, Certara, Princeton, NJ, USA). 
Stability of acylsulfamide 6 in whole blood 
Acylsulfamide 6 was incubated in drug-free rat blood at concentrations of 1 (low) and 10 (high) µg/mL, 
and samples of blood taken at 0, 15 min and 3 and 24 h. The samples were processed and subjected 
to liquid chromatography-mass spectrometry as described above. 
Stability of acylsulfamide 6 and amino sulfonylurea 7 in whole blood 
Fresh whole rat blood (490 μL) in separate tubes was spiked with 10 μL 0.5 mg/mL of either 
acylsulfamide 6 or amino sulfonylurea 7 (dissolved in methanol/water 50/50). Samples were mixed 
well and incubated at 22 °C for up to 21.5 h. Blood was then extracted for LC/MS by protein 
precipitation (10 μL blood + 100μL 1.4% ZnSO4 + 50μL methanol).  
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Pharmacokinetic study of amino sulfonylurea 7 
Nine, male Balb/C mice weighing 22.7 ± 0.6 g (mean ± SD) were administered a bolus dose of amino 
sulfonylurea 7 (10 mg/kg, 4.5 mg/mL in 10/90 DMSO/ 0.9% sodium chloride) via the tail vein. Three 
samples of blood (two from alternate cheek veins and a final one from cardiac puncture under 
anaesthesia) were collected from each mouse into polypropylene tubes containing 100 U of heparin. 
Collection of the twenty-seven samples were timed so that they were spread from 2 min to 5 h. 
Samples were centrifuged, and plasma harvested for storage at -20°C pending analysis. The 
concentrations of amino sulfonylurea 7 in plasma were measured by LC-MS/MS. Plasma (20 μL drug-
free rat plasma or the unknown samples of plasma plus 10 μL 50/50 methanol/water; 20 μL drug-free 
plasma plus 10 μL calibrator working solution in 50/50 methanol/water; 20 μL drug-free plasma plus 
10 μL quality control working solution in 50/50 methanol/water) were mixed with 10 μL of internal 
standard solution (2 µg/mL of β-ketosulfonamide 9 in 50/50 methanol/water) and then with 20 μL of 
2.8% (w/v) ZnSO4 solution and 100 μL methanol, vortex-mixed for 10 s then centrifuged at high speed 
for 10 min. The supernatant (5 μL) was eluted through a Phenomenex Kinetex column (5 μm C18, 3 x 
50 mm; Phenomenex, Australia, Lane Cove, NSW) under conditions identical to those described for 
acylsulfamide 6. The mass transitions m/z 527.2  312.1 (amino sulfonylurea 7); m/z 511.2   207.1 
(internal standard) were monitored. Peak area ratios of the signal responses of amino sulfonylurea 7 
and internal standard were used to construct a linear calibration curve spanning from 3.5 to 10,000 
ng/mL with a weighting of 1/x, using MultiQuant 3.0.1 software. If the volume of the unknown plasma 
sample was less than 20 µL, the remaining volume was supplemented with drug-free plasma and an 
appropriate correction made. For samples with a measured concentration exceeding 10,000 ng/mL), 
the supernatant was diluted ten-times with drug-plasma supernatant. Quality controls were prepared 
at concentrations of 15,400 and 4,000 ng/mL. Measured concentrations of these controls, including 
the highest diluted ten-times, were within 15% of their nominal values. Two-compartmental model 
was fitted over time (Phoenix 64 WinNonLin 6.4, Certara, Princeton, NJ, USA). 
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Figure S3. (A) Superposition of the time-averaged conformation of deprotonated form of 6 (cyan) 
with the cocrystal structure of 6 bound to SaBPL (magenta) - (RMSD - 0.62 Å). (B) Superposition of 
the time-averaged conformation of protonated form of 6 (orange) with the cocrystal structure of 6 
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Figure S4. (A) Superposition of the time-averaged conformation of deprotonated form of 7 (cyan) 
with the major conformer of 7 bound to SaBPL (green) - (RMSD - 1.02 Å). (B) Superposition of the 
time-averaged conformation of protonated form of 7 (orange) with the major conformer of 7 bound 
to SaBPL (green) - (RMSD - 0.86 Å). (C) Superposition of the time-averaged conformation of 
deprotonated form of 7 (cyan) with the minor conformer of 7 bound to SaBPL (yellow) - (RMSD - 
0.78 Å). (B) Superposition of the time-averaged conformation of protonated form of 7 (orange) with 







Figure S5. Change in the ratio of the peak responses to acylsulfamide 6 to internal standard against 










Figure S6. Peak responses for acylsulfamide 6 (A) and its decomposition product (B) at time 0 (purple 
lines), 3 h (red) and 71 h (green) from the commencement of the incubation of acylsulfamide 6 in rat 






Table S1.  Data collection and refinement statistics (molecular replacement). 
 
 SaBPL + 6 (PDB: 6ORU) SaBPL + 7 (PDB: 6NDL) 
Data collectiona 
MX1 Beamline  
Australian Synchrotron 
MX1 Beamline  
Australian Synchrotron  
Space group P 42212 P42212 
Cell dimensions   
    a, b, c (Å) 92.5, 92.5, 129.0 94.0, 94.0, 131.0 
,, ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Wavelength (Å) 0.95 0.95 
Resolution (Å) 45.93 - 2.392 (2.478 - 2.392)b 46.66 – 2.00 (2.05 – 2.00)b 
Rmerge 0.02762 (0.4816) 0.129 (6.729) 
CC(1/2) 0.997 (0.959) 1.000 (0.204) 
I / I 15.65 (1.49) 16.1 (0.7) 
Completeness (%) 99.94 (99.96) 100.0 (100.0) 
Redundancy 2.0 (2.0) 28.4 (29.5) 
   
Refinement   
Resolution (Å) 45.93 - 2.39 46.66 – 2.00 
No. reflections 22803 40340 
Rwork / Rfree 0.2069/0.2607 (0.3157/0.3536) 0.1693 (0.3650) / 0.2193 (0.3705) 
No. atoms   
    Protein 2610 2622 
    Ligand 34 35 
    Glycerol - 36 
    Water 43 347 
Average B-factors (Å2)   
    Protein 78.80 67.2 
    Ligand 95.80 51.9 
    Glycerol - 101.7 
    Water 58.70 78.7 
RMS deviations   
    Bond lengths (Å) 0.017 0.007 
    Bond angles () 1.56 0.870 
a Diffraction data were collected from one crystal for each structure.  
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HYBRID QM/MM MOLECULAR DYNAMICS SIMULATIONS  
Molecular dynamics simulations were performed for the protein-ligand complexes using the Sander 
algorithm as implemented in Amber 16 package,1 with the ligand molecule treated by the semi-
empirical PM6-DH+ method while the protein (SaBPL) by the Amber ff14SB force fields.  
Structure preparation. Initial geometry for the complex of SaBPL with 6 was taken from the X-ray 
crystallographic data revealed in this study. The complexes with other ligands were constructed by 
modifying the ligand molecule in the SaBPL-6 crystal structure (PDB code: 6ORU), as these ligands are 
structurally analogous to 6. In case of deprotonated 6 and 7, the involved proton was removed. Charge 
and spin multiplicity were manually specified for each ligand and their deprotonated state. The LEaP 
program from Antechamber tools (AmberTools 17) was used to prepare the parameter/topology 
(.top) and input coordinate (.crd) files. The net charge of each protein-ligand complex was neutralized 
by adding Na+ ions at positions of high negative electron potential around the complex. The system 
was immersed in a truncated octahedral box of pre-equilibrated TIP3P water molecules, ensuring that 
no atoms in the protein−ligand complex were closer than 12 Å to any of the sides of the water box. 
The solvent molecules and counter-ions were firstly minimized for 6000 steps (involving 1000 of the 
steepest decent steps and 5000 of conjugate gradient steps) to remove any bad steric contacts with 
the complexes, whereby the protein and ligand were position-restrained using a force constant of 100 
kcal·mol-1·Å-2. This was followed by additional 6000-step energy minimization without any restriction. 
Heating and production phases. MD simulation was carried out for the heating phase, under a 
constant volume periodic boundary condition with an initial temperature of 0 K, allowing to heat up 
to 300 K over 40 ps. The final production simulation was carried out under an NVT ensemble condition. 
The following settings were activated throughout the heating and production phases: The Langevin 
dynamics was used to control the temperature using a collision frequency of 1.0 ps-1 and 0.5 ps 
coupling time constant. The SHAKE algorithm was used to constrain bonds involving hydrogen, 
allowing time step of 2 fs, for a total of 2500000 steps (5 ns). The default particle mesh Ewald (PME) 
method was employed to compute the long range electrostatic interactions using a 1.0 A grid space 
and a fourth-order spline for interpolation. The non-bonded cutoff value was set to 10 Å in the QM 
and MM regions. In the production runs, the MD trajectory was written for every 50 steps, resulting 
in 50000 frames for subsequent time-averaged structures and QM/MM-GBSA analyses.  
Time-averaged structures. Time-averaged structures were calculated from 40000 trajectory frames 
(final 4 ns) of the production phase using the Cptraj program in AmberTools 17, with the water 
molecules and counter-ions stripped. 
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QM/MM-GBSA BINDING FREE ENERGY CALCULATIONS 
The binding free energies of ligands to SaBPL were calculated using MMPBSA.py2 in AmberTools 17. 
For each complex, we calculated the ΔGbind values for the 200 snapshots of the MD trajectory (one 
snapshot for each 20 ps during the last 4 ns of the stable trajectory) and the final ΔGbind value was 
the average of the calculated ΔGbind values for these snapshots. Specifically, the python utility ante-
MMPBSA.py was used to prepare the complex, protein and ligand topology files from the topology 
file of the solvated complex, by setting radii=mbondi2 and stripping water molecules (and counter-
ions). The default MM-GBSA parameters α, β, and γ have the values of 1.0, 0.8, and 4.85 respectively. 
The ligand was treated as the QM region using the semi-empirical PM6-DH+ Hamiltonian theory. As 
only one MD simulation for each complex was performed, this method is less computationally 
demanding and leads to an increase of convergence due to cancellation of errors, conformational 
restraints imposed by the complex geometry, and reduction of noise arising from flexible remote 







The preparation of 6-8 required preparation of the key intermediates 12, 17, 18, and 25 as outlined in 
Schemes S1 – S3. Biotin carbamate 12, required for the preparation of amino sulfonylurea 7, was 
prepared as shown in Scheme S1. In particular, biotin amine 114 was converted into biotin carbamate 
12 on reaction with diphenyl carbonate 
 
Scheme S1. Synthesis of biotin carbamate 12 
Adenine sulfamides 17 and 18 required for the synthesis of alkylsulfamide 8 and acylsulfamide 6 
respectively were prepared as shown in Scheme S2. Adenine was alkylated on reaction with caesium 
carbonate and Boc-protected amino bromide 135 to give Boc-protected adenine amine 14 in 68% yield. 
Treatment with TFA in DCM gave the amine salt 15, which was then reacted with 166 in THF to give 
Boc-protected sulfamide 17. The key starting material 17 could also be prepared via adenine 
phthalimide 20 in a superior overall yield of 13% as shown in Scheme S2. In particular, Adenine was 
reacted with N-(4-bromobutyl)phthalimide 19 in the presence of K2CO3 to give adenine phthalimide 
20 in 84% yield. Treatment with hydrazine in ethanol gave adenine amine 21, which was converted 




into Boc-protected adenine sulfamide 17 on reaction with 166 in DCM. Removal of the Boc protecting 
group from 17, on reaction with 10% TFA in DCM, gave the desired adenine sulfamide 18 as shown.  
Adenine sulfamides 25 required for the synthesis of amino sulfonylurea 7 was prepared as shown in 
Scheme S3. Boc-protected adenine amine 14 was reacted with benzoyl chloride, in the presence of 
pyridine, to give 22. This was then treated with TFA in DCM to give adenine amine salt 23, which was 
reacted with 166 in THF to give sulfamide 24 as per the preparation of 17, see Scheme S2.  Removal 
of the Boc group, on reaction with TFA in DCM, then gave the key benzoyl-protected adenine 
sulfamide 25. 
 
Scheme S3. Synthesis of adenine sulfamide building block 25 
Acylsulfamide 6, amino sulfonylurea 7, and alkylsulfamide 8 were next prepared as outlined in Scheme 
S4. In particular, D-(+)-biotin N-hydroxysuccinimide ester (Biotin-NHS) 267 was reacted with adenine 
sulfamide 18, in the presence of Cs2CO3, to give acylsulfamide 6 in 44% yield. Biotin carbamate 12 was 
coupled to benzoyl-protected adenine sulfamide 25, in the presence of DBU, to give benzoyl-
protected amino sulfonylurea 27, the benzoyl group of which was removed on treatment with NH4OH 
in MeOH to give amino sulfonylurea 7. Biotin bromide 284 was reacted with boc-protected adenine 
sulfamide 17 in the presence of K2CO3 in DMF to give boc-protected alkylsulfamide 29, which was then 
treated with TFA in DCM to give alkylsulfamide 8.  




The final derivatives, β-ketosulfonamide 9 and β-hydroxysulfonamide 10, were prepared as 
summarised in Scheme S5. Biotin ester 308 was coupled to sulphonamide 319 in the presence of LDA 
to give N-boc-β-ketosulfonamide 32. Reaction with TFA in DCM then gave the biotin β-
ketosulfonamide 33, which was alkylated with adenine bromide 34,10 in the presence of Cs2CO3, in 
DMF to give β-ketosulfonamide 9. N-Boc-β-ketosulfonamide 32 was also reduced with NaBH4 to give 
35, the boc group of which was removed on treatment with TFA in DCM to give the biotin β-
hydroxysulfonamide 36. Treatment with 34 in the presence of Cs2CO3 gave β-hydroxysulfonamide 10 
as per the synthesis of β-ketosulfonamide 9.  
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Chapter four   87 
_________________________________________________________________________ 
4.1 Introduction  
As discussed in chapter one, dethiobiotin synthetase (DTBS) is an enzyme responsible for 
catalysing a key step in biotin biosynthesis, the conversion of 7,8-diaminopelargonic acid 
(DAPA) 1.03 to dethiobiotin 1.04. The DTBS active site consists of three distinct pockets: 
the DAPA pocket, phosphate-binding loop (P-loop), and nucleoside pocket. 
Collaborators at the Department of Molecular and Biomedical Science, University of 
Adelaide carried out virtual screening in order to identify potential DTBS inhibitors. In 
particular, twenty-six hits (11 cytidine analogues and 15 ZINC fragments) were predicted 
to have lower binding energy than CTP by in silico screening. Surface plasmon resonance 
(SPR) binding experiments were carried out on the twenty-six virtual hits to identify 4 
cytidine analogues and 7 fragment hits as weak affinity binders. Interestingly, X-ray 
crystallography identified cyclopentylacetic acid 4.01 as a fragment binding to DAPA 
binding sites of MtbDTBS (Figure 4.1). Each of the four possible diastereomers 
(RS/SR/RR/SS) of 4.01 were modelled into the crystal structure to see which most closely 
matched the observed electron density of co-crystal structure of 4.01 with MtbDTBS. RS 
trans isomer exhibited the highest occupancy after refinement (RS: 0.51, SR: 0.13, RR: 
0.32, SS: 0.34) and the most preferable real-space refinement statistics. It was however 
impossible to distinguish the stereochemistry of 4.01 with confidence due to the minimal 
structural differences observed between stereoisomers. 
 
Figure 4.1. Structures of the fragment 4.01 and DAPA carbamate 1.16 binding to 
MtbDTBS. 
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Scheme 4.1. Induced degradation of 4.02 to trans-4.01. Stereochemical configurations are 
relative. 
The trans isomers of 4.01 were prepared by Birgit Gaiser (Department of Chemistry, 
University of Adelaide) as shown in Scheme 4.1. Compound 4.02 was treated with lithium 
hydroxide in THF/H2O at 45C to give trans-4.01. The cis-4.01 was not isolated under 
these basic hydrolysis conditions. Binding affinity and X-ray crystallography experiments 
were then carried out to reveal that trans-4.01 binds predominantly within the DAPA 
binding pocket of MtbDTBS with KD = 3.4 ± 0.4 mM (Figure 4.2). The absolute 
stereochemistry of trans-4.01 could not be definitively identified by crystallography. 
Consequently, the SR and RS compounds were simultaneously modelled into ligand bound 
MtbDTBS. The carboxyl group of trans-4.01 occupies a similar region to the γ-phosphate 
of CTP, forming interactions observed in its structure bound to MtbDTBS, for example 
hydrogen bonding to the side chain of Thr11 (2.36 – 2.71Å), Lys15 (2.96 – 3.45Å), amide 
backbone of Gly111 (3.02 – 3.21Å), and a water molecule. The disubstituted cyclopentane 
Figure 4.2. 3D depiction of racemic trans-4.01 (RS: magenta, SR: cyan) bound to 
MtbDTBS (PDB: 6NMZ) with hydrogen bonds shown in blue dashes (left). 2D interaction 
diagram of trans-4.01 bound to MtbDTBS with interactions shown in dashes (right). 
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ring of trans-4.01 overlaps with the amine terminus of DAPA carbamate 1.16, whilst the 
aromatic ring lies in the hydrophobic tunnel normally home to the alkyl chain of DAPA 
carbamate 1.16. This observation suggests that the DAPA pocket can accommodate larger, 
more complex structures than a simple alkyl chain.  
4.2 Design and synthesis of DAPA pocket binders 
The design of DAPA pocket binders, shown in Figure 4.3 and discussed in this chapter, 
was based on the co-crystal structure of trans-4.01 bound to MtbDTBS. A single RS-
isomer of trans-4.01 in the co-crystal structure was chosen to simplify the analysis. An 
overlay of RS-4.01 with DAPA carbamate 1.16 bound to MtbDTBS indicates that C4 on 
the benzene ring of RS-4.01 superimposes well with C3 of alkyl chain of DAPA carbamate 
1.16 (Figure 4.1 and 4.4). This suggests that appending carboxyl or carboxymethyl groups 
at C4 position on the aromatic ring of RS-4.01 would mimic the interactions made between 
the DAPA carboxyl group and residues Gly144, Leu146 and Asn147 of the adjacent 
MtbDTBS subunit, see structures 4.03 and 4.05. 
 
Figure 4.3. Proposed cyclopentylacetic acid analogues 4.03 – 4.08. Stereochemical 
configuration is relative. 
 
Figure 4.4. Overlay of DAPA carbamate 1.16 (blue)1 and RS-4.01 (magenta) binding to 
MtbDTBS with hydrogen bonds shown in blue dashes. 
Chapter four   90 
_________________________________________________________________________ 
The proposed cyclopentylacetic acid analogues 4.03 – 4.08 were docked with the X-ray 
crystal structure of MtbDTBS in complex with trans-4.01 by ICM software version 3.8-7, 
and results are discussed below in section 4.2.1, in order to predict and visualise the 
binding modes of these analogues. Key features of proposed cyclopentylacetic acid 
analogues 4.03 – 4.08 are summarised below.  
1. None of the proposed compounds (4.03 – 4.08) contains the o-phenol group of RS-4.01. 
This group does not seem to be important for binding to MtbDTBS as no strong 
interaction is found between the residues of the binding pocket and the o-phenol group. 
2. Cyclopentylacetic acids 4.03, 4.05, and 4.07 contain p-carboxyl, p-carboxymethyl, or p-
hydroxyethyl group respectively on the benzene ring. This is to explore potential 
hydrogen bonds between these functional groups and Leu146 and/or Asn147 of the 
binding pocket. An overlay of RS-4.01 and DAPA carbamate 1.16 bound to MtbDTBS, 
as shown in Figure 4.4, suggests introducing these substitution groups to increase the 
binding affinity toward MtbDTBS.  
3. Compounds 4.04, 4.06, and 4.08 lack the ketone functionality of compounds 4.03, 4.05, 
and 4.07. This allows to probe the importance of this group in the DAPA binding site.  
4.2.1 Docking  
Structures 4.03 – 4.08 (RS isomer) and the bound ligand RS-4.01 of the protein MtbDTBS 
were docked using ICM software version 3.8-7 (Molsoft L.L.C., San Diego, CA, USA) in 
order to examine whether appended functional groups at C4 position on the aromatic ring 
of RS-4.01 are able to interact with Gly144, Leu146 and Asn147, and also if appending 
these functional groups alters the entire binding conformation. Proteins for docking were 
retrieved from MtbDTBS in complex with trans-4.01 (PDB: 6NMZ). Formal charges were 
assigned, protonation states of histidines were adjusted, and hydrogens, histidine, 
glutamine, and asparagine were optimized using the protein preparation procedure 
implemented in ICM.2 The original bound ligand trans-4.01 and all water molecules were 
removed from the binding site before docking. The binding site was defined as the cavity 
enclosed by residues with at least one non-hydrogen atom within a 4.0 Å cut-off radius 
from the ligand trans-4.01. The pocket was represented by 0.5 Å grid maps accounting for 
hydrogen bonding, hydrophobic, van der Waals, and electrostatic interactions. All 
molecules were flexibly docked into the rigid binding site and scored based on the ICM 
scoring function. 
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The docking protocol was first validated by removing bound ligand (trans-4.01, Figure 4.2 
left) from its co-crystal structure with MtbDTBS, followed by redocking into the vacated 
enzyme. A low value of root-mean-square deviation of atomic positions (RMSD) is a good 
indicator of appropriate docking accuracy and values below 2 Å are generally considered 
acceptable. The RMSD value of the top-scoring pose in this study was 0.35 Å. As shown 
in Figure 4.5, the predicted binding conformation of RS-4.01 (yellow) superimposes well 
with the obtained ligand from the X-ray crystallography (magenta), suggesting that these 
docking parameters are amenable to docking studies of the proposed cyclopentylacetic acid 
analogues 4.03 – 4.08.  
 
Figure 4.5. A superimposed image of the predicted binding conformation of RS-4.01 
(yellow) with the original bound ligand (magenta). 
Final docked conformations were ranked by ICM scoring function and the conformation 
with the highest ranking was selected to compare and overlay with the original bound 
ligand RS-4.01. The overlayed images for compounds 4.03 – 4.08 (RS isomer) are listed in 
Figure 4.6. All docked structures adopt essentially the same geometrical orientation as was 
observed with the original ligand RS-4.01 bound to MtbDTBS, suggesting that the 
cyclopentylacetic acid analogues 4.03 – 4.08 can bind to DAPA binding pockets. In 
particular, p-carboxyl, p-carboxymethyl, and p-hydroxyethyl on the benzene ring of all 
docked compounds occupied the binding region of carboxylic acid group of DAPA 
carbamate 1.16. This then maximizes binding interactions with Leu146 and/or Asn147. 
Thus, the proposed analogues 4.03 – 4.08 were expected to have more binding interactions 
with MtbDTBS than trans-4.01, suggesting that these proposed analogues may possess 
improved binding affinities over trans-4.01.  
 
















Figure 4.6. Superimposed images of the proposed cyclopentylacetic acid analogues 4.03 – 
4.08 (RS isomer, grey) with the original bound ligand RS-4.01 (magenta). Hydrogen bonds 
are depicted by blue dashes. 
4.2.2 Synthesis of trans-4.01 
The trans-4.01 compounds were prepared from 4.02 as shown in Scheme 4.1. However, 
this synthetic method is not only inefficient, but is also inapplicable to the synthesis of the 
proposed compounds 4.03 - 4.08 since each derivative requires a variant of 4.02 as starting 
materials. An alternative and more widely applicable approach to trans-4.01 was therefore 
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investigated. This new synthetic strategy toward trans-4.01 was based on the retrosynthetic 
analysis outlined in Figure 4.7. Tentatively, the target compound trans-4.01 could be 
obtained from 2-bromoanisole 4.13 and cyclopent-1-enecarbaldehyde 4.14 via an 
organometallic addition reaction to generate the corresponding alcohol 4.12. Subsequent 
conversion of the hydroxyl group to the corresponding ketone, as shown in 4.11, would 
enable introduction of the required malonic acid moiety via Michael addition. Both cis and 
trans isomers could be synthesised to allow separation and isolation of the trans isomer 
(4.10). Dicarboxylic acid 4.10 could further be decarboxylated to the corresponding 
monocarboxylic acid 4.09. Finally, trans-4.01 could be obtained by O-demethylation.  
 
Figure 4.7. Retrosynthetic analysis. Stereochemical configurations are relative. 
Aryl vinyl ketone 4.11 
The synthesis of the key aryl vinyl ketone 4.11 is depicted in Scheme 4.2.  
 
Scheme 4.2. Synthesis of aryl vinyl ketone 4.11.  
Chapter four   94 
_________________________________________________________________________ 
1,2-Cyclohexanediol 4.15 was first treated with sodium periodate, followed by 20% 
aqueous potassium hydroxide, to give cyclopent-1-enecarbaldehyde 4.14 in 48% yield.3 
Treatment of 2-bromoanisole 4.13 with n-BuLi followed by addition of aldehyde 4.14, in 
THF at -78C, gave alcohol 4.12 in 64% yield after purification by flash chromatography. 
Subsequent oxidation of the alcohol 4.12 using Dess-Martin periodinane (DMP) gave 
ketone 4.11 in 74% yield.  
Dicarboxylic acid 4.10 
Dicarboxylic acid 4.10 was synthesised from the unsaturated ketone 4.11, with the 
malonate group introduced by Michael addition followed by basic ester hydrolysis 
(Scheme 4.3).  
 
Scheme 4.3. Synthesis of dicarboxylic acid 4.10. 
 
 
Figure 4.8. 1H proton NMR of the whole Michael adduct 4.16 (black), cis form of 4.16 
(blue), and trans from of 4.16 (red). 
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Unsaturated ketone 4.11 was treated with ethyl malonate in the presence of a catalytic 
amount of sodium ethoxide to give the Michael adduct 4.16 in 87% yield. This sample was 
found to be a mixture of cis and trans isomers based on 1H NMR analysis which revealed 
two singlet methoxy peaks and four triplet malonate CH3 peaks. The mixture was separated 
by silica gel chromatography to give the two isomers of 4.16 which were analysed by 1H 





Figure 4.9. (A) NOESY spectrum of cis-4.16. (B) NOESY spectrum of trans-4.16. 
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The relative stereochemistry of each isomer of 4.16 was determined with the aid of 
NOESY spectroscopy (Figure 4.9). The cis isomer showed a clear correlation between the 
resonances for Ha and Hb on the cyclopentane ring at 4.12 and 2.71 ppm respectively 
(Figure 4.9A). In comparison, the trans isomer showed a correlation between the ketone α-
proton (Ha) and the malonate α-proton (Hc) (Figure 4.9B). Notably, the ketone α-proton 
(Ha) and the malonate α-proton (Hc) of the cis isomer were significantly downfield 
compared to the trans isomer (δHa = 4.12 and 3.79 ppm; δHc = 3.82 and 3.42 ppm for cis 
and trans respectively), see Figure 4.9 and Table 4.1. 











δHa – δHb 
(ppm) 
δHa - δHc 
(ppm) 
δHc – δHb 
(ppm) 
cis-4.16 4.12 2.71 3.82 11.6 1.41 0.30 1.11 
trans-4.16 3.79 3.21 3.42 8.2 0.58 0.37 0.21 
4.10 3.87 3.18 3.51 7.4 0.69 0.36 0.33 
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Separate samples of cis-4.16 and trans-4.16 were hydrolysed with an excess of NaOH to 
give a single common dicarboxylic acid, assigned as 4.10. The relative configuration of Ha 
and Hb of 4.10 was assigned trans on the basis of its 
1H NMR data compared to the 1H 
NMR data of cis-4.16 and trans-4.16 (see Table 4.1). Chemical shifts of Ha and Hb for 4.10 
(3.87 and 3.18 ppm respectively) were similar with the values for trans-4.16 (δHa = 3.79 
and δHb = 3.21) compare to the values for cis-4.16 (δHa = 4.12 and δHb = 2.71). In particular, 
the difference in chemical shifts of Ha and Hb (δHa – δHb) in 4.10 (0.69 ppm) more closely 
resembled a value for trans-4.16 (0.58 ppm) rather than cis-4.16 (1.41 ppm). In addition, 
the observed coupling constant between Hb and Hc (JHbHc = 7.4 Hz) in 4.10 matches well 
with that of trans-4.16 (JHbHc = 8.2 Hz) compared to that of cis-4.16 (JHbHc = 11.6 Hz). 
These results support an assignment of a trans relative configuration of Ha and Hb for 4.10. 
Both cis-4.16 and trans-4.16 give rise to trans-dicarboxylic acid 4.10 under these basic 
hydrolysis conditions, likely due to deprotonation  to the ketone. Dicarboxylic acid 4.10 
did not give the NOE correlations observed for 4.16.  
Monocarboxylic acid 4.09 
Two methods were attempted for the synthesis of monocarboxylic acid 4.09 as summarised 
in Scheme 4.3. Treatment of ketodiester 4.16 with aqueous 6N hydrogen chloride at 90C 
for 2 days gave monocarboxylic acid 4.09 in a modest yield of 29%, with formation of 
dicarboxylic acid 4.10 and carboxylic acid trans-4.01 as by-products (route 1). An 
alternative two-step method (route 2) was thus investigated. The stereoisomer mixture 4.16 
(cis:trans = 1:2.5) was first hydrolysed with sodium hydroxide to give trans-dicarboxylic 
acid 4.10 in 93% yield without flash column purification. The dicarboxylic acid 4.10 was 
then heated in acetic acid to give the monocarboxylic acid 4.09 in 79% yield. 
Decarboxylation in acetic acid at 120C gave O-demethylated trans-4.01 also in an 
isolated yield of 5%. 
 
 
Scheme 4.3. Synthesis of monocarboxylic acid 4.09 and trans-4.01. Stereochemical 
configurations are relative. 
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4.2.3 Synthesis of cyclopentylacetic acid analogues 4.03 – 4.08 
The synthetic method used for the preparation of monocarboxylic acid 4.09 was next 
applied to preparation of cyclopentylacetic acid analogues 4.03 – 4.08. The synthesis of 
benzyl-protected monocarboxylic acid 4.23, a key intermediate for the preparation of 4.03 
– 4.08, is depicted in Scheme 4.4. Hydroxy bromobenzene 4.17 was treated with benzyl 
bromide, in the presence of sodium hydride in DMF, to give O-benzyl protected 
bromobenzene 4.18 in 78% yield. Treatment of bromobenzene 4.18 with n-BuLi followed 
by addition of aldehyde 4.14, in THF at -78C, gave alcohol 4.19 in 77% yield. This 
alcohol was oxidised using Dess-Martin periodinane (DMP) to give ketone 4.20 in 78% 
yield. Treatment of ketone 4.20 with ethyl malonate in the presence of a catalytic amount 
of sodium ethoxide then gave diester 4.21 (cis and trans mixture) in 87% yield. Subsequent 
hydrolysis of diester 4.21, using sodium hydroxide at 80C, gave dicarboxylic acid 4.22 
(trans form) in 91% yield after trituration with hexane. The dicarboxylic acid 4.22 was 
then refluxed in acetic acid to give monocarboxylic acid 4.23 in 78% yield. Alternatively, 
the monocarboxylic acid 4.23 was prepared from 4.22 by decarboxylation using 1,1-
carbonyldiimidazole (CDI) at ambient temperature based on optimised conditions reported 
by Lafrance et al.4 CDI-mediated decarboxylation is milder than decarboxylation by 
heating in acetic acid, but both reactions gave a similar yield of 4.23 (72% vs 78%).  
 
Scheme 4.4. Synthesis of benzyl-protected monocarboxylic acid 4.23. Stereochemical 
configurations are relative. 
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The preparation of cyclopentylacetic acid analogues 4.03 – 4.08 is shown in Scheme 4.5. 
O-Benzyl protected compound 4.23 was reduced to alcohol 4.08 in 89% yield by catalytic 
hydrogenation in the presence of 10% palladium carbon (Pd/C). Subsequent oxidation of 
alcohol 4.08, using pyridinium dichromate (PDC) in DMF, gave carboxyl benzene 4.04, 
formyl benzene 4.24, and carboxymethyl benzene 4.06. Carboxymethyl benzene 4.06 was 
the only expected product under the PDC/DMF oxidation, but compounds 4.24 and 4.04 
were also isolated from this reaction. This suggests that one carbon of the hydroxyethyl 
group in 4.08 is cleaved to produce 4.04 and 4.24 under these reaction conditions. A 
similar observation is reported.5 Exact reasons for this remain unclear, but likely involves 
benzylic oxidation. Selective removal of the O-benzyl protecting group of 4.23 in the 
presence of an aryl ketone moiety was achieved on reaction with ferric chloride in DCM to 
give alcohol 4.07 in 55% yield. Subsequent oxidation of 4.07 using PDC in DMF gave 
formyl benzene 4.25 and carboxyl benzene 4.03 as per the synthesis of 4.04 and 4.24. 
Presumably 4.05 was also produced under these conditions, but the reaction mixture 
proved too complex to isolate 4.05. Oxidation of the alcohol 4.07 using Jones reagent 
however gave carboxymethyl benzene 4.05 in 91% yield.  
 
Scheme 4.5. Synthesis of cyclopentylacetic acid analogues 4.03 – 4.08. Stereochemical 
configurations are relative. 
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4.3 DTBS binding affinity and antimicrobial activity of 
Cyclopentylacetic acid analogues 
Cyclopentylacetic acid analogues 4.03 – 4.10 and 4.22 – 4.25 were assayed against 
MtbDTBS by Surface Plasma Resonance (SPR) and the results are shown in Table 4.2. The 
assay was performed by collaborators at The Department of Molecular and Biomedical 
Science, University of Adelaide.  
Table 4.2. Binding affinities of analogues 4.03 – 4.10, 4.22 – 4.25 and parent compound 
trans-4.01 towards MtbDTBS. Stereochemical configurations are relative. 
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Replacing the phenol group of trans-4.01 with a methoxy group, as in 4.09, did not 
noticeably affect binding affinity (KD = 3.4 ± 1.3 mM), suggesting that the phenol group of 
trans-4.01 does not play an important role in binding to MtbDTBS.  Interestingly, 
compound 4.10, an intermediate in the synthesis of 4.09 with a malonic acid group, 
showed 74-fold improved binding affinity (KD = 46 ± 2 µM) compared to 4.09. The X-ray 
crystal structure of 4.10 bound to MtbDTBS was solved and this is discussed in Section 
4.4. Carboxybenzoyl compound 4.03 (KD = 19 ± 5 µM) and carboxymethylbenzoyl 
compound 4.05 (KD = 17 ± 1 µM) displayed more than 100-fold improved binding 
affinities towards MtbDTBS compared to the parent compound trans-4.01 (KD = 3.4 mM). 
These results support the importance of the interaction site of DAPA carboxyl group in 
MtbDTBS. Compounds lacking the ketone of 4.03 and 4.05, i.e. 4.04 and 4.06, have at 
least a 2-fold decrease in binding affinity toward MtbDTBS with KD = 39 ± 2 and 56 ± 8 
μM respectively, suggesting the importance of this group in the DAPA binding site. 
Alcohol analogues 4.07 and 4.08 and the aldehyde analogues 4.24 and 4.25 were all 
inactive toward MtbDTBS (KD > 1 mM). The limited binding observed for analogues 4.07, 
4.08, 4.24, and 4.25 suggests that introducing alcohol and aldehyde groups at p-position on 
benzene ring provides limited scope for improving binding affinity. O-Benzyl protected 
compounds 4.22 and 4.23 showed limited binding affinities toward MtbDTBS with KD > 
0.25 mM. This likely reflects the large size of the benzyl group or perhaps absence of the 
carboxyl group and associated hydrogen bonds. 
Figure 4.10. Antitubercular activity test of cyclopentylacetic acid analogues 4.03 – 4.06 
and 4.10 against M. tuberculosis strain H37Rv. 
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Selected compounds 4.03 – 4.06 and 4.10 were tested for antimicrobial activity against M. 
tuberculosis and results are shown in Figure 4.10. These studies were performed by a 
collaborator Gayathri Nagalingam (Laboratory of A/Prof Jamie Triccas, Department of 
Infectious Diseases and Immunology, University of Sydney). Growth of M. tuberculosis in 
a biotin depleted media was measured in the presence of a range of compound 
concentrations. None of cyclopentylacetic acid analogues 4.03 – 4.06 or 4.10 inhibited 
growth of M. tuberculosis strain H37Rv at concentrations up to 100 μM. A carboxylic acid 
residue in a compound can cause limited passive diffusion across biological membranes.6-7 
Based on this, it is perhaps not surprising that analogues 4.03 – 4.06 and 4.10 were inactive 
with likely limited permeability through the mycobacterial cell wall. The cell wall of M. 
tuberculosis consists mostly of mycolic acids, strong hydrophobic molecules which are 
thought to be a significant determinant of virulence.8-9 Mycolic acids are also thought to 
play key roles in the low cell permeability of M. tuberculosis by drugs, especially those 
that are hydrophilic. Small and hydrophilic TB drugs including isoniazid, ethambutol and 
pyrazinamide are thought to cross the mycobacterial cell wall through membrane bound 
porin proteins, which exhibit low rates of uptake.8, 10 
It is likely that compounds with higher binding affinity toward MtbDTBS will be required 
to show significant antitubercular activity. Considering the carboxyl group of trans-4.01 
occupies a similar region to the γ-phosphate of CTP, these compounds would likely 
compete with nucleoside triphosphates for binding to MtbDTBS. Since CTP exhibits a 
high binding with KD = 0.16 ± 0.01 µM,
11 CTP would likely outcompete cyclopentylacetic 
acid analogues 4.03 – 4.06 and 4.10 for binding to MtbDTBS. 
4.4 X-ray crystal structure of 4.03 – 4.06 and 4.10 bound to 
MtbDTBS 
Crystal structures of cyclopentylacetic acid analogues 4.03 – 4.06 and 4.10 bound to 
MtbDTBS were solved by collaborators at the Department of Molecular and Biomedical 
Science, University of Adelaide as depicted in Figure 4.11 – 4.13. RS isomers were 
modelled only as the inclusion of both isomers did not correlate with the crystallographic 
data. This manifested in either an occupancy refinement of less than 0.1 or negative peaks 
in the electron density map. 
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Figure 4.11. (A) 3D depiction of compound 4.03 (green) bound to MtbDTBS (PDB: 
6NU6) with hydrogen bonds shown in blue dashes. (B) 2D interaction diagram of 
compound 4.03 bound to MtbDTBS with interactions shown in dashes. (C) An overlay of 
4.03 (green) and 4.05 (magenta) bound to MtbDTBS. (D) An overlay of 4.03 (green) and 
4.04 (yellow) bound to MtbDTBS. (E) An overlay of 4.05 (magenta) and 4.06 (blue) bound 
to MtbDTBS. 
The crystal structure of 4.03 bound to MtbDTBS confirms that its benzoic acid moiety 
forms hydrogen bonds with residues Leu146 and Asn147 of the binding site as observed 
between the carboxyl group of 1.16 and the same residues (Figure 4.11A and B). The same 
interactions are evident within the crystal structures of 4.04 – 4.06 bound to MtbDTBS. 
Compounds 4.03 and 4.05 have similar binding conformations, however the binding pose 
of 4.05 is slightly shifted to accommodate the longer carboxymethyl moiety (Figure 
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of the ketone group of 4.03 and 4.05 does not alter the binding pose (Figure 4.11C and D). 
The ketone group of 4.03 forms a hydrogen bond to a neighbouring water molecule (3.56 
Å) that coordinates with the carboxyl group on cyclopentane ring of the compound (2.03 
Å), as show in Figure 4.12A. The crystal structure of 4.05 bound to MtbDTBS reveals an 
ordered water molecule interacts with the ketone and carboxyl group on cyclopentane ring 
of the compound (2.55 Å and 3.02 Å, respectively) (Figure 4.12B). These water-mediated 
interactions support the improved binding affinities of 4.03 and 4.05 compared to 4.04 and 
4.06 respectively, see Table 4.2.  
     
Figure 4.13. 3D depiction of compound 4.10 (yellow) bound to MtbDTBS (PDB: 6NWG) 
with hydrogen bonds shown in blue dashes (left). 2D interaction diagram of compound 
4.10 bound to MtbDTBS with interactions shown in dashes (right).     
B A 
Figure 4.12. Close up of the ketone group. (A) 3D depiction of 4.03 (green) bound to 
MtbDTBS (PDB: 6NU6). (B) 3D depiction of 4.05 (magenta) bound to MtbDTBS (PDB: 
6NVC). Hydrogen bonds are depicted by blue dashes with distances shown therein. 
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The crystal structure of 4.10 bound to MtbDTBS reveals that 4.10 retains all the hydrogen 
bonds between trans-4.01 and amino acid residues of the binding site, but with hydrogen 
bonding/electrostatic interaction of the additional carboxyl group with the side chains of 
Lys37 and Asn40 (Figure 4.13). These additional interactions support the observed 
improved binding affinity of 4.10 compared to 4.09, see Table 4.2. In particular, Lys37 is 
involved in stabilising the phosphorylated DAPA 1.17, indicating that this additional 
carboxyl group acts as a bioisostere of the phosphoryl group of the reaction intermediate 
1.17 (Figure 4.14).  
 
Figure 4.14. Schematic view of the interactions of the phosphorylated DAPA 1.17 with 
enzymic residues at the active site of E. coli DTBS. 
4.5 Conclusion 
A library of cyclopentylacetic acid analogues 4.03 – 4.10 and 4.22 – 4.25, with varying p-
substitution groups on benzene ring, were synthesised and assayed for binding affinity 
toward MtbDTBS (see Table 4.2). Analogues 4.03 and 4.05, with carboxylic acid group 
attached to the para position of benzene ring, were shown to be potent toward MtbDTBS 
(KD = 19 ± 5 and 17 ± 1 µM respectively). Crystallographic analysis reveals the carboxylic 
acid groups of 4.03 and 4.05 form hydrogen bonds with residues Leu146 and Asn147 in 
the binding site as observed in DAPA carbamate 1.16. Analogues 4.04 and 4.06, which 
lack the ketone functionality of compounds 4.03 and 4.05, were at least 2-fold less potent 
toward MtbDTBS. Attachment of different C4 functional groups (see Figure 4.1 for 
numbering) including hydroxyl (4.07 and 4.08), formyl (4.24 and 4.25), and benzylether 
(4.22 and 4.23) resulted in loss of potency against MtbDTBS (KD > 250 µM).  
Interestingly, analogue 4.10, with two carboxyl groups, was 74-fold more potent than 4.09 
(see Table 4.2). The crystal structure of 4.10 bound to MtbDTBS confirms that this 
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additional carboxyl group forms hydrogen bonds with Lys37 and Asn40 of the enzyme. 
None of cyclopentylacetic acid analogues 4.03 – 4.06 or 4.10 showed antibacterial activity 
against clinically significant strains of M. tuberculosis.  
Future compound development would involve combining the malonate substituent of 4.10 
with the carboxy or carboxymethyl substituents present in 4.03 and 4.05 in order to 
increase affinity for MtDTBS (Figure 4.15A). Replacing the carboxylic acid groups of 4.03 
and 4.05 with bioisosteres such as tetrazole, acylsulfonamide and oxazolidinedione could 
increase binding affinity and permeability through the mycobacterial cell and consequently 
show antituberculosis activity (Figure 4.15B). Acyclic analogues as well as other ring 
systems such as THF and cyclopropane could be investigated given their enhanced 
metabolic stability, solubility and ease of synthesis (Figure 4.15C).  
 




Chapter four   107 
_________________________________________________________________________ 
4.6 References for Chapter Four 
1. Dey, S.; Lane, J. M.; Lee, R. E.; Rubin, E. J.; Sacchettini, J. C., Structural 
Characterization of the Mycobacterium tuberculosis Biotin Biosynthesis Enzymes 
7,8-Diaminopelargonic Acid Synthase and Dethiobiotin Synthetase. Biochemistry 
2010, 49 (31), 6746-6760. 
2. Neves, M. A.; Totrov, M.; Abagyan, R., Docking and scoring with ICM: the 
benchmarking results and strategies for improvement. J Comput Aided Mol Des 
2012, 26 (6), 675-86. 
3. Meyers, M. J.; Arhancet, G. B.; Hockerman, S. L.; Chen, X. Y.; Long, S. A.; 
Mahoney, M. W.; Rico, J. R.; Garland, D. J.; Blinn, J. R.; Collins, J. T.; Yang, S. T.; 
Huang, H. C.; McGee, K. F.; Wendling, J. M.; Dietz, J. D.; Payne, M. A.; Homer, B. 
L.; Heron, M. I.; Reitz, D. B.; Hu, X. A., Discovery of (3S,3aR)-2-(3-Chloro-4-
cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic 
Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) 
Antagonist for Hypertension and Nephropathy. J. Med. Chem. 2010, 53 (16), 5979-
6002. 
4. Lafrance, D.; Bowles, P.; Leeman, K.; Rafka, R., Mild Decarboxylative Activation 
of Malonic Acid Derivatives by 1,1 '-Carbonyldiimidazole. Org. Lett. 2011, 13 (9), 
2322-2325. 
5. Fernandes, R. A.; Kumar, P., PCC-mediated novel oxidation reactions of 
homobenzylic and homoallylic alcohols. Tetrahedron Lett. 2003, 44 (6), 1275-1278. 
6. Ballatore, C.; Huryn, D. M.; Smith, A. B., Carboxylic Acid (Bio)Isosteres in Drug 
Design. Chemmedchem 2013, 8 (3), 385-395. 
7. Lassalas, P.; Gay, B.; Lasfargeas, C.; James, M. J.; Tran, V.; Vijayendran, K. G.; 
Brunden, K. R.; Kozlowski, M. C.; Thomas, C. J.; Smith, A. B.; Huryn, D. M.; 
Ballatore, C., Structure Property Relationships of Carboxylic Acid Isosteres. J. Med. 
Chem. 2016, 59 (7), 3183-3203. 
8. Lambert, P. A., Cellular impermeability and uptake of biocides and antibiotics in 
Gram-positive bacteria and mycobacteria. J. Appl. Microbiol. 2002, 92, 46s-54s. 
Chapter four   108 
_________________________________________________________________________ 
9. Takayama, K.; Wang, C.; Besra, G. S., Pathway to synthesis and processing of 
mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2005, 18 (1), 81-
+. 
10. Masi, M.; Refregiers, M.; Pos, K. M.; Pages, J. M., Mechanisms of envelope 
permeability and antibiotic influx and efflux in Gram-negative bacteria. Nature 
Microbiology 2017, 2 (3). 
11. Thompson, A. P.; Salaemae, W.; Pederick, J. L.; Abell, A. D.; Booker, G. W.; 
Bruning, J. B.; Wegener, K. L.; Polyak, S. W., Mycobacterium tuberculosis 
Dethiobiotin Synthetase Facilitates Nucleoside Triphosphate Promiscuity through 







Chapter five   110 
_________________________________________________________________________ 
5.1 Introduction  
The DTBS active site can be divided into three distinct pockets, particularly the DAPA 
pocket, phosphate-binding loop (P-loop), and nucleoside pocket as discussed in Chapter 1. 
Based on this structural information, Chapter 4 described the design and development of 
cyclopentylacetic acid analogues 4.03 – 4.10 and 4.22 – 4.25 that target the DAPA pocket 
of MtbDTBS. An investigation of the nucleoside pocket is considered here to develop 
potent DTBS inhibitors, where the DAPA pocket alone is too small to allow the 
development of new antibiotics. 
                              
      
Figure 5.1. 3D depiction of 2ʹ-deoxycytidine 5.01 bound to MtbDTBS (PDB: 6NKA) 
(left). 3D depiction of cytidine 5.02 bound to MtbDTBS (PDB: 6CVU)1 (right). 
Commercially available nucleoside analogues including cytidine, guanosine, adenine, 
uridine and cytidine derivatives were subjected to crystallographic screening against 
MtbDTBS. Of those tested, 2ʹ-deoxycytidine 5.01 and cytidine 5.02 were found to bind the 
nucleoside binding site of MtbDTBS (Figure 5.1). Compound 5.01 lacks the 2ʹ hydroxyl 
group of the ribose ring of cytidine 5.02. The nucleoside binding site of MtbDTBS thus 
appears able to accommodate substituents at the 2ʹ position of ribose ring as depicted in 
Figure 5.1. The cytosine NH2 of 5.01 forms hydrogen bonds with the backbone carbonyl 
groups of Pro197 and Gly169, while the cytosine N3 of 5.01 forms hydrogen bonds with 
the backbone amide nitrogen of Ala200. The same hydrogen bonding interactions are 
apparent in the crystal structures of 5.02 bound to MtbDTBS as shown in Figure 5.1. 
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Hydrophobic interactions are also apparent between cytosine C4 and C5 of both 5.01 and 
5.02, and the side chain of Val17. The 2ʹ position of the ribose ring of 5.01 and 5.02 are 
proximal to the hydrophobic sidechains of Ala201 and Val17 in the binding site, 
suggesting 5.01 would be a better binder than 5.02, which contains 2ʹ OH of ribose ring. 
The binding affinities of 2ʹ-deoxycytidine 5.01 and cytidine 5.02 against MtbDTBS were 
determined by Surface Plasma Resonance (SPR) to be KD > 1 mM, too weak to probe the 
effect of the 2ʹ position of ribose ring on binding. However, 2ʹ-deoxycytidine diphosphate 
(dCDP; KD = 120 nM) bound to MtbDTBS approximately 3-fold tighter than CDP (KD = 
450 nM)1, while 2ʹ-deoxycytidine triphosphate (dCTP; KD = 47 nM) bound with 
approximately 3-fold higher affinity than CTP (KD = 160 nM)
1 (Table 5.1). Binding 
kinetics values including association (ka) and dissociation (kd) constants for CTP, CDP, 
dCDP and dCTP demonstrate that the 2ʹ hydroxy group of ribose ring leads to a slower 
association and faster dissociation. In addition, X-ray crystallographic analysis revealed 
binding modes of dCDP and dCTP are identical to binding poses of CDP and CTP 
respectively (Figure 5.2). These results support the notion that 2ʹ-deoxycytidine 5.01 would 
be a better binder for the nucleoside binding site than cytidine 5.02.  
Table 5.1. Affinity (KD), association (ka), and dissociation (kd) constants determined by 
SPR binding assay. 
substrate structure KD ka kd 
(nM) (105 M-1s-1) (10-2 s-1) 
CDP 
 
450 ± 50 3.4 ± 0.3 15.0 ± 0.8 
dCDP 
 
120 ± 30 12 ± 4 12 ± 3 
CTP 
 
160 ± 10 3.2 ± 0.3 5.3 ± 0.4 
dCTP 
 
47 7.13 ± 0.05 3.41 ± 0.02 




           
Figure 5.2. Overlays of the binding poses of CDP (green sticks) and dCDP (orange sticks) 
(left), as well as CTP (blue sticks) and dCTP (black sticks) (right).  
Having identified optimised ligands for the nucleoside and DAPA binding pockets, 
compound development efforts turned to the synthesis of linker functionalised derivatives 
(Figure 5.3). Such a strategy involves linking the DAPA pocket binders with 2-
deoxycytidine 5.01 to allow the linked compounds to have enhanced binding affinities 
compared to parent fragments as discussed further below. 
 
Figure 5.3. Linking DAPA pocket binders to 2-deoxycytidine 5.01. 
5.2 Design and synthesis of linked compounds 
The design of linked compounds, shown in Figure 5.4 and discussed in this chapter, was 
based on an overlay of crystal structures of trans-4.01 and 2ʹ-deoxycytidine 5.01 bound to 
MtbDTBS (Figure 5.5). These two compounds appear to bind to distinct parts of the active 
site. Cyclopentylacetic acid trans-4.01 binds in the DAPA binding pocket, while 2ʹ-
deoxycytidine 5.01 binds in nucleoside binding pocket. Sulfate ions from the 
crystallisation buffer were also observed in the crystal structure to bind in P-loop, where 
the β-phosphate of CTP binds. 




Figure 5.4. Proposed linked compounds 5.03 – 5.05.  represents relative stereochemical 
configurations. 
 
Figure 5.5. Overlay of trans-4.01 (RS: magenta, SR: cyan), 2ʹ-deoxycytidine 5.01 (green), 
and sulfate ions (yellow) binding to MtbDTBS. 
Key features of proposed linked compounds 5.03 – 5.05 are summarised below. 
1. Compound 5.03 contains a 1,2,3-triazole linker to link two fragments of trans-4.01 
and 2ʹ-deoxycytidine 5.01, providing a simple robust method of linking the two 
fragments on binding toward MtbDTBS. The triazole linker offers advantages of 
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reliable and efficient formation through copper(I)-catalysed azide alkyne cycloaddition 
(CuAAC) as depicted in Figure 5.6.2 CuAAC allows linking of a range of azides and 
alkynes in a facile, selective and high yielding manner that is compatible with a 
variety of functional groups.2 Here we establish the 1,4-triazole as a viable linker 
between cyclopentylacetic acid analogues and cytidine analogues, with potential to 
undertake a fragment-based approach in developing DTBS inhibitors. 
 
Figure 5.6. Routes to 1,4-triazole (CuAAC) from alkyne and azide. 
2. Compounds 5.04 and 5.05 contain aspartic acid and glutamic acid respectively, which 
provide additional carboxyl groups for further potential electrostatic interactions 
within P-loop of MtbDTBS (Figure 5.7). These compounds also allow an investigation 
of linker length between the key components (cyclopentylacetic acid analogues and 
cytidine analogues); the glutamic acid-based linker has one additional methylene 
group in its side chain compared to the aspartic acid linker. 
 
Figure 5.7. Proposed binding poses of 5.04 and 5.05. 
5.2.1 Cytidine building blocks for the synthesis of 5.03 – 5.05  
The synthesis of triazole 5.03 utilises alkyne 5.06/5.07 and azide 5.08/5.09 and involves 
CuAAC reaction as shown in Scheme 5.1A. The proposed synthesis of amino acid linked 
compounds 5.04 and 5.05 involves attachment of the linker moiety to cytidine amine 5.10 
with subsequent coupling with 4.06 as outlined in Scheme 5.1B.  
 
 






Scheme 5.1. Proposed synthesis of 5.03 – 5.05.  represents relative stereochemical 
configurations. 
Cytidine azides 5.08 and 5.09 
2-Deoxycytidine azide analogues 5.08 and 5.09 were prepared as shown in Scheme 5.2. 2-
Chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) was first reacted with N-methylmorpholine 
(NMM) to generate 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
in situ (Scheme 5.3).3 This was followed by the addition of benzoic acid to generate a 
reactive ester (Scheme 5.3) that was further treated with 2-deoxycytidine 5.01 to give N-
benzoylated-2-deoxycytidine 5.11 in 71% yield. This benzoylation strategy does not 
require temporary protection of free hydroxyl groups that is required in conventional two 
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step procedures.4 Treatment with triphenylphosphine, carbon tetrabromide, and sodium 
azide gave 5-azido-2,5-dideoxy-N4-benzoylcytidine azide 5.08 through an Appel 
reaction5 and in situ conversion of bromide into azide.6 5-Azido-2,5-dideoxycytidine 
5.09 required for the synthesis of triazole linked compound 5.03 was also prepared from 
2-deoxycytidine 5.01 as shown in Scheme 5.2. 2-Deoxycytidine 5.01 was reacted with 
tosyl chloride in pyridine to give tosylated-2-deoxycytidine 5.12 in 40% yield. Treatment 
with sodium azide in DMF gave 5-azido-2,5-dideoxycytidine 5.09 in 73% yield. 
 
Scheme 5.2. Synthesis of cytidine azide 5.08 and 5.09. 
 
Scheme 5.3. In situ generation of active ester of CDMT. The scheme is adapted from Rode 
et al.3 
5-Amino-2,5-dideoxy-N4-benzoylcytidine 5.10 
The preparation of 2-deoxycytidine amine 5.10 was attempted using two different 
conditions as listed in Table 5.2. Hydrogenation of 2-deoxycytidine azide 5.08 with 
palladium on carbon was initially attempted to give 5.10. However, desired amine 5.10 
was not isolated under this condition (Table 5.2, entry 1), rather it gave a complex reaction 
mixture. Alternatively, the Staudinger reaction7, which is a very mild azide reduction, was 
examined. The 2-deoxycytidine azide 5.08 was treated with triphenylphosphine and water 
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in pyridine and the crude product was purified by flash column chromatography to give the 
desired reduced product 5.10 in 43% yield (Table 5.2, entry 2). 
Table 5.2. Synthesis of 2-deoxycytidine amine 5.10. 
 
Entry Regent Solvent Time Yield (%) 
1 10% Pd/C, H2 MeOH/DMF (1:1) 2 h 0
a 
2 Ph3P, H2O pyridine 6 h 43
b 
 
a unidentified complex mixture; b isolated yield after flash chromatogaphy. 
5.2.2 Synthesis of triazole linked compound 5.03 
The synthesis of triazole linked compound 5.03 was accomplished as outlined in Scheme 
5.4. Carboxylic acid 4.09 was first reacted with propargyl amine, in the presence of HATU 
and DIPEA, to give alkyne 5.07 in 90% yield. Treatment with azide 5.08, in the presence 
Scheme 5.4. Synthesis of triazole linked compound 5.03.  represents relative 
stereochemical configurations. 
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of 20 mol% copper nano powder, gave triazole 5.13 in 74% yield through a CuAAC 
reaction. The benzoyl protecting group of 5.13 was removed on treatment with ammonium 
hydroxide to give triazole linked compound 5.14 in 85% yield. Treatment with anhydrous 
aluminium chloride in DCM gave a crude mixture of O-demethylated compound 5.03 and 
the starting material 5.14 as confirmed by 1H NMR which revealed a small singlet 
methoxy peak of 5.14 at δ 3.87. However, 5.14 could not be separated from 5.03 by normal 
phase flash chromatography. Thus trans-4.01 was first converted to alkyne 5.06 according 
to the procedure described for the synthesis of compound 5.07. Alkyne 5.06 was then 
reacted with 5.09 through a CuAAC reaction described above using copper nano powder to 
give triazole linked compound 5.03 in 53% yield after purification by flash 
chromatography. These results suggest that protection of cytosine amine group is not 
necessary for the synthesis of triazole linked compounds using a CuAAC reaction. 
5.2.3 Synthesis of amino acid linked compound 5.05 
The preparation of cytidine aspartate 5.18 required for the synthesis of linked compound 
5.04 was attempted as shown in Scheme 5.5. An initial sequence involving reaction of 
cytidine amine 5.10 with Z-Asp-OMe, HATU, and DIPEA in DMF failed to give cytidine 
Scheme 5.5. Attempted synthesis of cytidine aspartate 5.18.  represents relative 
stereochemical configurations.  
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aspartate 5.16, with only cytidine aspartimide 5.15 being isolated in 90% yield. Formation 
of aspartimides by intramolecular cyclization is known to be a severe side reaction in the 
chemical synthesis of aspartic acid containing peptides.8-9 The addition of 
hydroxybenzotriazole (HOBt) is reported to suppress aspartimide formation, where 
intramolecular cyclization is much more facile under basic conditions.10 As expected, 
reaction of cytidine amine 5.10 with Z-Asp-OMe in the presence of EDC and HOBt gave 
cytidine aspartate 5.16 in 81% yield. However, subsequent treatment of 5.16 with 10% 
Pd/C in MeOH in an attempt to prepare 5.18 resulted in a complex mixture, with only Cbz-
deprotected aspartimide 5.17 being isolated in 22% yield after flash chromatography. The 
synthesis of cytidine aspartate 5.18 and the subsequent linked compound 5.04 was 
therefore not examined further.  
Rozners and Xu11 reported a selective oxidation of a primary alcohol in the presence of a 
secondary alcohol and a sensitive uracil residue using (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (TEMPO). Based on this observation, we next attempted to synthesise linked 
compound 5.05. Access to the glutamate linked compound 5.05 required the conversion of 
the primary alcohol functionality of 5.21 to the carboxylic acid of 5.22 (Scheme 5.6). The 
cytidine amine 5.10 was treated with Boc-Glu-OBzl, EDC, and HOBt in DMF to give 
Scheme 5.6. Attempted synthesis of 5.22 as a precursor of linked compound 5.05.  
represents relative stereochemical configurations. 
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cytidine glutamate 5.19 in 92% yield. Deprotection of the Boc group of 5.19 was achieved 
on treatment with 1N aqueous HCl to give 5.20, which was directly used in the next step 
without further purification, see Scheme 5.6. Amine 5.20 was reacted with carboxylic acid 
4.07 in the presence of EDC, HOBT and TEA in DMF to give alcohol 5.21 in 82% yield. 
Carboxylic acid 4.07 was used in this step since use of the dicarboxylic acid 4.05 would 
present problems with regioselectivity. The alcohol 5.21 was then treated with 
bis(acetoxy)iodobenzene (BAIB) and catalytic TEMPO in 1:1 MeCN/H2O using the 
protocol of Rozners and Xu11 in an attempt to prepare 5.22. However, only starting 
material was recovered under these conditions, without evidence for the formation of the 
desired product 5.22.  
Given the limited success in the selective oxidation of the primary alcohol of 5.21, an 
alternative synthetic route to the glutamate linked compound 5.05 was devised. This 
approach involved protection of the secondary alcohol of 5.19 to give acetate 5.23 with 
subsequent coupling with 4.07, as shown in Scheme 5.7. The secondary alcohol 5.19 was 
thus treated with acetic anhydride, TEA, and DMAP in MeCN to give acetate 5.23 in 97% 
yield. Deprotection of the Boc group with TFA in DCM gave the aminium salt 5.24, which 
was coupled with carboxylic acid 4.07, in the presence of EDC, HOBT, and TEA, in DMF 
to give the linked alcohol 5.25 in 65% yield. The alcohol 5.25 was treated with Jones 
Scheme 5.7. Synthesis of linked compound 5.05.  represents relative stereochemical 
configurations. 
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reagent12 to give the corresponding carboxylic acid 5.26 in 67% yield. Finally, treatment 
with lithium hydroxide in 3:1:1 THF/MeOH/H2O gave the desired linked compound 5.05 
in 32% yield after purification by reverse phase flash chromatography. Interestingly, all 
protecting groups of 5.26 including benzoyl, benzyl, and acetyl groups were removed 
under these conditions.  
5.3 DTBS binding assay results 
Compounds 5.03 and 5.05 were assayed against MtbDTBS by collaborators at the 
Department of Molecular and Biomedical Science, University of Adelaide, using Surface 
Plasma Resonance (SPR) analysis. The results are summarised in Table 5.3. 
Table 5.3. SPR determined binding affinity of linked compounds 5.03 and 5.05 towards 
MtbDTBS.  represents relative stereochemical configurations. 
Compound KD (mM) 
 
5.03 
0.6 ± 0.2 
 
5.05 
0.7 ± 0.2 
Linked compound 5.03, the direct triazole linked analogue of trans-4.01 and 2-
deoxycytidine 5.01, showed enhanced binding affinity toward MtbDTBS (KD = 0.6 ± 0.2 
mM) compared to the original substituents trans-4.01 (KD = 3.4 mM) and 5.01 (KD = >1 
mM). However, the calculated KD value (0.6 ± 0.2 mM) was beyond the range of 
concentrations used in the assay due to the limited solubility of linked compound 5.03 
(Figure 5.8). Therefore, the KD value of 5.03 could be subject to larger error than indicated. 
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Figure 5.8. SPR sensorgram (left) and concentration vs response plot (right) of 5.03 and 
5.05. 
Linked compound 5.05 (KD = 0.7 ± 0.2 mM) demonstrated a similar level of binding 
affinity toward MtbDTBS as 5.03 (KD = 0.6 ± 0.2 mM). Interestingly, the binding affinity 
of 5.05 was approximately 40-fold weaker than 4-carboxymethylbenzoyl compound 4.05 
(KD = 17 ± 1 µM). Linked compound 5.05 was expected to have a higher binding affinity 
toward MtbDTBS than triazole linked compound 5.03 due to the inclusion of both the 
glutamate linker and 4.05 moiety, which exhibit the highest affinity for MtbDTBS 
amongst cyclopentylacetic acid analogues discussed in Chapter 4 (Figure 5.9). A carboxyl 
group of glutamate linker was expected to bind to the P-loop in the binding site. The low 
binding affinity of 5.05 suggests that the glutamate linker may not interact with the P-loop, 
possibly due to its flexibility. Excessive conformational flexibility would increase the 
entropic penalty of binding.13 Indeed, the glutamate linker moiety of 5.05 possesses 
multiple rotatable bonds, affording it more conformational flexibility than the triazole 





KD = 3400 ± 400 µM KD = 17 ± 1 µM 
Figure 5.9. Comparison of trans-4.01 and 4.05. Stereochemical configurations are relative. 
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5.4 X-ray crystal structure of 5.03 and 5.05 bound to DTBS 
The structures of linked compounds 5.03 and 5.05 bound to MtbDTBS were solved by 
collaborators at the Department of Molecular and Biomedical Science, University of 
Adelaide as depicted in Figure 5.10 and 5.11. One stereoisomer was modelled only as the 
inclusion of both stereoisomers did not correlate with the crystallographic data.  
 A  
 
        B                                                                        C 
                     
Figure 5.10. The binding mode of linked compound 5.03 to MtbDTBS. (A) 5.03 (green) 
binds to the MtbDTBS active site above a sulfate ion (yellow) that is bound to the P-loop. 
(B) The cyclopentylacetic acid moiety of 5.03 (green) exhibits conformational differences 
from RS-4.01 binding pose (magenta). (C) The 2-deoxycytidine moiety of 5.03 (green) 
overlays well with 2-deoxycytidine 5.01 (blue). 
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The X-ray crystal structure of 5.03 bound to MtbDTBS is shown in Figure 5.10. The 
triazole linker moiety is not bound to the P-loop, but is rather located away from the 
protein surface, around a sulfate ion bound at this position (Figure 5.10A). The 
conformation of cyclopentylacetic acid moiety of 5.03 slightly differs from RS-4.01 
binding conformation (Figure 5.10B), whilst the 2-deoxycytidine moiety of 5.03 binds in 
the same pose as 5.01 (Figure 5.10C). The conformational difference of cyclopentylacetic 
acid moiety is presumably due to the conversion of the carboxyl group of 4.01 to the amide 
group of 5.03, abrogating several interactions with the enzyme to accommodate the linker 
Figure 5.11. The binding mode of linked compound 5.05 to MtbDTBS. (A) 5.05 exhibits 
a binding conformation adjacent to the crystallographic precipitant, citrate (yellow). (B) 
The cyclopentylacetic acid moiety of 5.05 (green) exhibits conformational differences from 
the original RS-4.05 binding pose (megenta). (C) The 2-deoxycytidine moiety of 5.05 
(green) overlays well with 2-deoxycytidine 5.01 (blue).  
A 
B C 
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moiety. The carboxyl group of trans-4.01 forms hydrogen bonds with residues Thr11, 
Lys15 and Gly111 in the active site, whereas the amide carbonyl group of 5.03 does not 
interact with these amino acid residues. Crystallography results propose that the triazole 
linker moiety does not favourably interact with the P-loop. 
The X-ray crystallographic structure of linked compound 5.05 reveals a similar binding 
pose to 5.03 as discussed above. The cyclopentylacetic acid and 2-deoxycytidine moieties 
bind to the DAPA and nucleoside pockets respectively, but with the linker moiety bound 
adjacent to the crystallographic precipitant, citrate (Figure 5.11). The linker likely has 
multiple disordered conformations as the observed electron density for the glutamate linker 
is weaker than that for the cyclopentylacetic acid and 2-deoxycytidine moieties (Figure 
5.12). The combined binding affinity and X-ray crystallographic data demonstrates that the 
use of a glutamic acid to link fragments 4.05 and 5.01 does not enhance binding over 
triazole linked compound 5.03. Considering that linkers of 5.03 and 5.05 are located 
around the crystallographic precipitant (sulfate or citrate) instead of binding to the P-loop, 
the linker moiety requires further optimisation in order to encourage interactions with the 
P-loop in the binding site. 
 
Figure 5.12. Electron density for 5.05 is strong (grey mesh) for cyclopentylacetic acid and 
2-deoxycytidine moieties but weak (cyan mesh) for the glutamate linker moiety. 
5.5 Conclusion 
The linked compound 5.03 was successfully synthesised by a CuAAC reaction of 5.06 
with 5.09 (see Scheme 5.4) and assayed for binding affinity toward MtbDTBS. Triazole 
linked compound 5.03 (KD = 0.6 ± 0.2 mM), the direct triazole linked analogue of trans-
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4.01 and 5.01, was more potent than the original substituents trans-4.01 (KD = 3.4 mM) 
and 5.01 (KD > 1 mM). X-ray crystallography of 5.03 bound to MtbDTBS reveals that the 
cyclopentylacetic acid and cytidine moieties of 5.03 bind to DAPA and nucleoside pockets 
respectively as per trans-4.01 and 5.01. The triazole linker moiety does not bind to the P-
loop of the enzyme, with a sulfate ion occupying this site.  
The linked compound 5.05 was synthesised by attachment of glutamate to cytidine amine 
5.10 with subsequent coupling with 4.07 (see Scheme 5.6 and 5.7) and assayed against 
MtbDTBS. The binding affinity of 5.05 (KD = 0.7 ± 0.2 mM) was similar to that of 5.03 
(KD = 0.6 ± 0.2 mM). Compound 5.05, the direct glutamate linked analogue of 4.05 and 
5.01, was approximately 40-fold less potent than the original substituent 4.05, suggesting 
the use of a glutamic acid as a linker moiety does not enhance binding over 4.05. The 
crystal structure of 5.05 bound to MtbDTBS was determined to reveal that the 
cyclopentylacetic acid and cytidine moieties adopted poses similar to those previously 
observed for 4.03 and 5.01. The glutamate linker moiety is not bound the P-loop, but rather 
located adjacent to a citrate ion at this position as per the triazole moiety of 5.03.  
Future work toward more potent linked MtbDTBS inhibitors would require optimising the 
linker moiety between cyclopentylacetic acid 4.05 and 2-deoxycytidine 5.01. A carboxyl 
group of 4.05 forms hydrogen bonds with residues Thr11, Lys15 and Gly111 of MtbDTBS, 
while the amide carbonyl group of 5.05 does not form a hydrogen bond with the enzyme. 
Thus, acidic moieties (e.g. acylsulfamide), with a low pKa value as per the carboxyl group 
of 4.05, could be considered to link the fragments 4.05 and 5.01 (Figure 5.13). Given that 
sulfate and citrate ions are known to bind the P-loop of the enzyme, analogues of sulfate or 
citrate also should be investigated as a linker moiety. 
 
Figure 5.13. Future compound development of linked MtbDTBS inhibitors. 
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6.1 General methods 
All reagents were obtained from commercial sources and are of reagent grade or as specified. 
Solvents were also obtained from commercial sources, except for anhydrous THF, 
anhydrous DCM and anhydrous DMF which were dried over solvent purifier (PS-Micro, 
Innovative Technology, USA). Reactions were monitored by TLC using precoated plates 
(silica gel 60 F254, 250 μm, Merck, Darmstadt, Germany), spots were visualised under 
ultraviolet light at 254 nm and with either sulphuric acid-vanillin spray, potassium 
permanganate dip or Hanessian’s stain. Flash column chromatography was performed with 
silica gel (40-63 μm 60 Å, Davisil, Grace, Germany). Preparative TLC was carried out on 
20 x 20 cm plates coated with silica gel 60 F254 and having a 2 mm thickness which were 
purchased from Analtech, Inc. Microwave reactions were performed on a CEM Discovery 
SP with external IR temperature monitoring. Reactions were stirred for 5 min in a sealed 
container at ambient temperature, followed by 5 min stirring with increased microwave 
power until the prescribed temperature was reached. Both power and pressure were kept 
variable.  1H, 13C and 19F NMR spectra were recorded on a Varian Inova 500 MHz or a 
Varian Inova 600 MHz. Chemical shifts are given in ppm (δ) relative to the residue signals, 
which in the case of DMSO-d6 were 2.50 ppm for 
1H and 39.55 ppm for 13C, CDCl3 were 
7.26 ppm for 1H and 77.23 ppm for 13C and D2O was 4.79 for 
1H. Structural assignment was 
confirmed with COSY, NOESY, HSQC and HMBC. High-resolution mass spectra (HRMS) 
were recorded on an Agilent 6230 time of flight (TOF) liquid chromatography mass spectra 
(LC/MS) ( < 5 ppm). Infrared mass spectra were recorded on PerkinElmer Spectrum 100 
FTIR with a Universal Zinc Selenide crystal ATR attachment. 
6.2 Experimental work as described in Chapter 2 
General Procedure for CuAAC  
Copper nano powder (40 mol %) was added to a stirring suspension of biotin acetylene 81 
(1.0 equiv) and corresponding azide (1.5 equiv) in CH3CN:H2O (2:1) (1 mL per 60 mg of 
8). The reaction was sonicated for 15 min and stirred at ambient temperature for 17 hours. 
The reaction mixture was then concentrated under reduced pressure and the residue purified 
by column chromatography on silica gel. See individual experiments for details. 
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General Procedure for Synthesis of 5-Iodo-1,2,3-triazoles 
To a solution of 1-iodoalkyne 10 (1.0 equiv) and corresponding azide (1.0 - 1.2 equiv) in dry 
DMF (1 ml per 10 mg of 1-iodoalkyne) was added CuI (0.05 equiv) and TEA (2.0 equiv) 
and the mixture was stirred at ambient temperature for 1 day. The mixture was quenched 
with 10% NH4OH and extracted with DCM twice. The combined organics were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue 
was purified by column chromatography on silica gel. See individual experiments for details. 
General Procedure for Halogen Exchange of 5-Iodo-1,2,3-triazole 
To a round-bottomed microwave vial was added 5-iodo-1,2,3-triazole (1.0 equiv) and 
potassium halide (5.0 equiv). The solids were washed off of the side with acetonitrile (1 ml 
per 50 mg of triazole) and then deionised water (1 ml per 50 mg of triazole). The vial was 
placed into the microwave reactor set at a pressure of 200 psi and heated at 180 C for 5-10 
min based on 1H NMR. After the vial was cooled to ambient temperature, the mixture was 
diluted with EtOAc and the organic layer was extracted with a Pasture pipette. The resulting 
aqueous layer was extracted three additional times and the combined organics were dried 
over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel. See individual experiments for details. 
General Procedure for Synthesis of Benzyl Azides 
A solution of the benzyl halide (1.0 equiv) and sodium azide (1.3 equiv) in DMF (1 mL per 
50mg of benzyl halide) was stirred at ambient temperature for 5 hours. The reaction mixture 
was diluted with ether and wash with water three times. The organic layer was dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. See individual 
experiments for details. 
General Procedure for Hydrolysis of Ester 
To a mixture of ester (1.0 equiv) in THF:MeOH:H2O (3:1:1) (1 mL per 10 mg of ester) was 
added LiOH (2.2 equiv) and the mixture was stirred for 17 hours. The resulting mixture was 
acidified with 1 M HCl to pH = 4. The mixture was diluted with DCM:MeOH (9:1) and 
washed with 0.5M HCl, water, and brine. The organic layer was dried over anhydrous 
sodium sulfate and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel. See individual experiments for details. 
 
 




To a solution of biotin acetylene 81 (100 mg, 0.42 mmol) in dry DMF (5 ml) was added CuI 
(5 mg, 0.08 mmol) and N-iodomorpholine (286 mg, 0.84 mmol). The reaction mixture was 
stirred at ambient temperature. After full conversion (>99%) was achieved in 1 hour as 
judged by 1H NMR, the reaction mixture was filtered through a pad of neutral aluminium 
oxide, washed with 10% MeOH in DCM (3 x 20 ml) and dried in vacuo to give 10 as a pale 




The iodo-acetylene 10 (20 mg, 0.06 mmol) and azide 91 (14 mg, 0.06 mmol) was reacted 
according to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by 
flash chromatography on silica eluting with 5% MeOH in DCM to give a yellowish solid 
(12 mg, 36%).  1H NMR (500 MHz; CDCl3) δ 7.08 (d, J = 8.1 Hz, 1H), 6.90 - 6.92 (m, 1H), 
6.78 (m, 1H), 5.08 (br s, 1H), 4.86 (br s, 1H), 4.50 - 4.53 (m, 1H), 4.42 (t, J = 6.9 Hz, 2H), 
4.30 - 4.33 (m, 1H), 3.84 (t, J = 6.9 Hz, 2H), 3.14 - 3.19 (m, 1H), 2.93 (dd, J = 5.0, 12.8 Hz, 
1H), 2.74 (d, J = 12.8 Hz, 1H), 2.64 (d, J = 7.5 Hz, 2H), 2.40 (s, 3H), 1.97 - 2.02 (m, 2H), 
1.79 - 1.84 (m, 2H), 1.64 - 1.72 (m, 4H), 1.38 - 1.49 (m, 4H); 13C NMR (125 MHz; CDCl3) 
δ 162.8, 154.9, 151.8, 140.7, 134.0, 130.8, 122.9, 109.7, 108.8, 61.9, 60.1, 55.5, 49.7, 41.3, 
40.6, 28.9, 28.6, 28.6, 28.4, 26.6, 25.8, 24.5, 21.5; HRMS calcd. for [M + H]+ C24H32IN6O3S, 
requires 611.1301, found 611.1298. 
3-(4-(5-fluoro-4-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl)pentyl)-
1H-1,2,3-triazol-1-yl)butyl)-5-methylbenzo[d]oxazol-2(3H)-one (4c)   
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The 5-iodo-triazole 4b (15 mg, 0.03 mmol) was reacted with potassium fluoride (7 mg, 0.12 
mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole for 10 
min and was purified by flash chromatography on silica eluting with 5% MeOH in DCM to 
yield 5-fluoro-triazole as an off white solid (11 mg, 89%). 1H NMR (500 MHz; CDCl3) δ 
7.08 (d, J = 8.1 Hz, 1H), 6.90-6.92 (m, 1H), 6.76 - 6.77 (m, 1H), 5.06 (br s, 1H), 4.82 (br s, 
1H), 4.49 - 4.52 (m, 1H), 4.30 - 4.33 (m, 1H), 4.27 (t, J = 6.9 Hz, 2H), 3.85 (t, J = 6.9 Hz, 
2H), 3.14 - 3.17 (m, 1H), 2.92 (dd, J = 5.0, 12.8 Hz, 1H), 2.73 (d, J = 12.8 Hz, 1H), 2.62 (d, 
J = 7.5 Hz, 2H), 2.40 (s, 3H), 1.96 - 2.02 (m, 2H), 1.79 - 1.85 (m, 2H), 1.63 - 1.70 (m, 4H), 
1.37 - 1.48 (m, 4H); 13C NMR (125 MHz; CDCl3) δ 162.8, 154.9, 140.7, 134.0, 130.7, 122.9, 
110.0, 109.7, 108.7, 61.9, 60.0, 55.5, 46.1, 41.2, 40.5, 28.9, 28.6, 28.6, 28.0, 26.2, 24.7, 23.4, 




The 5-iodo-triazole 4b (15 mg, 0.03 mmol) was reacted with potassium chloride (9 mg, 0.12 
mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole for 10 
min and was purified by flash chromatography on silica eluting with 5% MeOH in DCM to 
yield 5-fluoro-triazole as an off white solid (10 mg, 80%). 1H NMR (500 MHz; CDCl3) δ 
7.03 (m, 1H), 6.97 - 6.99 (m, 1H), 6.83 (d, J = 8.1 Hz, 1H), 5.39 (br s, 1H), 5.08 (br s, 1H), 
4.49 - 4.51 (m, 1H), 4.35 (t, J = 6.9 Hz, 2H), 4.29 - 4.32 (m, 1H), 3.84 (t, J = 6.9 Hz, 2H), 
3.13 - 3.17 (m, 1H), 2.91 (dd, J = 5.0, 12.8 Hz, 1H), 2.72 (d, J = 12.8 Hz, 1H), 2.62 (t, J = 
7.5 Hz, 2H), 2.38 (s, 3H), 1.95 - 2.01 (m, 2H), 1.77 - 1.83 (m, 2H), 1.63 - 1.73 (m, 4H), 1.36 
- 1.47 (m, 4H); 13C NMR (125 MHz; CDCl3) δ 163.1, 154.8, 143.6, 142.8, 132.7, 128.4, 
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124.3, 122.2, 110.8, 107.8, 62.0, 60.1, 55.6, 47.3, 41.3, 40.5, 28.9, 28.6, 28.5, 28.0, 26.2, 




Benzyl bromide (343 mg, 2.00 mmol) and sodium azide (169 mg, 2.60 mmol) was reacted 
according to general procedure for synthesis of benzyl azides to give a yellow liquid (245 




Biotin acetylene 81 (60 mg, 0.25 mmol) was reacted with azide 11a (51 mg, 0.38 mmol) and 
Cu nanopowder (6 mg, 0.1 mmol) according to general procedure for CuAAC and purified 
by flash chromatography on silica gel eluting with 5% MeOH in DCM to give an off white 
solid (53 mg, 57%). 1H NMR (500 MHz, CDCl3) δ 7.33 - 7.41 (m, 3H), 7.25 - 7.29 (m, 2H), 
7.20 (s, 1H), 5.50 (s, 2H), 5.14 (br s, 1H), 4.87 (br s, 1H), 4.49 - 4.53 (m, 1H), 4.28 - 4.33 
(m, 1H), 3.13 - 3.18 (m, 1H), 2.92 (dd, J = 5.01, 12.84 Hz, 1H), 2.67 - 2.75 (m, 3H), 1.60 - 
1.73 (m, 4H), 1.36 - 1.50 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.9, 148.6, 134.9, 129.1, 
128.6, 128.0, 120.6, 61.9, 60.0, 55.5, 54.0, 40.5, 29.0, 28.7, 28.5, 25.5; HRMS calcd for 
C19H25N5OS [M + H]
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The iodo-acetylene 10 (0.25 mmol) and azide 11a (37 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (31 mg, 
25%). 1H NMR (500 MHz, CDCl3) δ 7.30 - 7.40 (m, 3H), 7.25 (s, 2H), 5.58 (s, 2H), 4.90 (br 
s, 1H), 4.72 (br s, 1H), 4.49 - 4.54 (m, 1H), 4.29 - 4.34 (m, 1H), 3.14 - 3.20 (m, 1H), 2.93 
(dd, J = 5.01, 12.84 Hz, 1H), 2.73 (d, J = 12.96 Hz, 1H), 2.66 (t, J = 7.58 Hz, 2H), 1.61 - 
1.77 (m, 4H), 1.37 - 1.54 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.7, 152.2, 134.5, 128.8, 
128.4, 127.7, 61.9, 60.0, 55.4, 54.2, 40.5, 28.9, 28.6, 28.5, 28.4, 25.9; HRMS calcd for 
C19H24IN5OS [M + NH3]




The 5-iodo-triazole 6a (12 mg, 0.024 mmol) was reacted with potassium fluoride (7 mg, 
0.12 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (6 mg, 64%). 1H NMR (500 MHz, 
CDCl3) δ 7.29 - 7.41 (m, 5H), 5.48 (br s, 1H), 5.39 (s, 2H), 5.15 (s, 1H), 4.48 - 4.52 (m, 1H), 
4.28 - 4.32 (m, 1H), 3.12 - 3.17 (m, 1H), 2.91 (dd, J = 5.01, 12.84 Hz, 1H), 2.72 (d, J = 
12.96 Hz, 1H), 2.61 (t, J = 7.58 Hz, 2H), 1.60 - 1.75 (m, 4H), 1.35 - 1.51 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 163.2, 133.8, 129.0, 128.7, 127.9, 62.0, 60.1, 55.6, 50.9, 40.5, 29.0, 
28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR (470 MHz, CDCl3) δ -158.02 (s); HRMS calcd for 
C19H24FN5OS [M + Na]
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The iodo-acetylene 10 (0.25 mmol) and azide 11b (42 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (46 mg, 
36%). 1H NMR (500 MHz, CDCl3) δ 7.28 -7.37 (m, 1H), 7.08 - 7.15 (m, 2H), 6.98 (t, J = 
7.46 Hz, 1H), 5.64 (s, 2H), 4.87 (br s, 1H), 4.70 (br s, 1H), 4.50 - 4.55 (m, 1H), 4.30 - 4.35 
(m, 1H), 3.15 - 3.20 (m, 1H), 2.94 (dd, J = 4.89, 12.72 Hz, 1H), 2.74 (d, J = 12.96 Hz, 1H), 
2.68 (t, J = 7.58 Hz, 2H), 1.65 - 1.77 (m, 4H), 1.38 - 1.52 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ 162.7, 130.3, 130.2, 129.3, 129.2, 124.6, 124.6, 115.7, 115.5, 78.5, 61.9, 60.0, 
55.4, 47.6, 47.6, 40.5, 28.9, 28.6, 28.5, 28.4, 25.9; 19F NMR (470 MHz, CDCl3) δ -117.37 
to -117.45 (m); HRMS calcd for C19H23FIN5OS [2M + Na]




The 5-iodo-triazole 6b (20 mg, 0.039 mmol) was reacted with potassium fluoride (11 mg, 
0.20 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (12 mg, 76%). 1H NMR (500 MHz, 
CDCl3) δ 7.32 - 7.38 (m, 1H), 7.25 (t, J = 7.21 Hz, 1H), 7.08 - 7.18 (m, 2H), 5.67 (br s, 1H), 
5.45 (s, 2H), 5.30 (br s, 1H), 4.47 - 4.52 (m, 1H), 4.28 - 4.32 (m, 1H), 3.12 - 3.18 (m, 1H), 
2.90 (dd, J = 5.14, 12.72 Hz, 1H), 2.72 (d, J = 12.72 Hz, 1H), 2.62 (t, J = 7.58 Hz, 2H), 1.61 
- 1.74 (m, 4H), 1.36 - 1.50 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.4, 130.8, 130.7, 
130.1, 130.0, 124.7, 124.7, 115.8, 115.7, 62.0, 60.1, 55.6, 44.2, 44.2, 40.5, 29.0, 28.6, 28.5, 
27.9, 23.5, 23.5; 19F NMR (470 MHz, CDCl3) δ -118.20 to -118.27 (m), -156.78 (d); HRMS 
calcd for C19H23F2N5OS [M + H]
+ 408.1669, found 408.1648. 
(3aS,4S,6aR)-4-(5-(1-(3-fluorobenzyl)-5-iodo-1H-1,2,3-triazol-4-yl)pentyl)tetrahydro-1H-
thieno[3,4-d]imidazol-2(3H)-one (6c) 
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The iodo-acetylene 10 (0.21 mmol) and azide 11c (35 mg, 0.23 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (71 mg, 
66%). 1H NMR (500 MHz, DMSO-d6) δ 7.38 - 7.44 (m, 1H), 7.15 (t, J = 8.44 Hz, 1H), 6.99 
(d, J = 9.78 Hz, 1H), 6.93 (d, J = 7.83 Hz, 1H), 6.41 (br s, 1H), 6.33 (br s, 1H), 5.63 (s, 2H), 
4.27 - 4.31 (m, 1H), 4.09 - 4.14 (m, 1H), 3.05 - 3.11 (m, 1H), 2.80 (dd, J = 5.01, 12.35 Hz, 
1H), 2.53 - 2.60 (m, 3H), 1.55 - 1.65 (m, 3H), 1.26 - 1.49 (m, 5H); 13C NMR (125 MHz, 
DMSO-d6) δ 163.1, 162.7, 151.3, 138.3, 138.3, 130.9, 130.8, 123.2, 123.2, 114.9, 114.7, 
114.2, 114.0, 106.8, 82.7, 61.0, 59.1, 55.5, 52.5, 28.4, 28.3, 28.2, 28.2, 25.4; HRMS calcd 
for C19H23FIN5OS [M + H]




The 5-iodo-triazole 6c (30 mg, 0.058 mmol) was reacted with potassium fluoride (17 mg, 
0.29 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (18 mg, 76%). 1H NMR (500 MHz, 
CDCl3) δ 7.32 - 7.38 (m, 1H), 6.98 - 7.11 (m, 3H), 5.51 (br s, 1H), 5.38 (s, 2H), 5.18 (br s, 
1H), 4.48 - 4.53 (m, 1H), 4.28 - 4.33 (m, 1H), 3.15 (td, J = 5.47, 8.38 Hz, 1H), 2.91 (dd, J 
= 5.01, 12.84 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.63 (t, J = 7.58 Hz, 2H), 1.60 - 1.75 (m, 
4H), 1.35 - 1.52 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.9, 163.2, 148.9, 136.1, 136.0, 
130.8, 130.7, 127.6, 127.5, 123.4, 123.4, 115.9, 115.7, 115.0, 114.8, 62.0, 60.1, 55.6, 50.2, 
40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR (470 MHz, CDCl3) δ -111.63 to -111.69 
(m), -157.01 (s); HRMS calcd for C19H23F2N5OS [M + H]
+ 408.1669, found 408.1641. 





The iodo-acetylene 10 (0.21 mmol) and azide 11d (35 mg, 0.23 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (69 mg, 
64%). 1H NMR (500 MHz, DMSO-d6) δ 7.16 - 7.25 (m, 4H), 6.41 (br s, 1H), 6.33 (br s, 1H), 
5.59 (s, 2H), 4.27 - 4.32 (m, 1H), 4.09 - 4.14 (m, 1H), 3.05 - 3.12 (m, 1H), 2.80 (dd, J = 
5.14, 12.47 Hz, 1H), 2.52 - 2.60 (m, 3H), 1.52 - 1.65 (m, 3H), 1.25 - 1.49 (m, 5H); 13C NMR 
(125 MHz, DMSO-d6) δ 162.7, 162.6, 151.2, 131.7, 131.7, 129.5, 129.5, 115.6, 115.5, 82.4, 
61.0, 59.1, 55.5, 52.4, 28.4, 28.3, 28.2, 28.2, 25.4; HRMS calcd for C19H23FIN5OS [M + 




The 5-iodo-triazole 6d (20 mg, 0.039 mmol) was reacted with potassium fluoride (11 mg, 
0.20 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (11 mg, 69%). 1H NMR (500 MHz, 
CDCl3) δ 7.32 (dd, J = 5.14, 8.56 Hz, 2H), 7.04 - 7.10 (m, 2H), 5.41 (br s, 1H), 5.35 (s, 2H), 
5.09 (br s, 1H), 4.48 - 4.53 (m, 1H), 4.28 - 4.33 (m, 1H), 3.12 - 3.18 (m, 1H), 2.91 (dd, J = 
5.14, 12.72 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.61 (t, J = 7.58 Hz, 2H), 1.62 - 1.74 (m, 
4H), 1.36 - 1.50 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.8, 163.1, 161.9, 129.9, 129.9, 
129.6, 116.1, 116.0, 62.0, 60.1, 55.6, 50.2, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR 
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(470 MHz, CDCl3) δ -112.70 to -112.77 (m), -157.15 (s); HRMS calcd for C19H23F2N5OS 




The iodo-acetylene 10 (0.25 mmol) and azide 11e (47 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (43 mg, 
32%). 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 8.07 Hz, 1H), 7.28 - 7.31 (m, 1H), 7.18 - 
7.23 (m, 1H), 6.67 (d, J = 7.34 Hz, 1H), 5.70 (s, 2H), 4.91 (br s, 1H), 4.72 (br s, 1H), 4.50 - 
4.55 (m, 1H), 4.30 - 4.36 (m, 1H), 3.15 - 3.21 (m, 1H), 2.94 (dd, J = 4.65, 12.72 Hz, 1H), 
2.67 - 2.77 (m, 3H), 1.63 - 1.80 (m, 4H), 1.39 - 1.55 (m, 4H); 13C NMR (125 MHz, CDCl3) 
δ 178.5, 162.7, 152.3, 132.5, 132.4, 129.6, 129.5, 128.2, 127.4, 61.9, 60.1, 55.4, 51.4, 40.5, 
28.9, 28.6, 28.6, 28.4, 25.9; HRMS calcd for C19H23ClIN5OS [2M + Na]





The 5-iodo-triazole 6e (20 mg, 0.038 mmol) was reacted with potassium fluoride (11 mg, 
0.19 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (10 mg, 62%). 1H NMR (500 MHz, 
CDCl3) δ 7.42 (d, J = 7.58 Hz, 1H), 7.24 - 7.34 (m, 2H), 7.10 (d, J = 7.34 Hz, 1H), 5.75 (br 
s, 1H), 5.52 (s, 2H), 5.36 (br s, 1H), 4.47 - 4.52 (m, 1H), 4.28 - 4.33 (m, 1H), 3.12 - 3.18 (m, 
1H), 2.90 (dd, J = 5.14, 12.72 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.64 (t, J = 7.58 Hz, 
2H), 1.61 - 1.76 (m, 4H), 1.36 - 1.51 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.4, 133.1, 
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131.6, 130.0, 129.8, 129.4, 127.4, 62.0, 60.1, 55.6, 48.0, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 
23.5; 19F NMR (470 MHz, CDCl3) δ -156.18 (s); HRMS calcd for C19H23ClFN5OS [M + 




The iodo-acetylene 10 (0.25 mmol) and azide 11f (47 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (55 mg, 
41%). 1H NMR (500 MHz, CDCl3) δ 7.24 - 7.32 (m, 3H), 7.13 (d, J = 7.09 Hz, 1H), 5.54 (s, 
2H), 5.15 (br s, 1H), 4.91 (br s, 1H), 4.49 - 4.54 (m, 1H), 4.29 - 4.34 (m, 1H), 3.14 - 3.20 
(m, 1H), 2.93 (dd, J = 5.01, 12.84 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.66 (t, J = 7.46 Hz, 
2H), 1.64 - 1.77 (m, 4H), 1.37 - 1.54 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.9, 152.4, 
136.4, 134.8, 130.2, 128.7, 127.9, 125.9, 62.0, 60.1, 55.5, 53.5, 40.5, 28.9, 28.6, 28.5, 28.4, 
25.9; HRMS calcd for C19H23ClIN5OS [M + Na]




The 5-iodo-triazole 6f (20 mg, 0.038 mmol) was reacted with potassium fluoride (11 mg, 
0.19 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (12 mg, 74%). 1H NMR (500 MHz, 
CDCl3) δ 7.28 - 7.35 (m, 3H), 7.19 (d, J = 6.85 Hz, 1H), 5.72 (br s, 1H), 5.35 (br s, 3H), 
4.47 - 5.52 (m, 1H), 4.28 - 4.32 (m, 1H), 3.11 - 3.18 (m, 1H), 2.90 (dd, J = 5.01, 12.84 Hz, 
1H), 2.72 (d, J = 12.72 Hz, 1H), 2.62 (t, J = 7.58 Hz, 2H), 1.60 - 1.75 (m, 4H), 1.36 - 1.49 
(m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.4, 151.1, 135.6, 134.9, 130.4, 129.0, 128.0, 
Chapter Six   141 
_________________________________________________________________________ 
127.6, 127.5, 126.0, 62.0, 60.1, 55.6, 50.1, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR 






The iodo-acetylene 10 (0.25 mmol) and azide 11g (47 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (56 mg, 
42%). 1H NMR (500 MHz, CDCl3) δ 7.31 - 7.35 (m, 2H), 7.19 - 7.23 (m, 2H), 5.54 (s, 2H), 
4.93 (br s, 1H), 4.74 (br s, 1H), 4.50 - 4.54 (m, 1H), 4.30 - 4.34 (m, 1H), 3.14 - 3.19 (m, 1H), 
2.93 (dd, J = 5.14, 12.72 Hz, 1H), 2.74 (d, J = 12.72 Hz, 1H), 2.66 (t, J = 7.58 Hz, 2H), 1.64 
- 1.76 (m, 4H), 1.38 - 1.53 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.7, 152.4, 134.5, 
132.9, 129.2, 129.1, 78.1,61.9, 60.1, 55.4, 53.5, 40.5, 28.9, 28.6, 28.5, 28.4, 25.9; HRMS 
calcd for C19H23ClIN5OS [M + H]




The 5-iodo-triazole 6g (20 mg, 0.038 mmol) was reacted with potassium fluoride (11 mg, 
0.19 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (13 mg, 81%). 1H NMR (500 MHz, 
CDCl3) δ 7.35 (d, J = 8.56 Hz, 2H), 7.25 (d, J = 8.31 Hz, 2H), 5.74 (br s, 1H), 5.37 (br s, 
1H), 5.35 (s, 2H), 4.47 - 4.52 (m, 1H), 4.27 - 4.32 (m, 1H), 3.11 - 3.17 (m, 1H), 2.90 (dd, J 
= 4.89, 12.72 Hz, 1H), 2.73 (d, J = 12.96 Hz, 1H), 2.61 (t, J = 7.58 Hz, 2H), 1.60 - 1.75 (m, 
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4H), 1.35 - 1.50 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.4, 151.1, 134.8, 132.2, 129.3, 
129.2, 62.0, 60.1, 55.6, 50.2, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR (470 MHz, 
CDCl3) δ -157.05 (s); HRMS calcd for C19H23ClFN5OS [M + H]




The iodo-acetylene 10 (0.25 mmol) and azide 11h (73 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (85 mg, 
55%). 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 7.83 Hz, 1H), 7.63 (s, 1H), 7.21 (d, J = 
7.58 Hz, 1H), 7.09 (t, J = 7.70 Hz, 1H), 5.51 (s, 2H), 4.99 (br s, 1H), 4.78 (br s, 1H), 4.50 - 
4.54 (m, 1H), 4.30 - 4.34 (m, 1H), 3.14 - 3.20 (m, 1H), 2.93 (dd, J = 5.01, 12.84 Hz, 1H), 
2.73 (d, J = 12.96 Hz, 1H), 2.67 (t, J = 7.58 Hz, 2H), 1.64 - 1.77 (m, 4H), 1.37 - 1.54 (m, 
4H); 13C NMR (125 MHz, CDCl3) δ 162.7, 152.4, 137.6, 136.7, 136.6, 130.6, 127.0, 94.5, 
61.9, 60.0, 55.4, 53.2, 40.6, 28.9, 28.6, 28.6, 28.4, 25.9; HRMS calcd for C19H23I2N5OS [M 




The 5-iodo-triazole 6h (20 mg, 0.032 mmol) was reacted with potassium fluoride (9.3 mg, 
0.16 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (11 mg, 67%). 1H NMR (500 MHz, 
CDCl3) δ 7.69 (d, J = 8.07 Hz, 1H), 7.66 (s, 1H), 7.25 - 7.30 (m, 2H), 7.11 (t, J = 7.83 Hz, 
1H), 5.51 (br s, 1H), 5.32 (s, 2H), 5.17 (br s, 1H), 4.48 - 4.53 (m, 1H), 4.28 - 4.33 (m, 1H), 
3.12 - 3.18 (m, 1H), 2.91 (dd, J = 4.89, 12.72 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.63 (t, 
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J = 7.58 Hz, 2H), 1.60 - 1.76 (m, 4H), 1.36 - 1.51 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 
163.2, 137.9, 136.7, 135.9, 130.7, 127.1, 94.7, 62.0, 60.1, 55.6, 50.0, 40.5, 29.0, 28.6, 28.5, 
27.9, 23.5, 23.5; 19F NMR (470 MHz, CDCl3) δ -156.93 (s); HRMS calcd for C19H23FIN5OS 




The iodo-acetylene 10 (0.21 mmol) and azide 11i (60 mg, 0.23 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 6% MeOH in DCM to give an off white solid (121 
mg, 92%). 1H NMR (500 MHz, CDCl3) δ 7.67 - 7.71 (m, 2H), 6.99 - 7.03 (m, 2H), 5.51 (s, 
2H), 4.84 (br s, 1H), 4.68 (br s, 1H), 4.51 - 4.54 (m, 1H), 4.30 - 4.34 (m, 1H), 3.15 - 3.20 
(m, 1H), 2.94 (dd, J = 5.01, 12.84 Hz, 1H), 2.74 (d, J = 12.96 Hz, 1H), 2.66 (t, J = 7.58 Hz, 
2H), 1.64 - 1.76 (m, 4H), 1.37 - 1.52 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.6, 152.4, 
138.0, 134.1, 129.6, 107.3, 94.2, 61.9, 60.0, 55.4, 53.6, 40.6, 28.8, 28.6, 28.5, 28.4, 25.9; 
HRMS calcd for C19H23I2N5OS [M + H]




The 5-iodo-triazole 6i (20 mg, 0.032 mmol) was reacted with potassium fluoride (9.3 mg, 
0.16 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (11 mg, 67%). 1H NMR (500 MHz, 
CDCl3) δ 7.70 - 7.74 (m, 2H), 7.04 - 7.09 (m, 2H), 5.33 (s, 2H), 4.97 (br s, 1H), 4.77 (br s, 
1H), 4.50 - 4.54 (m, 1H), 4.29 - 4.34 (m, 1H), 3.13 - 3.19 (m, 1H), 2.93 (dd, J = 5.14, 12.96 
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Hz, 1H), 2.73 (d, J = 12.96 Hz, 1H), 2.62 (t, J = 7.58 Hz, 2H), 1.62 - 1.74 (m, 4H), 1.36 - 
1.52 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 162.8, 138.2, 133.4, 129.8, 94.6, 61.9, 60.0, 
55.4, 50.3, 40.5, 28.9, 28.6, 28.5, 27.9, 23.5, 23.4; 19F NMR (470 MHz, CDCl3) δ -157.09 
(s); HRMS calcd for C19H23FIN5OS [M + H]




The iodo-acetylene 10 (0.25 mmol) and azide 11j (49 mg, 0.30 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give an off white solid (34 mg, 
26%). 1H NMR (500 MHz, DMSO-d6) δ 7.28 - 7.33 (m, 1H), 7.05 (d, J = 8.31 Hz, 1H), 6.89 
(t, J = 7.46 Hz, 1H), 6.60 (d, J = 7.34 Hz, 1H), 6.43 (br s, 1H), 6.34 (br s, 1H), 5.50 (s, 2H), 
4.27 - 4.32 (m, 1H), 4.10 - 4.14 (m, 1H), 3.83 (s, 3H), 3.06 - 3.12 (m, 1H), 2.81 (dd, J = 
5.14, 12.47 Hz, 1H), 2.54 - 2.60 (m, 3H), 1.56 - 1.65 (m, 3H), 1.26 - 1.49 (m, 5H); 13C NMR 
(125 MHz, DMSO-d6) δ 162.7, 156.2, 150.8, 129.3, 127.7, 123.4, 120.4, 111.0, 83.0, 61.0, 
59.2, 55.5, 48.5, 28.5, 28.4, 28.3, 28.2, 28.2, 25.4; HRMS calcd for C20H26IN5O2S [M + K]
+ 




The 5-iodo-triazole 6j (17 mg, 0.032 mmol) was reacted with potassium fluoride (9.3 mg, 
0.16 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (10 mg, 74%). 1H NMR (500 MHz, 
CDCl3) δ 7.29 - 7.35 (m, 1H), 7.10 (d, J = 7.34 Hz, 1H), 6.88-6.96 (m, 2H), 5.75 (br s, 1H), 
5.40 (s, 2H), 5.35 (br s, 1H), 4.46 - 4.51 (m, 1H), 4.27 - 4.32 (m, 1H), 3.85 (s, 3H), 3.11 - 
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3.17 (m, 1H),  2.89 (dd, J = 4.89, 12.72 Hz, 1H), 2.72 (d, J = 12.72 Hz, 1H), 2.62 (t, J = 
7.58 Hz, 2H), 1.61 - 1.76 (m, 4H), 1.36 - 1.51 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 163.4, 
156.9, 130.0, 129.2, 122.3, 120.7, 110.5, 62.0, 60.1, 55.7, 55.4, 45.7, 40.5, 29.0, 28.7, 28.5, 
28.0, 23.6, 23.5; 19F NMR (470 MHz, CDCl3) δ -156.43 (s); HRMS calcd for C20H26FN5O2S 




The iodo-acetylene 10 (0.25 mmol) and azide 11k (53 mg, 0.28 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give an off white solid (41 mg, 
30%). 1H NMR (500 MHz, CDCl3) δ 7.34 - 7.39 (m, 2H), 7.19 - 7.24 (m, 2H), 5.53 (s, 2H), 
5.27 (br s, 1H), 4.99 (br s, 1H), 4.49 - 4.54 (m, 1H), 4.29 - 4.34 (m, 1H), 3.14 - 3.20 (m, 1H), 
2.92 (dd, J = 5.01, 12.84 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.65 (t, J = 7.58 Hz, 2H), 1.61 
- 1.77 (m, 4H), 1.37 - 1.53 (m, 4H), 1.31 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 163.0, 
152.1, 151.5, 131.4, 127.6, 125.7, 61.9, 60.1, 55.5, 53.8, 40.5, 34.6, 31.3, 29.0, 28.6, 28.5, 
28.4, 26.0; HRMS calcd for C23H32IN5OS [M + K]




The 5-iodo-triazole 6k (25 mg, 0.045 mmol) was reacted with potassium fluoride (14 mg, 
0.23 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (14 mg, 70%). 1H NMR (500 MHz, 
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CDCl3) δ 7.37 - 7.41 (m, 2H), 7.23 - 7.27 (m, 2H), 5.54 (br s, 1H), 5.34 (s, 2H), 5.18 (br s, 
1H), 4.48 - 4.52 (m, 1H), 4.28 - 4.33 (m, 1H), 3.12 - 3.18 (m, 1H), 2.90 (dd, J = 5.14, 12.72 
Hz, 1H), 2.72 (d, J = 12.72 Hz, 1H), 2.61 (t, J = 7.58 Hz, 2H), 1.60 - 1.76 (m, 4H), 1.37 - 
1.50 (m, 4H), 1.31 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 163.2, 151.8, 130.8, 127.7, 127.4, 
125.9, 62.0, 60.1, 55.6, 50.6, 40.5, 34.6, 31.2, 29.0, 28.6, 28.5, 28.0, 23.6, 23.5; 19F NMR 
(470 MHz, CDCl3) δ -157.02 (s); HRMS calcd for C23H32FN5OS [M]




2-nitrobenzyl chloride (500 mg, 2.91 mmol) and sodium azide (246 mg, 3.78 mmol) was 
reacted according to general procedure for synthesis of benzyl azides to give a yellow liquid 
(489 mg, 94%). 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.31 Hz, 1H), 7.66 - 7.73 (m, 
2H), 7.51 - 7.55 (m, 1H), 4.87 (s, 2H) 
(3aS,4S,6aR)-4-(5-(5-iodo-1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl)pentyl)tetrahydro-1H-
thieno[3,4-d]imidazol-2(3H)-one (6l) and (3aS,4S,6aR)-4-(5-(1-(2-nitrobenzyl)-1H-1,2,3-
triazol-4-yl)pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one (5l) 
        
The iodo-acetylene 10 (0.50 mmol) and azide 11l (98 mg, 0.55 mmol) was reacted according 
to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give 6l (81 mg, 30%) as a 
yellow solid and 5l (40 mg, 19%) as a yellow solid.  
6l. 1H NMR (500 MHz, DMSO-d6) δ 8.17 (d, J = 7.34 Hz, 1H), 7.73 (t, J = 7.58 Hz, 1H), 
7.64 (t, J = 7.58 Hz, 1H), 6.76 (d, J = 7.34 Hz, 1H), 6.42 (br s, 1H), 6.34 (br s, 1H), 5.93 (s, 
2H), 4.27 - 4.32 (m, 1H), 4.10 - 4.15 (m, 1H), 3.06 - 3.12 (m, 1H), 2.81 (dd, J = 5.01, 12.35 
Hz, 1H), 2.54 - 2.62 (m, 3H), 1.56 - 1.67 (m, 3H), 1.27 - 1.50 (m, 5H); 13C NMR (125 MHz, 
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DMSO-d6) δ 162.7, 151.3, 147.4, 134.4, 130.4, 129.5, 129.2, 125.2, 83.6, 61.0, 59.2, 55.5, 
50.6, 28.4, 28.4, 28.3, 28.2, 25.4; HRMS calcd for C19H23IN6O3S [M + H]
+ 543.0675, found 
543.0688. 
5l. 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.07 Hz, 1H), 7.63 (t, J = 7.46 Hz, 1H), 7.54 
(t, J = 7.83 Hz, 1H), 7.44 (s, 1H), 7.08 (d, J = 7.58 Hz, 1H), 5.92 (s, 2H), 4.96 (br s, 1H), 
4.73 (br s, 1H), 4.50 - 4.54 (m, 1H), 4.30 - 4.34 (m, 1H), 3.15 - 3.20 (m, 1H), 2.94 (dd, J = 
5.01, 12.84 Hz, 1H), 2.71 - 2.78 (m, 3H), 1.62 - 1.76 (m, 4H), 1.39 - 1.52 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 162.7, 134.3, 131.0, 130.3, 129.5, 125.3, 121.8, 61.9, 60.0, 55.4, 50.6, 
40.5, 29.0, 28.7, 28.6, 25.5; HRMS calcd for C19H24N6O3S [M + K]





The 5-iodo-triazole 6l (46 mg, 0.085 mmol) was reacted with potassium fluoride (25 mg, 
0.43 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as a yellow solid (27 mg, 73%). 1H NMR (500 MHz, CDCl3) 
δ 8.21 (dd, J = 1.22, 8.31 Hz, 1H), 7.65 (dt, J = 1.22, 7.70 Hz, 1H), 7.53 - 7.58 (m, 1H), 
6.99 (d, J = 7.83 Hz, 1H), 5.85 (s, 2H), 5.48 (br s, 1H), 5.11 (br s, 1H), 4.49 - 4.54 (m, 1H), 
4.30 - 4.34 (m, 1H), 3.14 - 3.20 (m, 1H), 2.92 (dd, J = 5.01, 12.84 Hz, 1H), 2.74 (d, J = 
12.72 Hz, 1H), 2.68 (t, J = 7.58 Hz, 2H), 1.62 - 1.79 (m, 4H), 1.38 - 1.54 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 163.2, 151.6, 134.5, 129.9, 129.6, 129.2, 125.6, 62.0, 60.1, 55.6, 47.7, 
40.5, 28.9, 28.6, 28.6, 28.1, 27.9, 23.5, 23.5; 19F NMR (470 MHz, CDCl3) δ -156.42 (s); 
HRMS calcd for C19H23FN6O3S [M + H]
+ 435.1614, found 435.1618. 
(3aS,4S,6aR)-4-(5-(5-iodo-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one (6m) 
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To a mixture of biotin acetylene 81 (50 mg, 0.21 mmol), LiI (112 mg, 0.84 mmol), and 
Cu(ClO4)2·6H2O (195 mg, 0.53 mmol) in THF (3 mL) was added TEA (68 µL) and the 
mixture was stirred for 30 min. To the reaction mixture was added azide 11m (42 mg, 0.21 
mmol) and the mixture was stirred for 5 hours. The mixture was quenched with 10% NH4OH 
and extracted with DCM twice. The combined organics were dried over anhydrous sodium 
sulfate and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give an off white solid (88 mg, 
74%). 1H NMR (500 MHz, DMSO-d6) δ 7.72 - 7.78 (m, 2H), 7.31 - 7.36 (m, 2H), 6.42 (br 
s, 1H), 6.34 (br s, 1H), 5.73 (s, 2H), 4.26 - 4.32 (m, 1H), 4.09 - 4.14 (m, 1H), 3.05 - 3.12 (m, 
1H), 2.81 (dd, J = 5.01, 12.35 Hz, 1H), 2.53 - 2.60 (m, 3H), 1.55 - 1.67 (m, 3H), 1.26 - 1.50 
(m, 5H); 13C NMR (125 MHz, DMSO-d6) δ 162.7, 151.4, 140.3, 128.0, 125.7, 125.7, 125.6, 
82.8, 61.0, 59.2, 55.5, 52.6, 28.5, 28.4, 28.3, 28.2, 25.4; 19F NMR (470 MHz, DMSO-d6) δ 
-61.05 (s); HRMS calcd for C20H23F3IN5OS [M + H]




The 5-iodo-triazole 6m (35 mg, 0.062 mmol) was reacted with potassium fluoride (18 mg, 
0.31 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (21 mg, 74%). 1H NMR (500 MHz, 
CDCl3) δ 7.63 - 7.67 (m, 2H), 7.41 - 7.45 (m, 2H), 5.41 - 5.47 (m, 3H), 5.11 (br s, 1H), 4.49 
- 4.53 (m, 1H), 4.29 - 4.33 (m, 1H), 3.13 - 3.18 (m, 1H), 2.92 (dd, J = 5.01, 12.84 Hz, 1H), 
2.73 (d, J = 12.72 Hz, 1H), 2.63 (t, J = 7.58 Hz, 2H), 1.61 - 1.75 (m, 4H), 1.36 - 1.52 (m, 
4H); 13C NMR (125 MHz, CDCl3) δ 163.2, 151.2, 137.6, 128.2, 127.7, 127.6, 126.1, 126.1, 
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126.1, 126.0, 62.0, 60.1, 55.6, 50.2, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR (470 
MHz, CDCl3) δ -62.80 (s), -157.08 (s); HRMS calcd for C20H23F4N5OS [M + H]
+ 458.1637, 
found 458.1632. 
methyl 4-(azidomethyl)benzoate (11n)4 
 
To the suspension of 4-(bromomethyl)benzoic acid (431 mg, 2.00 mmol) in MeOH (12.5 
mL) was added dropwise SOCl2 (435 µL, 6.00 mmol) and the mixture was stirred for 20 
hours at ambient temperature. The resulting clear solution was concentrated under reduced 
pressure to give a dark yellow liquid. The yellow liquid was treated with sodium azide (169 
mg, 2.60 mmol) according to general procedure for synthesis of benzyl azides to give a 
yellow liquid (366 mg, 96%). 1H NMR (500 MHz, CDCl3) δ 8.05 - 8.09 (m, 2H), 7.39 - 7.42 




Biotin acetylene 81 (60 mg, 0.25 mmol) was reacted with azide 11n (73 mg, 0.38 mmol) and 
Cu nanopowder (6 mg, 0.1 mmol) according to general procedure for CuAAC and purified 
by flash chromatography on silica gel eluting with 5% MeOH in DCM to give an off white 
solid (41 mg, 38%). 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.31 Hz, 2H), 7.31 (d, J = 
8.31 Hz, 2H), 7.23 (s, 1H), 5.57 (s, 2H), 5.06 (br s, 1H), 4.81 (br s, 1H), 4.49 - 4.54 (m, 1H), 
4.29 - 4.34 (m, 1H), 3.93 (s, 3H), 3.13 - 3.18 (m, 1H), 2.92 (dd, J = 5.01, 12.84 Hz, 1H), 
2.68 - 2.76 (m, 3H), 1.59 - 1.74 (m, 4H), 1.35 - 1.51 (m, 4H); 13C NMR (125 MHz, CDCl3) 
δ 166.4, 162.8, 148.8, 139.8, 130.5, 130.3, 127.7, 120.7,61.9, 60.0, 55.5, 53.5, 52.3, 40.5, 
29.0, 29.0, 28.7, 28.5, 25.5; HRMS calcd for C21H27N5O3S [M + H]
+ 430.1913, found 
430.1907. 





The iodo-acetylene 10 (0.50 mmol) and azide 11n (115 mg, 0.60 mmol) was reacted 
according to general procedure for synthesis of 5-Iodo-1,2,3-triazoles and was purified by 
flash chromatography on silica eluting with 5% MeOH in DCM to give an off white solid 
(124 mg, 45%). 1H NMR (500 MHz, DMSO-d6) δ 7.95 (d, J = 8.31 Hz, 2H), 7.25 (d, J = 
8.07 Hz, 2H), 6.42 (br s, 1H), 6.34 (br s, 1H), 5.71 (s, 2H), 4.27 - 4.32 (m, 1H), 4.09 - 4.15 
(m, 1H), 3.84 (s, 3H), 3.06 - 3.11 (m, 1H), 2.80 (dd, J = 5.01, 12.35 Hz, 1H), 2.53 - 2.60 (m, 
3H), 1.55 - 1.65 (m, 3H), 1.25 - 1.49 (m, 5H); 13C NMR (125 MHz, DMSO-d6) δ 165.8, 
162.7, 151.3, 140.8, 129.6, 129.2, 127.4, 82.8, 61.0, 59.2, 55.5, 52.8, 52.2, 28.4, 28.4, 28.3, 
28.2, 25.4; HRMS calcd for C21H26IN5O3S [M + Na]




The 5-iodo-triazole 6n (41 mg, 0.074 mmol) was reacted with potassium fluoride (21 mg, 
0.37 mmol) according to general procedure for halogen exchange of 5-Iodo-1,2,3-triazole 
for 5 min and was purified by flash chromatography on silica eluting with 6% MeOH in 
DCM to yield 5-fluoro-triazole as an off white solid (18 mg, 54%). 1H NMR (500 MHz, 
CDCl3) δ 8.02 - 8.06 (m, 2H), 7.34 - 7.38 (m, 2H), 5.46 (br s, 1H), 5.44 (s, 2H), 5.13 (br s, 
1H), 4.48 - 4.53 (m, 1H), 4.28 - 4.33 (m, 1H), 3.92 (s, 3H), 3.12 - 3.18 (m, 1H), 2.91 (dd, J 
= 5.14, 12.72 Hz, 1H), 2.73 (d, J = 12.72 Hz, 1H), 2.63 (t, J = 7.58 Hz, 2H), 1.60 - 1.75 (m, 
4H), 1.36 - 1.51 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 166.4, 163.2, 138.5, 130.6, 130.3, 
127.7, 107.3, 62.0, 60.1, 55.6, 52.3, 50.4, 40.5, 29.0, 28.6, 28.5, 27.9, 23.5, 23.5; 19F NMR 
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(470 MHz, CDCl3) δ -157.01 (s); HRMS calcd for C21H26FN5O3S [M + H]
+ 448.1818, found 
448.1811. 
4-((5-iodo-4-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentyl)-1H-
1,2,3-triazol-1-yl)methyl)benzoic acid (6o) 
 
The ester 6n (20 mg, 0.036 mmol) was reacted with LiOH (2 mg, 0.08 mmol) according to 
general procedure for hydrolysis of ester and was purified by flash chromatography on silica 
eluting with 30% MeOH in DCM to yield carboxylic acid as an off white solid (8 mg, 41%). 
1H NMR (500 MHz, DMSO-d6) δ 7.90 - 7.96 (m, 2H), 7.19 - 7.26 (m, 2H), 6.42 (br s, 1H), 
6.34 (br s, 1H), 5.69 (s, 2H), 4.26 - 4.32 (m, 1H), 4.09 - 4.14 (m, 1H), 3.05 - 3.12 (m, 1H), 
2.81 (dd, J = 5.14, 12.47 Hz, 1H), 2.54 - 2.60 (m, 3H), 1.55 - 1.65 (m, 3H), 1.26 - 1.50 (m, 
5H); 13C NMR (125 MHz, DMSO-d6) δ 166.9, 162.7, 151.3, 140.2, 129.7, 127.2, 82.7, 61.0, 
59.2, 55.5, 52.8, 28.5, 28.4, 28.3, 28.2, 27.5, 25.4; HRMS calcd for C20H24IN5O3S [M + H]
+ 
542.0723, found 542.0767. 
4-((5-fluoro-4-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentyl)-
1H-1,2,3-triazol-1-yl)methyl)benzoic acid (7o) 
 
The ester 7n (8 mg, 0.018 mmol) was reacted with LiOH (1 mg, 0.04 mmol) according to 
general procedure for hydrolysis of ester and was purified by flash chromatography on silica 
eluting with 30% MeOH in DCM to yield carboxylic acid as an off white solid (6 mg, 77%). 
1H NMR (500 MHz, DMSO-d6) δ 7.81 - 7.87 (m, 2H), 7.14 - 7.18 (m, 2H), 6.43 (br s, 1H), 
6.35 (br s, 1H), 5.49 (s, 2H), 4.27 - 4.31 (m, 1H), 4.09 - 4.13 (m, 1H), 3.04 - 3.10 (m, 1H), 
2.80 (dd, J = 5.14, 12.47 Hz, 1H), 2.52 - 2.59 (m, 3H), 1.53 - 1.63 (m, 3H), 1.22 - 1.46 (m, 
5H); 13C NMR (125 MHz, DMSO-d6) δ 168.9, 162.7, 150.8, 129.4, 126.5, 61.1, 59.2, 55.5, 
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50.0, 37.3, 28.4, 28.2, 28.2, 27.7, 22.9; 19F NMR (470 MHz, DMSO-d6) δ -156.77 (s); HRMS 
calcd for C20H24FN5O3S [M + H]
+ 434.1662, found 434.1656. 




To a mixture of compound 115 (300 mg, 1.19 mmol) in water/THF (9:1, 3.33 mL) were 
added diphenyl carbonate (255 mg, 1.19 mmol) and TEA (0.33 mL, 2.38 mmol) and the 
mixture was stirred for 6 h. The mixture was poured into water and extracted with DCM. 
The organic layer was washed with cold aqueous 10 % NaOH solution and brine. The 
organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography on silica (DCM:MeOH = 10:1) to yield a white solid (223 mg, 56 %). 1H 
NMR (500 MHz, DMSO-d6) δ 7.71 (t, J = 5.7 Hz, 1H), 7.40 – 7.33 (m, 2H), 7.22 – 7.15 (m, 
1H), 7.11 – 7.06 (m, 2H), 6.43 (s, 1H), 6.35 (s, 1H), 4.31 (ddt, J = 7.6, 5.0, 1.1 Hz, 1H), 4.14 
(ddd, J = 7.8, 4.5, 1.9 Hz, 1H), 3.12 (ddd, J = 8.2, 6.4, 4.4 Hz, 1H), 3.05 (q, J = 6.6 Hz, 2H), 
2.83 (dd, J = 12.4, 5.1 Hz, 1H), 2.58 (d, J = 12.4 Hz, 1H), 1.69 – 1.58 (m, 1H), 1.57 – 1.27 
(m, 5H); 13C NMR (126 MHz, DMSO-d6) δ 162.7, 154.3, 151.1, 129.2, 124.8, 121.7, 60.9, 
59.2, 55.4, 40.2, 39.8, 29.2, 28.0, 25.8. 
2-(4-(6-Amino-9H-purin-9-yl)butyl)isoindoline-1,3-dione (20)  
 
To a suspension of adenine (1.1 g, 8.14 mmol) in DMF (11 mL) was added K2CO3 (1.8 g, 
13.23 mmol) and N-(4-bromobutyl)phthalamide 19 (2.75 g, 9.75 mmol) and the mixture was 
stirred at 70 °C overnight. The mixture was allowed to cool down to room temperature and 
partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc. The 
combined organics were washed with brine and water, dried over Na2SO4, filtrated and 
concentrated under reduced pressure. The solid obtained was triturated from diethyl ether 
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affording the title compound as a pale yellow solid (2.5 g, 84%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.12 (s, 1H), 8.07 (s, 1H), 7.84 (m, 4H), 7.16 (s, 2H), 4.17 (t, J = 6.7 Hz, 2H), 
3.61 (t, J = 6.7 Hz, 2H), 1.83 (dd, J = 14.7, 6.9 Hz, 2H), 1.56 (dt, J = 13.8, 6.9 Hz, 2H); 13C 
NMR (125 MHz, DMSO-d6) δ 167.9, 155.9, 152.3, 149.5, 140.8, 134.3, 131.6, 123.0,118.7, 




To a suspension of 2-(4-(6-amino-9H-purin-9-yl)butyl)isoindoline-1,3-dione 20 (2.5 g, 7.43 
mmol) in ethanol (125 mL) was added hydrazine hydrate (3.5 mL, 114.45 mmol) and the 
mixture was stirred at reflux overnight. The mixture was allowed to cool down to room 
temperature and concentrated under reduced pressure. A solid was formed which was 
filtrated and washed with DCM. Trituration from MeOH afforded the title compound (1.0 g, 
67%) as a colourless solid. 1H NMR (500 MHz, DMSO-d6) δ 8.12 (s, 1H), 8.11 (s, 1H), 7.14 
(2, 2H), 4.11 (t, J = 7.1 Hz, 2H), 3.08 (br s, 2H), 2.51 (t, J = 6.9 Hz, 2H), 1.79 (dd, J = 14.9, 
7.3 Hz, 2H), 1.28 (dd, J = 14.9, 7.3 Hz, 2H); 13C NMR (125 MHz, DMSO-d6) δ 155.9, 152.3, 
149.5, 140.8, 118.7, 42.8, 41.0, 30.0, 26.9; HRMS calcd. for [M + H+] C9H15N6: requires 
207.1358, found 207.1365; IR (ATR) ʋ: 3149 (NH2), 2932 (=CH), 1677 (N=C and C=C) 
cm-1. 
tert-Butyl (4-(6-amino-9H-purin-9-yl)butyl)carbamate (14)  
 
To a suspension of adenine (1.10 g, 8.14 mmol) in DMF (12 mL) was added Cs2CO3 (3.98 
g, 12.2 mmol) and bromide 136 (2.45 g, 9.77 mmol). The mixture was stirred overnight, 
poured onto water and extracted with EtOAc twice. The combined organic layers were 
washed with brine and water. The organic layer was dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified by flash chromatography on silica 
(DCM:MeOH = 15:1 → 10:1) to yield a white solid (1.70 g, 68 %). 1H NMR (500 MHz, 
DMSO-d6) δ 8.12 (s, 1H), 8.11 (s, 1H), 7.16 (s, 2H), 6.80 (t, J = 5.8 Hz, 1H), 4.12 (t, J = 7.0 
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Hz, 2H), 2.92 (q, J = 6.6 Hz, 2H), 1.76 (m, 2H), 1.38 – 1.28 (m, 11H); 13C NMR (126 MHz, 
DMSO-d6) δ 155.9, 155.6, 152.3, 149.5, 140.8, 118.7, 77.4, 42.6, 28.2, 26.8, 26.7. 
tert-Butyl (N-(4-(6-amino-9H-purin-9-yl)butyl)sulfamoyl)carbamate (17)  
 
Method 1. To a solution of amine 21 (1.6 g, 7.75 mmol) in DCM (16 ml) was added TEA 
(2.1 mL, 15.5 mmol), followed by addition of sulfamoylating agent 167 (2.6 g, 7.75 mmol). 
The reaction mixture was stirred at room temperature for 12 h. The mixture was concentrated 
under reduced pressure and the residue was purified by flash chromatography on silica (5% 
MeOH in DCM) to give a crystalline white solid (664 mg, 23%). 1H NMR (500 MHz, 
DMSO-d6) δ 10.77 (s, 1H), 8.12 (s, 1H), 8.11 (s, 1H), 7.58 (t, J = 5.8 Hz, 1H), 7.16 (s, 2H), 
4.12 (t, J = 7.0 Hz, 2H), 2.90 (q, J = 6.6 Hz, 2H), 1.80 (q, J = 7.4 Hz, 2H), 1.41 (m, 2H),  
1.38 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 155.9, 152.3, 150.6, 149.5, 140.7, 118.7, 
81.1, 42.4, 42.2, 27.7, 26.7, 25.8.; IR (ATR) ʋ: 3455 (NH2), 3358 (NH), 2980 (=CH), 
1714 (C=O), 1643 (N=C and C=C), 1329 (SO2) cm
-1. 
Method 2. To a mixture of compound 14 (613 mg, 2.00 mmol) in DCM (9 mL) was added 
TFA (0.83 mL, 10.8 mmol) and the mixture was stirred for 3 hours. TEA (1.5 mL) was added 
dropwise to the reaction mixture to form a white solid. The solid was collected by filtration 
and washed with DCM. To a mixture of the collected solid in THF (20mL) were added TEA 
(0.45 mL, 4.00 mmol) and sulfamoylating agent 167 (602 mg 2.00 mmol) and the mixture 
was stirred at 60C overnight. The mixture was concentrated under reduced pressure and the 
residue was purified by flash chromatography on silica (DCM:MeOH = 20:1 → 15:1) to 
yield a white sold (116 mg, 15 %). 
N-(4-(6-Amino-9H-purin-9-yl)butyl)-sulfamide (18) 
 
A solution of compound 17 (664 mg, 1.72 mmol) in DCM (12 mL) cooled down to 0 °C was 
treated with TFA (1.2 mL) and stirred at room temperature. After 2 h TFA (1.2 mL) was 
added. After being stirred at room temperature overnight the solvent was removed under 
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reduced pressure. The title compound was obtained as a colourless solid (641 mg) and was 
used without further purification. HRMS (ESI) calcd. for C9H15N7NaO2S [M + Na
+]: 
308.0906, found 308.0883; IR (ATR) ʋ: 3324 (NH2), 3212 (NH), 3011 (=CH), 1626 (N=C 
and C=C), 1332 (SO2) cm
-1. 
tert-Butyl (4-(6-benzamido-9H-purin-9-yl)butyl)carbamate (22)  
 
To a mixture of compound 14 (1.03 g, 3.36 mmol) in pyridine (5 mL) was slowly added 
BzCl (0.39 mL, 3.36 mmol) and the mixture was stirred at 100 C for 1 h. The mixture was 
concentrated under reduced pressure and the residue was purified by flash chromatography 
on silica (DCM:MeOH = 20:1) to yield a white solid (0.83 g, 60 %). 1H NMR (600 MHz, 
CDCl3) δ 9.30 (s, 1H), 8.74 (s, 1H), 8.06 – 7.93 (m, 3H), 7.59 – 7.52 (m, 1H), 7.47 (t, J = 
7.8 Hz, 2H), 4.71 (t, J = 6.2 Hz, 1H), 4.28 (t, J = 7.3 Hz, 2H), 3.16 (q, J = 6.7 Hz, 2H), 2.40 
(s, 1H), 1.92 (m, 2H), 1.50 (m, 2H), 1.39 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 164.9, 
156.2, 152.6, 152.2, 149.6, 143.1, 133.7, 132.8, 128.9, 128.0, 123.1, 79.5, 43.7, 39.6, 28.5, 
27.4, 27.2. 
tert-Butyl (N-(4-(6-benzamido-9H-purin-9-yl)butyl)sulfamoyl)carbamate (24)  
 
To a mixture of compound 22 (820 mg, 2.00 mmol) in DCM (9 mL) was added TFA (0.83 
mL, 10.8 mmol) and the mixture was stirred for 3 hours. TEA (1.5 mL) was added dropwise 
to the reaction mixture to form a white solid. The solid was collected by filtration and washed 
with DCM. To a mixture of the collected solid in THF (20mL) were added TEA (0.45 mL, 
4.00 mmol) and sulfamoylating agent 167 (602 mg 2.00 mmol) and the mixture was stirred 
at 60C overnight. The mixture was concentrated under reduced pressure and the residue 
was purified by flash chromatography on silica (DCM:acetone:MeOH = 50:25:1) to yield a 
white sold (320 mg, 34 %). 1H NMR (500 MHz, CDCl3) δ 9.26 (br s, 1H), 8.79 (s, 1H), 8.10 
– 7.99 (m, 3H), 7.66 – 7.57 (m, 1H), 7.52 (t, J = 7.6 Hz, 2H), 5.81 (br s, 1H), 4.33 (t, J = 7.1 
Hz, 2H), 3.14 (q, J = 5.9 Hz, 2H), 2.03 (m, 2H), 1.69 – 1.55 (m, 2H), 1.46 (s, 9H); 13C NMR 
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(126 MHz, CDCl3) δ 152.6, 152.4, 150.6, 149.7, 143.2, 133.7, 132.9, 128.9, 128.2, 123.3, 
83.9, 68.1, 43.6, 43.1, 28.1, 27.3, 26.2. 
N-(9-(4-(Sulfamoylamino)butyl)-9H-purin-6-yl)benzamide (25)  
 
To a mixture of compound 24 (140 mg, 0.286 mmol) in DCM (5 mL) was added TFA (0.5 
mL) and the mixture was stirred for 2 h. The mixture was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica (DCM:MeOH = 
6:1) to yield a white solid (105 mg, 94 %). 1H NMR (500 MHz, DMSO-d6) δ 11.11 (br s, 
1H), 8.73 (s, 1H), 8.50 (s, 1H), 8.09 – 8.00 (m, 2H), 7.69 – 7.60 (m, 1H), 7.55 (t, J = 7.7 Hz, 
2H), 6.47 (m, 3H), 4.28 (t, J = 7.1 Hz, 2H), 2.91 (q, J = 6.5 Hz, 2H), 1.91 (m, 2H), 1.52 – 
1.40 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 152.4, 151.3, 150.0, 144.7, 133.5, 132.3, 




To a mixture of sulfamide 18 (258 mg, 1.00 mmol) in DMF (3 ml) was added Cs2CO3 (232 
mg, 1.20 mmol) and biotin-NHS 268 (375 mg, 1.10 mmol). The mixture was concentrated 
under reduced pressure and the residue was purified by flash chromatography on silica (10% 
MeOH in DCM) to give the title compound as a crystalline solid (178 mg, 35%). 1H NMR 
(500 MHz, DMSO-d6) δ 11.25 (br s, 1H), 8.13 (s, 1H), 8.11 (s, 1H), 7.59 (t, J = 5.7 Hz, 1H), 
7.20 (s, 2H), 6.50 (s, 1H), 6.38 (s, 1H), 4.30 (dd, J = 7.6, 5.2 Hz, 1H), 4.20  4.07 (m, 3H), 
3.12  3.04 (m, 1H), 2.88 (dd, J = 12.9, 6.7 Hz, 2H), 2.80 (dd, J = 12.4, 5.1 Hz, 1H), 2.57 
(d, J = 12.4 Hz, 1H), 2.18 (t, J = 7.4 Hz, 2H), 1.91  1.73 (m, 2H), 1.67  1.55 (m, 1H), 
1.55  1.36 (m, 5H), 1.35  1.21 (m, 2H); 13C NMR (125 MHz, DMSO-d6): 171.6, 162.8, 
156.0, 152.4, 149.6, 140.8, 118.7, 61.1, 59.2, 55.4, 48.6, 42.5, 42.2, 35.0, 28.0, 26.8, 25.8, 
24.4; HRMS (ESI) calcd. for C19H30N9O4S2 [M + H
+]: 512.1857, found 512.1834; IR (ATR) 
ʋ: 3315 (NH2), 3283 (NH), 1638 (C=O), 1342 (SO2) cm
-1. 
Chapter Six   157 
_________________________________________________________________________ 
N-(9-(4-((N-((4-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)butyl)carbamoyl)sulfamoyl)amino)butyl)-9H-purin-6-yl)benzamide (27)  
 
To a mixture of compound 12 (77 mg, 0.23 mmol) and compound 25 (74 mg, 0.19 mmol) in 
MeCN (10 mL) was added DBU (43 µL, 0.29 mmol) and the resulting mixture was refluxed 
for 17 h. The solvent was evaporated under reduced pressure. The residue was dissolved in 
EtOAc and the organic layer was washed with 0.1N HCl, brine, and water. The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica (DCM:MeOH = 9:1) to yield a white solid (58 mg, 48%). 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (br s, 1H), 9.74 (br s, 1H), 8.72 (s, 1H), 8.47 (s, 
1H), 8.09 – 8.00 (m, 2H), 7.70 – 7.60 (m, 1H), 7.55 (t, J = 7.7 Hz, 2H), 7.35 (br s, 1H), 6.41 
(s, 1H), 6.34 (s, 1H), 6.26 (m, 1H), 4.27 (m, 3H), 4.11 (ddd, J = 7.5, 4.5, 1.7 Hz, 1H), 3.07 
(ddd, J = 8.4, 6.3, 4.4 Hz, 1H), 3.01 (q, J = 6.6 Hz, 2H), 2.93 (m, 2H), 2.79 (dd, J = 12.5, 
5.1 Hz, 1H), 2.56 (d, J = 12.5 Hz, 1H), 1.89 (m,2H), 1.62 (m, 1H), 1.54 – 1.24 (m, 7H); 13C 
NMR (126 MHz, DMSO-d6) δ 162.7, 152.4, 152.30, 152.29, 151.3, 150.0, 144.6, 132.3, 
128.42, 128.40, 125.3, 61.0, 59.2, 55.4, 42.8, 42.1, 39.8, 29.4, 27.9, 26.6, 25.9, 25.8. 
(3aS,4S,6aR)-4-(4-((((4-(6-Amino-9H-purin-9-
yl)butyl)sulfamoyl)carbamoyl)amino)butyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-
one (7)  
 
To a solution of compound 27 (50 mg, 0.079 mmol) in MeOH (1.6 mL) was added 30 % 
NH4OH (2.4 mL) and the mixture was stirred overnight. The mixture was concentrated under 
reduced pressure and the residue was purified by flash chromatography on silica 
(DCM:MeOH = 4:1) to yield a white solid (22 mg, 53 %). 1H NMR (500 MHz, DMSO-d6) 
δ 9.74 (br s, 1H), 8.13 (s, 1H), 8.11 (s, 1H), 7.33 (br s, 1H), 7.17 (s, 2H), 6.47 (s, 1H), 6.35 
(s, 1H), 6.21 (br s, 1H), 4.29 (dd, J = 7.7, 5.0 Hz, 1H), 4.17 – 4.09 (m, 3H), 3.08 (ddd, J = 
8.6, 6.2, 4.4 Hz, 1H), 3.01 (q, J = 6.6 Hz, 2H), 2.90 (q, J = 6.6 Hz, 2H), 2.80 (dd, J = 12.4, 
5.1 Hz, 1H), 2.57 (d, J = 12.4 Hz, 1H), 1.87 – 1.77 (m, 2H), 1.67 – 1.56 (m, 1H), 1.51 – 1.19 
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(m, 7H); 13C NMR (126 MHz, DMSO-d6) δ 162.7, 155.9, 152.3, 149.5, 140.7, 118.7, 61.0, 
59.2, 55.5, 42.4, 42.1, 38.8, 29.4, 28.0, 26.8, 25.82, 25.78; HRMS (ESI) calcd. for 
C19H30N10O4S2 [M + H
+]: 527.1966, found 527.1966. 
tert-Butyl (N-(4-(6-amino-9H-purin-9-yl)butyl)sulfamoyl)(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentyl)carbamate (29)  
 
To a mixture of sulfamide 17 (50 mg, 0.13 mmol) in DMF (2 mL) was added K2CO3 (27 
mg, 0.20 mmol) and biotin bromide 285 (42 mg, 0.14 mmol). The mixture was concentrated 
under reduced pressure and the residue was purified by flash chromatography on silica 
(DCM:MeOH = 15:1) to give a white solid (38 mg, 49%). 1H NMR (500 MHz, DMSO-d6) 
δ 8.12 (s, 1H), 8.11 (s, 1H), 7.61 (br s, 1H), 7.16 (s, 2H), 6.47 (s, 1H), 6.34 (s, 1H), 4.35 – 
4.25 (m, 1H), 4.12 (m, 3H), 3.48 (t, J = 7.5 Hz, 2H), 3.14 – 3.04 (m, 1H), 2.88 (m, 2H), 2.81 
(dd, J = 12.4, 5.1 Hz, 1H), 2.57 (d, J = 12.4 Hz, 1H), 1.82 (m, 2H), 1.59 (m, 1H), 1.55 – 
1.19 (m, 18H); 13C NMR (126 MHz, DMSO-d6) δ 162.7, 155.9, 152.3, 151.1, 149.6, 140.7, 
118.7, 82.4, 61.0, 59.2, 55.5, 47.4, 42.4, 42.3, 29.1, 28.3, 28.2, 27.6, 26.7, 26.1, 25.7. 
N-(4-(6-Amino-9H-purin-9-yl)butyl)-N-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentyl)sulfuric diamide (8)  
 
To a mixture of compound 29 (21 mg, 0.035 mmol) in DCM (0.5 mL) was added TFA (24 
µL, 0.32 mmol) and the mixture was stirred overnight. The mixture was quenched with TEA 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica (DCM:MeOH = 5:1) to yield a white solid (14 mg, 80 %). 1H NMR (500 MHz, 
DMSO-d6) δ 8.12 (d, 2H), 7.18 (s, 2H), 6.75 (t, J = 5.9 Hz, 1H), 6.71 (t, J = 5.9 Hz, 1H), 
6.48 (s, 1H), 6.36 (s, 1H), 4.30 (dd, J = 7.7, 5.1 Hz, 1H), 4.13 (m, 3H), 3.08 (ddd, J = 8.5, 
6.1, 4.3 Hz, 1H), 2.87 – 2.77 (m, 3H), 2.73 (m, 2H), 2.57 (d, J = 12.4 Hz, 1H), 1.82 (m, 2H), 
1.58 (m, 1H), 1.51 – 1.18 (m, 9H); 13C NMR (126 MHz, DMSO-d6) δ 162.8, 155.9, 152.3, 
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149.5, 140.8, 118.7, 61.0, 59.2, 55.5, 42.5, 42.1, 41.6, 39.8, 28.7, 28.3, 28.2, 27.0, 26.3, 26.1; 
HRMS (ESI) calcd. for C19H31N9O3S2 [M + H
+]: 498.2064, found 498.2069. 
tert-Butyl ((2-oxo-6-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)hexyl)sulfonyl)carbamate (32)  
 
To a mixture of sulfonamide 319 (0.90 g, 4.59 mmol) in anhydrous THF (30 mL) was added 
dropwise LDA (1.0 M in THF/hexane; 14.22 mL, 14.22 mmol) at 0C and the mixture was 
stirred for 1 h at 0C. Biotin ester 3010 (1.38 g, 5.07 mmol) was added and the reaction 
mixture was stirred for 3 h at 0C. The mixture was warmed to room temperature and stirred 
overnight. The reaction mixture was quenched with saturated aq NaCl (15 mL) and 0.5 M 
aq NaH2PO4 (15 mL) and extracted with EtOAc (2 X 15 mL). The aqueous layer was 
extracted with 10 % MeOH/DCM (6 X 15 mL) and the combined DCM extracts were dried 
over Na2SO4. The mixture was concentrated under reduced pressure and the residue was 
purified by flash chromatography on silica (DCM:MeOH = 15:1) to yield a white solid (223 
mg, 17 %). 1H NMR (500 MHz, DMSO-d6) δ 11.45 (br s, 1H), 6.41 (s, 1H), 6.34 (s, 1H), 
4.52 (s, 2H), 4.30 (dd, J = 7.7, 5.1 Hz, 1H), 4.12 (ddd, J = 7.5, 4.5, 1.8 Hz, 1H), 3.09 (ddd, 
J = 8.5, 6.3, 4.4 Hz, 1H), 2.81 (dd, J = 12.4, 5.1 Hz, 1H), 2.64 (td, J = 7.0, 4.1 Hz, 2H), 2.57 
(d, J = 12.4 Hz, 1H), 1.60 (m, 1H), 1.54 – 1.21 (m, 14H); 13C NMR (126 MHz, DMSO-d6) 
δ 198.9, 162.7, 61.8, 61.0, 59.2, 55.3, 42.9, 31.3, 28.1, 27.8, 27.7, 22.6. 
2-Oxo-6-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)hexane-1-
sulfonamide (33)  
 
To a solution of compound 32 (50 mg, 0.12 mmol) in DCM (1 mL) was added TFA (81 µL) 
and the mixture was stirred overnight. The mixture was concentrated under reduced pressure 
and was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ 7.10 (br s, 2H), 
4.30 (ddd, J = 7.7, 5.1, 1.0 Hz, 1H), 4.17 (s, 2H), 4.12 (dd, J = 7.7, 4.4 Hz, 1H), 3.09 (ddd, 
J = 8.5, 6.3, 4.4 Hz, 1H), 2.82 (dd, J = 12.4, 5.1 Hz, 1H), 2.72 – 2.59 (m, 2H), 2.57 (d, J = 
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12.4 Hz, 1H), 1.66 – 1.56 (m, 1H), 1.55 – 1.41 (m, 3H), 1.38 – 1.23 (m, 2H); 13C NMR (126 
MHz, DMSO-d6) δ 200.1, 162.7, 65.6, 61.0, 59.2, 55.3, 42.5, 28.1, 27.9, 22.7. 
N-(4-(6-Amino-9H-purin-9-yl)butyl)-2-oxo-6-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)hexane-1-sulfonamide (9)  
 
To a mixture of compound 33 (27 mg, 0.084 mmol) and adenine bromide 3411 (25 mg, 0.093 
mmol) in DMF (1 mL) was added Cs2CO3 (33 mg, 0.10 mmol) and the mixture was stirred 
overnight. The mixture was concentrated under reduced pressure and the residue was 
purified by flash chromatography on silica (DCM:MeOH = 5:1) to yield a white solid (22 
mg, 51 %). 1H NMR (500 MHz, DMSO-d6) δ 8.13 (s, 1H), 8.12 (s, 1H), 7.34 (t, J = 5.8 Hz, 
1H), 7.18 (s, 2H), 6.44 (s, 1H), 6.36 (s, 1H), 4.32 – 4.27 (m, 1H), 4.21 (s, 2H), 4.17 – 4.10 
(m, 3H), 3.08 (ddd, J = 8.5, 6.2, 4.4 Hz, 1H), 2.96 (m, 2H), 2.81 (dd, J = 12.5, 5.1 Hz, 1H), 
2.62 (td, J = 7.1, 2.8 Hz, 2H), 2.57 (d, J = 12.4 Hz, 1H), 1.87 – 1.77 (m, 2H), 1.59 (m, 1H), 
1.52 – 1.20 (m, 7H); 13C NMR (126 MHz, DMSO-d6) δ 200.1, 162.7, 155.9, 152.4, 149.5, 
140.8, 118.7, 62.1, 61.0, 59.2, 55.3, 42.7, 42.4, 42.0, 28.1, 27.9, 26.7, 26.6, 22.7; HRMS 
(ESI) calcd. for C20H30N8O4S2 [M + H
+]: 511.1904, found 511.1910. 
tert-Butyl ((2-hydroxy-6-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)hexyl)sulfonyl)carbamate (35)  
 
To a mixture of compound 32 (84 mg, 0.20 mmol) in MeOH (2 mL) was added NaBH4 (8 
mg, 0.21 mmol) and the mixture was stirred for 4 h. The reaction mixture was quenched with 
adding HCl to adjust pH of around 5. The mixture was concentrated under reduced pressure 
and the residue was purified by flash chromatography on silica (DCM:MeOH = 5:1) to yield 
a white solid (78 mg, 92 %). 1H NMR (500 MHz, DMSO-d6) δ 11.05 (br s, 1H), 6.41 (s, 
1H), 6.34 (s, 1H), 4.93 (br s, 1H), 4.30 (dd, J = 7.7, 5.1 Hz, 1H), 4.16 – 4.10 (m, 1H), 3.87 
(br s, 1H), 3.45 – 3.33 (m, 2H), 3.10 (ddd, J = 8.5, 6.1, 4.4 Hz, 1H), 2.82 (dd, J = 12.4, 5.1 
Hz, 1H), 2.57 (d, J = 12.4 Hz, 1H), 1.60 (m, 1H), 1.55 – 1.20 (m, 16H); 13C NMR (126 
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MHz, DMSO-d6) δ 162.7, 150.6, 81.9, 65.49, 65.47, 61.03, 61.00, 60.7, 59.2, 58.4, 55.5, 
55.4, 39.8, 36.41, 36.38, 29.2, 28.5, 28.4, 28.3, 28.2, 27.7, 24.70, 24.67. 
2-Hydroxy-6-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)hexane-1-
sulfonamide (36)  
 
To a solution of compound 37 (56 mg, 0.13 mmol) in DCM (1 mL) was added TFA (81 µL) 
and the mixture was stirred overnight. The mixture was concentrated under reduced pressure 
and was used without further purification. 
N-(4-(6-Amino-9H-purin-9-yl)butyl)-2-hydroxy-6-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)hexane-1-sulfonamide (10)  
 
To a mixture of compound 36 (21 mg, 0.064 mmol) and adenine bromide 3411 (19 mg, 0.070 
mmol) in DMF (1 mL) was added Cs2CO3 (25 mg, 0.077 mmol) and the mixture was stirred 
overnight. The mixture was concentrated under reduced pressure and the residue was 
purified by flash chromatography on silica (DCM:MeOH = 10:1 → 5:1) to yield a white 
solid (22 mg, 67 %). 1H NMR (500 MHz, Methanol-d4) δ 8.22 (s, 1H), 8.15 (d, J = 2.0 Hz, 
1H), 4.55 (br s, 1H), 4.50 (dd, J = 7.9, 5.0 Hz, 1H), 4.35 – 4.25 (m, 2H), 4.06 (m, 1H), 3.22 
(dt, J = 9.8, 5.3 Hz, 1H), 3.17 – 3.08 (m, 3H), 2.97 – 2.90 (m, 1H), 2.71 (d, J = 12.7 Hz, 
1H), 2.02 – 1.94 (m, 2H), 1.79 – 1.70 (m, 1H), 1.65 – 1.37 (m, 7H); 13C NMR (126 MHz, 
Methanol-d4) δ 166.1, 157.3, 153.7, 150.7, 142.8, 120.1, 68.1, 68.0, 67.9, 63.43, 63.41, 
63.39, 61.6, 59.6, 59.02, 58.97, 57.10, 57.08, 44.4, 43.3, 41.0, 37.8, 37.7, 37.5, 30.1, 30.01, 
30.00, 29.8, 29.7, 29.6, 28.3, 28.2, 26.2.; HRMS (ESI) calcd. for C20H32N8O4S2 [M + H
+]: 
513.2061, found 513.2066. 
6.4 Experimental work as described in Chapter 4 
cyclopent-1-ene-1-carbaldehyde (4.14) 
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To a solution of sodium periodate (7.1 g, 33.2 mmol) in water (62 mL) was added an ethyl 
ether solution (37 mL) of trans-1,2-cyclohexanediol 4.15 (3.0 g, 25.8 mmol). The solution 
was stirred for 30 min at ambient temperature. To the solution was added 20% aqueous KOH 
(10 mL) and the solution was stirred for 1 hour. The resulting organic layer was washed with 
water and brine. The organic layer was dried over anhydrous sodium sulfate and 
concentrated under reduced pressure to give a pale-yellow oil (1.20 g, 48%). 1H NMR (500 
MHz, CDCl3) δ 9.80 (s, 1H), 6.89 – 6.86 (m, 1H), 2.61 (tq, J = 7.5, 2.4 Hz, 2H), 2.54 (tq, J 
= 8.1, 2.2 Hz, 2H), 2.06 – 1.96 (m, 2H).; 13C NMR (126 MHz, CDCl3) δ 190.0, 153.2, 148.1, 
33.8, 28.5, 23.0.  
cyclopent-1-en-1-yl(2-methoxyphenyl)methanol (4.12) 
 
To a solution of 2-bromoanisole 4.13 (1.12 g, 6.0 mmol) in anhydrous THF (30 mL) was 
added n-BuLi (2 M solution, 3.1 mL, 6.2 mmol) at -78C over 10 min. After 1 hour, a 
solution of 4.14 (0.38 g, 4.0 mmol) in anhydrous THF (10 mL) was added to the mixture at 
-78C over 10 min and the mixture was stirred at -78C for 4 h. The reaction mixture was 
quenched with water. The mixture was extracted with EtOAc (30 mL) three times and the 
organics were washed with water (40 mL) and brine. The organic layer was dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica eluting with 5% → 10% EtOAc in hexane to give a 
colourless oil (0.52 g, 64%). 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.23 (m, 2H), 6.96 (td, J 
= 7.4, 1.1 Hz, 1H), 6.90 (d, J = 8.1 Hz, 1H), 5.64 (q, J = 2.0 Hz, 1H), 5.55 (d, J = 5.8 Hz, 
1H), 3.86 (s, 3H), 2.74 (d, J = 6.0 Hz, 1H), 2.41 – 2.19 (m, 4H), 1.95 – 1.82 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 157.1, 146.0, 130.8, 128.7, 127.9, 125.7, 120.9, 110.9, 70.1, 55.6, 
32.6, 32.5, 23.5. 
cyclopent-1-en-1-yl(2-methoxyphenyl)methanone (4.11) 
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To a solution of the alcohol 4.12 (440 mg, 2.15 mmol) in DCM (14 mL) was added Dess-
Martin Periodinane (1.37 g, 3.23 mmol) and the mixture was stirred overnight. DCM was 
evaporated and EtOAc (13 mL) an aqueous solution of 1:1 10 % sodium thiosulphate to 
saturated sodium bicarbonate (13 mL) was then added. After stirring for 10 min, the biphasic 
mixture was extracted with EtOAc (20 mL) three times. The combined organic phase was 
washed with saturated sodium bicarbonate (20 mL) and dried over anhydrous sodium 
sulphate. The organic phase was concentrated under reduced pressure and purified by flash 
chromatography on silica eluting with 5% EtOAc in hexane to give a colourless oil (321 mg, 
74%). 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.36 (m, 1H), 7.25 (dd, J = 7.5, 1.8 Hz, 1H), 
7.00 – 6.94 (m, 2H), 6.42 (ddt, J = 4.0, 2.9, 1.8 Hz, 1H), 3.81 (s, 3H), 2.76 – 2.68 (m, 2H), 
2.56 (tq, J = 7.5, 2.5 Hz, 2H), 2.06 – 1.97 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 194.4, 
156.9, 148.7, 146.5, 131.1, 130.3, 128.9, 120.2, 111.6, 55.9, 34.3, 30.7, 23.2. 
diethyl 2-(2-(2-methoxybenzoyl)cyclopentyl)malonate (4.16) 
 
NaH (60% dispersion in mineral oil; 11 mg, 0.27 mmol) was added slowly with ice-cooling 
under an N2 atmosphere to a solution of 4.11 (319 mg, 1.58 mmol) and diethylmalonate (320 
µL, 2.11 mmol) in EtOH (5 mL). The reaction mixture was stirred at ambient temperature 
for 15 min and then refluxed at 80C for 24 h. The reaction was quenched by addition of 
water. Ethanol was evaporated and the residue was extracted with EtOAc twice. The 
combined organic phase was dried over anhydrous sodium sulphate. The organic phase was 
concentrated under reduced pressure and purified by flash chromatography on silica eluting 
with 5% → 10% EtOAc in hexane to give 4.16 (1 : 2.5, cis : trans) as a colourless oil (498 
mg, 87%). A sample of the mixture was further purified to give pure cis and pure trans for 
characterisation.  
cis-4.16. 1H NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 7.7, 1.8 Hz, 1H), 7.42 (ddd, J = 8.2, 
7.3, 1.8 Hz, 1H), 6.98 (td, J = 7.5, 1.0 Hz, 1H), 6.93 (dd, J = 8.4, 0.9 Hz, 1H), 4.26 – 4.15 
(m, 2H), 4.12 (ddd, J = 8.4, 7.0, 3.5 Hz, 1H), 3.95 (dq, J = 10.8, 7.2 Hz, 1H), 3.88 (s, 3H), 
3.86 – 3.79 (m, 2H), 2.76 – 2.66 (m, 1H), 2.03 (dtd, J = 13.0, 8.7, 6.0 Hz, 1H), 1.96 – 1.75 
(m, 4H), 1.73 – 1.63 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.1 Hz, 3H); 13C NMR 
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(126 MHz, CDCl3) δ 206.0, 169.7, 169.3, 158.3, 133.2, 130.4, 129.6, 120.6, 111.7, 61.4, 
61.1, 55.7, 53.4, 51.4, 43.6, 30.8, 30.0, 23.6, 14.3, 13.9. 
trans-4.16. 1H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 7.6, 1.8 Hz, 1H), 7.43 (ddd, J = 8.4, 
7.4, 1.8 Hz, 1H), 7.00 (td, J = 7.5, 1.0 Hz, 1H), 6.95 (dd, J = 8.3, 1.0 Hz, 1H), 4.24 – 4.10 
(m, 2H), 4.04 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 3.79 (ddd, J = 9.8, 7.3, 5.9 Hz, 1H), 3.42 (d, 
J = 8.2 Hz, 1H), 3.21 (p, J = 8.1 Hz, 1H), 2.11 – 1.96 (m, 2H), 1.77 – 1.61 (m, 3H), 1.56 – 
1.48 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ 204.9, 169.1, 169.0, 158.2, 133.1, 130.6, 129.0, 120.8, 111.6, 61.31, 61.26, 56.1, 55.7, 
54.2, 41.0, 31.8, 31.3, 25.2, 14.2, 14.1. 
()-2-(trans-2-(2-methoxybenzoyl)cyclopentyl)malonic acid (4.10) 
 
Method 1. A mixture of 4.16 (1 : 2.5, cis : trans; 650 mg, 1.79 mmol) in 6N aqueous HCl 
(10 mL) was stirred at 90C for 2 days. The mixture was concentrated under reduced 
pressure and purified by flash chromatography on silica eluting with 25% → 80% EtOAc in 
hexane to give 4.10 (trans) as a white solid (346 mg, 63%). 
Method 2. A mixture of 4.16 (1 : 2.5, cis : trans; 186 mg, 0.51 mmol), THF (7.7 mL), and 
20% aqueous NaOH (2.6 mL) was refluxed at 80C for 6 h. THF was evaporated and the 
residue was extracted with ether, then with 10% aqueous NaOH three times. The aqueous 
layer was acidified with conc. HCl and extracted with DCM three times. The combined 
organic layer was dried over anhydrous sodium sulphate and concentrated under reduced 
pressure. The residue was triturated with hexane to give 4.10 (trans) as a pale yellow solid 
(145 mg, 93%). 1H NMR (500 MHz, DMSO-d6) δ 12.60 (br s, 2H), 7.52 – 7.42 (m, 2H), 
7.11 (d, J = 8.4 Hz, 1H), 6.99 (t, J = 7.4 Hz, 1H), 3.82 (s, 3H), 3.63 (dt, J = 9.4, 5.7 Hz, 
1H), 3.20 (d, J = 9.0 Hz, 1H), 2.98 – 2.87 (m, 1H), 1.97 – 1.79 (m, 2H), 1.67 – 1.39 (m, 4H); 
13C NMR (126 MHz, DMSO-d6) δ 204.3, 170.30, 170.25, 157.5, 132.9, 129.6, 128.7, 120.3, 
112.2, 55.8, 55.7, 53.6, 40.4, 30.9, 30.8, 24.7; HRMS calcd for C16H18O6 [M + H]
+ 307.1176, 
found 307.1176. 
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The reaction was repeated on separate samples of cis and trans to give 4.10 (trans) in both 
cases.  
()-2-(trans-2-(2-methoxybenzoyl)cyclopentyl)acetic acid (4.09) and ()-2-(trans-2-(2-
hydroxybenzoyl)cyclopentyl)acetic acid (trans-4.01) 
               
Method 1. A mixture of 4.16 (650 mg, 1.79 mmol) in 6N aqueous HCl (10 mL) was stirred 
at 90C for 2 days. The mixture was concentrated under reduced pressure and purified by 
flash chromatography on silica eluting with 25% → 33% EtOAc in hexane to give 4.09 as a 
yellow oil (134 mg, 29%) and trans-4.01 as a yellow oil (29 mg, 7%). 
Method 2. A solution of 4.10 (340 mg, 1.11 mmol) in AcOH (5 mL) was refluxed at 120C 
for 6 h. The solvent was evaporated and the residue was treated with water. The aqueous 
phase was extracted with DCM three times. The combined organic phase was dried over 
anhydrous sodium sulphate and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica eluting with 66% EtOAc in hexane to give 4.09 
as a colourless oil (229 mg, 79%) and trans-4.01 as a colourless oil (13 mg, 5%).  
4.09. 1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J = 7.6, 1.8 Hz, 1H), 7.43 (ddd, J = 8.3, 7.3, 
1.8 Hz, 1H), 6.99 (td, J = 7.5, 1.0 Hz, 1H), 6.95 (dd, J = 8.3, 1.0 Hz, 1H), 3.88 (s, 3H), 3.49 
(dt, J = 9.2, 7.4 Hz, 1H), 2.84 – 2.71 (m, 1H), 2.53 (dd, J = 15.5, 5.8 Hz, 1H), 2.33 (dd, J = 
15.5, 8.6 Hz, 1H), 2.10 – 1.94 (m, 2H), 1.83 – 1.64 (m, 3H), 1.37 (dq, J = 12.5, 8.3 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 206.1, 179.0, 157.9, 133.0, 130.0, 129.5, 120.8, 111.5, 56.5, 
55.6, 39.3, 39.1, 32.7, 30.6, 24.7. 
trans-4.01. 1H NMR (500 MHz, CDCl3) δ 12.46 (s, 1H), 7.77 (dd, J = 8.1, 1.6 Hz, 1H), 7.47 
(ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 6.99 (dd, J = 8.4, 1.2 Hz, 1H), 6.91 (ddd, J = 8.2, 7.1, 1.2 
Hz, 1H), 3.53 (dt, J = 9.6, 7.5 Hz, 1H), 2.97 – 2.84 (m, 1H), 2.49 (dd, J = 15.4, 6.4 Hz, 1H), 
2.38 (dd, J = 15.3, 7.9 Hz, 1H), 2.24 – 2.07 (m, 2H), 1.87 – 1.72 (m, 3H), 1.51 – 1.37 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ 208.4, 178.273, 163.1, 136.4, 130.3, 119.4, 119.0, 
118.7, 51.5, 38.7, 38.5, 32.6, 32.3, 24.9. 




To a slurry of NaH (60%, 0.92 g) in DMF (30 mL) was added dropwise 2-(4-
bromophenyl)ethanol 4.17 (2.80 mL, 20.0 mmol) at 0C, and the mixture was stirred at 
ambient temperature for 1 h. To the reaction mixture was added dropwise benzyl bromide 
(2.72 mL, 23.0 mmol) at 0C and the mixture was stirred at room temperature for 6 h. The 
resulting mixture was partitioned between saturated aqueous NH4Cl and EtOAc. The organic 
layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica eluting with 0% → 15% EtOAc 
in hexane to give a colourless oil (4.52 g, 78%). 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.39 
(m, 2H), 7.38 – 7.28 (m, 5H), 7.12 (dt, J = 8.3, 2.6 Hz, 2H), 4.54 – 4.50 (m, 2H), 3.69 (td, J 
= 6.9, 2.1 Hz, 2H), 2.89 (td, J = 6.9, 2.1 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 138.4, 




To a solution of 4.18 (4.37 g, 15 mmol) in anhydrous THF (75 mL) was added n-BuLi (2 M 
solution, 7.75 mL, 15.5 mmol) at -78C over 15 min. After 1 hour, a solution of 4.14 (0.96 
g, 10 mmol) in anhydrous THF (25 mL) was added to the mixture at -78C over 15 min and 
the mixture was stirred at -78C for 4 h. The reaction mixture was quenched with water (50 
mL). The mixture was extracted with EtOAc (50 mL) three times and the organics were 
washed with water (70 mL) and brine. The organic layer was dried over anhydrous sodium 
sulphate and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica eluting with 10% → 20% EtOAc in hexane to give a colourless 
oil (2.37 g, 77%). 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.26 (m, 7H), 7.24 – 7.18 (m, 2H), 
5.71 (td, J = 2.2, 1.4 Hz, 1H), 5.31 (t, J = 2.8 Hz, 1H), 4.54 (s, 2H), 3.70 (t, J = 7.1 Hz, 2H), 
2.94 (t, J = 7.2 Hz, 2H), 2.41 – 2.33 (m, 2H), 2.26 – 2.18 (m, 2H), 1.94 – 1.83 (m, 3H); 13C 
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NMR (126 MHz, CDCl3) δ 146.7, 140.6, 138.6, 138.5, 129.1, 128.5, 127.74, 127.68, 126.6, 
126.1, 74.0, 73.1, 71.3, 36.2, 32.4, 31.8, 23.5. 
(4-(2-(benzyloxy)ethyl)phenyl)(cyclopent-1-en-1-yl)methanone (4.20) 
 
To a solution of the alcohol 4.19 (2.23 g, 7.23 mmol) in DCM (45 mL) was added Dess-
Martin Periodinane (4.60 g, 10.85 mmol) and the mixture was stirred overnight. DCM was 
evaporated and EtOAc (30 mL) an aqueous solution of 1:1 10 % sodium thiosulphate to 
saturated sodium bicarbonate (30 mL) was then added. After stirring for 10 min, the biphasic 
mixture was extracted with EtOAc three times. The combined organic phase was washed 
with saturated sodium bicarbonate (60 mL) and dried over anhydrous sodium sulphate. The 
organic phase was concentrated under reduced pressure and purified by flash 
chromatography on silica eluting with 7.5% EtOAc in hexane to give a colourless oil (1.73 
g, 78%). 1H NMR (500 MHz, CDCl3) δ 7.72 – 7.67 (m, 2H), 7.39 – 7.28 (m, 7H), 6.54 (h, J 
= 2.0 Hz, 1H), 4.54 (s, 2H), 3.73 (t, J = 6.9 Hz, 2H), 2.99 (t, J = 6.9 Hz, 2H), 2.76 (ddt, J = 
9.9, 7.2, 2.2 Hz, 2H), 2.63 (tq, J = 7.5, 2.5 Hz, 2H), 2.02 (p, J = 7.6 Hz, 2H); 13C NMR (126 
MHz, CDCl3) δ 194.1, 146.4, 144.7, 143.6, 138.4, 137.2, 129.2, 128.9, 128.5, 127.72, 
127.69, 73.2, 70.8, 36.4, 34.5, 32.1, 22.9. 
diethyl 2-(2-(4-(2-(benzyloxy)ethyl)benzoyl)cyclopentyl)malonate (4.21)  
 
NaH (60% dispersion in mineral oil; 40 mg, 1.0 mmol) was added slowly with ice-cooling 
under an N2 atmosphere to a solution of 4.20 (1.73 g, 5.65 mmol) and diethylmalonate (1.14 
mL, 7.15 mmol) in EtOH (18 mL). The reaction mixture was stirred at ambient temperature 
for 15 min and then refluxed at 80C for 24 h. The reaction was quenched by addition of 
water. Ethanol was evaporated and the residue was extracted with EtOAc twice. The 
combined organic phase was dried over anhydrous sodium sulphate. The organic phase was 
concentrated under reduced pressure and purified by flash chromatography on silica eluting 
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with 10% → 15% EtOAc in hexane to give 4.21 (colourless oil) as a mixture of stereoisomers 
(2.29 g, 87%). 
1H NMR of 4.21 
 
13C NMR of 4.21 
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()-2-(trans-2-(4-(2-(benzyloxy)ethyl)benzoyl)cyclopentyl)malonic acid (4.22) 
 
A mixture of 4.21 (2.27 g, 4.87 mmol), THF (75 mL), and 20% aqueous NaOH (5 mL) was 
refluxed at 80C for 6 h. THF was evaporated and the residue was extracted with ether, then 
with 10% aqueous NaOH three times. The aqueous layer was acidified with conc. HCl and 
extracted with DCM three times. The combined organic layer was dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The residue was triturated with 
hexane to give a pale yellow solid (1.81 g, 91%). 1H NMR (500 MHz, DMSO-d6) δ 12.60 
(br s, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.35 – 7.29 (m, 2H), 7.29 – 
7.23 (m, 3H), 4.48 (s, 2H), 3.76 (dt, J = 9.7, 6.2 Hz, 1H), 3.68 (t, J = 6.7 Hz, 2H), 3.24 (d, 
J = 9.6 Hz, 1H), 3.05 – 2.97 (m, 1H), 2.92 (t, J = 6.7 Hz, 2H), 2.06 (ddt, J = 12.5, 9.9, 7.2 
Hz, 1H), 1.96 – 1.86 (m, 1H), 1.66 (tdd, J = 11.4, 6.8, 4.8 Hz, 1H), 1.57 – 1.36 (m, 3H); 13C 
NMR (126 MHz, DMSO-d6) δ 201.1, 170.37, 170.35, 144.7, 138.4, 134.6, 129.1, 128.3, 
128.2, 127.42, 127.38, 71.8, 70.0, 56.0, 48.9, 40.1, 35.4, 32.1, 31.1, 25.0. 
()-2-(trans-2-(4-(2-(benzyloxy)ethyl)benzoyl)cyclopentyl)acetic acid (4.23) 
 
Method1. A solution of 4.22 (1.70 g, 4.14 mmol) in AcOH (16 mL) was refluxed at 120C 
for 10 h. The solvent was evaporated and the residue was treated with water. The aqueous 
phase was extracted with DCM three times. The combined organic phase was dried over 
anhydrous sodium sulphate and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica eluting with 33% EtOAc in hexane to give a 
colourless oil (1.18 g, 78%). 
Method 2. To a mixture of 4.22 (1.00g, 2.44 mmol) in THF (10 mL) was portionwise added 
CDI (0.44 g, 2.68 mmol) and the mixture was stirred for 1 h. To the reaction mixture was 
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added 1 mL aqueous solution of NaOH (0.15 g, 3.65 mmol) and the mixture was stirred for 
2 h. THF was evaporated and acidified with 1N HCl. The mixture was extracted with DCM 
twice and the combined organic phase was dried over anhydrous sodium sulphate. The 
organic phase was concentrated under reduced pressure and purified by flash 
chromatography on silica eluting with 33% EtOAc in hexane to give a colourless oil (0.63 
g, 72%). 1H NMR (500 MHz, CDCl3) δ 7.92 – 7.86 (m, 2H), 7.38 – 7.28 (m, 7H), 4.53 (s, 
2H), 3.73 (t, J = 6.8 Hz, 2H), 3.53 – 3.45 (m, 1H), 2.99 (t, J = 6.8 Hz, 2H), 2.93 – 2.82 (m, 
1H), 2.49 (dd, J = 15.3, 6.2 Hz, 1H), 2.35 (dd, J = 15.3, 8.0 Hz, 1H), 2.19 – 2.04 (m, 2H), 
1.83 – 1.68 (m, 3H), 1.43 (dq, J = 12.2, 8.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 201.8, 
177.3, 144.9, 138.3, 135.3, 129.3, 128.7, 128.5, 127.78, 127.76, 73.2, 70.6, 52.0, 38.7, 38.6, 
36.5, 32.6, 31.7, 24.9. 
()-2-(trans-2-(4-(2-hydroxyethyl)benzyl)cyclopentyl)acetic acid (4.08) 
 
4.23 (550 mg, 1.50 mmol) in EtOH (15 mL) was hydrogenated under Pd/C (10%, 55 mg) 
and H2 balloon for 2 h. The mixture was filtered over a Celite pad, washed with EtOH, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on 
silica eluting with 3.3% → 10% MeOH in DCM to give a colourless oil (350 mg, 89%). 1H 
NMR (500 MHz, CDCl3) δ 7.18 – 7.09 (m, 4H), 3.86 (td, J = 6.6, 0.9 Hz, 2H), 2.85 (t, J = 
6.5 Hz, 2H), 2.75 (dd, J = 13.5, 5.6 Hz, 1H), 2.49 (dd, J = 13.4, 8.4 Hz, 1H), 2.40 (dd, J = 
15.0, 5.1 Hz, 1H), 2.18 (dd, J = 14.9, 8.4 Hz, 1H), 2.05 – 1.91 (m, 2H), 1.83 – 1.69 (m, 2H), 
1.66 – 1.51 (m, 2H), 1.37 – 1.24 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 178.1, 139.7, 135.9, 
129.3, 129.1, 63.9, 47.4, 41.6, 40.8, 39.5, 38.7, 32.6, 32.3, 23.7. 
()-4-((trans-2-(carboxymethyl)cyclopentyl)methyl)benzoic acid (4.04), ()-2-(trans-2-(4-
(carboxymethyl)benzyl)cyclopentyl)acetic acid (4.06), and ()-2-(trans-2-(4-
formylbenzyl)cyclopentyl)acetic acid (4.24) 
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To a solution of 4.08 (220 mg, 0.84 mmol) in DMF (10 mL) was added PDC (1.58 g, 4.19 
mmol) and the mixture was stirred for 24 h. The mixture was poured onto water and extracted 
with EtOAc three times. The combined organic phase was washed with brine and water, 
dried over anhydrous sodium sulphate, and concentrated under reduced pressure. The residue 
was purified by flash chromatography on silica eluting with 2.5% → 5% MeOH in DCM to 
give 4.24 as a white solid (31 mg, 15%) and a mixture of 4.04 and 4.06. The mixture of 4.04 
and 4.06 was purified by flash chromatography on silica eluting with 25% → 50% EtOAc 
in hexane to give 4.04 as a white solid (35 mg, 16%) and 4.06 as a white solid (71 mg, 31%). 
4.04. 1H NMR (500 MHz, DMSO-d6) δ 12.37 (br s, 2H), 7.84 (d, J = 7.9 Hz, 2H), 7.29 (d, J 
= 7.9 Hz, 2H), 2.87 (dd, J = 13.3, 4.9 Hz, 1H), 2.44 (dd, J = 13.3, 9.5 Hz, 1H), 2.36 (dd, J 
= 15.2, 4.3 Hz, 1H), 2.06 (dd, J = 15.1, 8.7 Hz, 1H), 1.84 (tq, J = 13.5, 7.8, 6.5 Hz, 2H), 
1.72 (tt, J = 13.8, 6.9 Hz, 1H), 1.60 – 1.42 (m, 3H), 1.27 – 1.15 (m, 2H); 13C NMR (126 
MHz, DMSO-d6) δ 174.1, 167.3, 146.8, 129.3, 128.9, 128.3, 46.3, 41.5, 40.0, 39.0, 31.8, 
31.2, 22.7; HRMS calcd for C15H18O4 [M + H]
+ 263.1278, found 263.1284. 
4.06. 1H NMR (500 MHz, DMSO-d6) δ 12.08 (s, 2H), 7.14 (d, J = 7.9 Hz, 2H), 7.10 (d, J = 
8.2 Hz, 2H), 3.50 (s, 2H), 2.78 (dd, J = 13.4, 4.8 Hz, 1H), 2.41 – 2.28 (m, 2H), 2.05 (dd, J 
= 15.1, 9.0 Hz, 1H), 1.89 – 1.76 (m, 2H), 1.72 – 1.62 (m, 1H), 1.60 – 1.41 (m, 3H), 1.25 – 
1.15 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 174.1, 172.8, 139.6, 132.2, 129.1, 128.6, 
46.5, 41.4, 40.3, 39.6, 39.0, 31.8, 31.2, 22.8; HRMS calcd for C16H20O4 [M + Na]
+ 299.1254, 
found 299.1262. 
4.24. 1H NMR (500 MHz, CDCl3) δ 9.98 (s, 1H), 7.81 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 7.9 
Hz, 2H), 2.92 (dd, J = 13.4, 5.3 Hz, 1H), 2.55 (dd, J = 13.4, 9.3 Hz, 1H), 2.46 (dd, J = 15.1, 
4.8 Hz, 1H), 2.24 (dd, J = 15.2, 8.5 Hz, 1H), 2.05 – 1.94 (m, 2H), 1.87 – 1.78 (m, 1H), 1.75 
– 1.52 (m, 3H), 1.39 – 1.24 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 192.2, 178.0, 149.1, 
134.7, 130.1, 129.7, 47.1, 41.9, 41.3, 39.2, 32.4, 32.1, 23.5; HRMS calcd for C15H18O3 [M 
+ H]+ 247.1329, found 247.1338. 
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()-2-(trans-2-(4-(2-hydroxyethyl)benzoyl)cyclopentyl)acetic acid (4.07) 
 
To a solution of 4.23 (135 mg, 0.37 mmol) in anhydrous DCM (10 mL) was added anhydrous 
FeCl3 (179 mg, 1.11 mmol) and the mixture was stirred for 3.5 h. The reaction was quenched 
with water and diluted with DCM. The mixture was washed with brine and water, dried over 
anhydrous sodium sulphate, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica eluting with 5% MeOH in DCM to give a white 
solid (56 mg, 55%). 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.1 
Hz, 2H), 3.89 (t, J = 6.5 Hz, 2H), 3.49 (dt, J = 9.1, 7.1 Hz, 1H), 2.92 (t, J = 6.5 Hz, 2H), 
2.84 (dt, J = 8.9, 7.5 Hz, 1H), 2.45 (dd, J = 15.3, 6.7 Hz, 1H), 2.36 (dd, J = 15.3, 7.6 Hz, 
1H), 2.17 – 2.01 (m, 2H), 1.84 – 1.67 (m, 3H), 1.42 (dq, J = 12.3, 8.2 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 202.1, 177.8, 144.4, 135.5, 129.4, 128.9, 63.3, 51.9, 39.2, 38.9, 38.8, 
32.7, 31.7, 24.9; HRMS calcd for C16H20O4 [M + Na]
+ 299.1254, found 299.1254. 
()-4-(trans-2-(carboxymethyl)cyclopentane-1-carbonyl)benzoic acid (4.03) and ()-2-
(trans-2-(4-formylbenzoyl)cyclopentyl)acetic acid (4.25) 
 
To a solution of 4.07 (35 mg, 0.127 mmol) in DMF (2 mL) was added PDC (239 mg, 0.635 
mmol) and the mixture was stirred for 24 h. The mixture was poured onto water and extracted 
with EtOAc three times. The combined organic phase was washed with brine and water, 
dried over anhydrous sodium sulphate, and concentrated under reduced pressure. The residue 
was purified by flash chromatography on silica eluting with 5% → 10% MeOH in DCM to 
give 4.25 as a white solid (4 mg, 12%) and impure 4.03. This sample of 4.03 was further 
purified by preparative TLC eluting with 0.5% AcOH in hexane/EtOAc (1:3) to give 4.03 as 
a white solid (9 mg, 26%). 
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4.03. 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.3 Hz, 2H), 8.00 (d, J = 8.4 Hz, 2H), 3.64 
– 3.53 (m, 1H), 2.87 (h, J = 7.8 Hz, 1H), 2.50 (dd, J = 15.1, 6.3 Hz, 1H), 2.41 (dd, J = 15.1, 
8.6 Hz, 1H), 2.11 (dq, J = 15.1, 9.8, 7.6 Hz, 2H), 1.84 – 1.74 (m, 3H), 1.52 – 1.38 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 202.8, 176.7, 168.9, 140.9, 133.3, 130.4, 128.4, 51.8, 39.8, 
39.4, 33.3, 32.1, 25.5; HRMS calcd for C15H16O5 [M + Na]
+ 299.0890, found 299.0894. 
4.25. 1H NMR (500 MHz, CDCl3) δ 10.11 (s, 1H), 8.09 (d, J = 8.3 Hz, 2H), 7.98 (d, J = 8.3 
Hz, 2H), 3.57 – 3.49 (m, 1H), 2.94 – 2.84 (m, 1H), 2.51 – 2.38 (m, 2H), 2.20 – 2.07 (m, 2H), 
1.85 – 1.71 (m, 3H), 1.44 (dq, J = 12.5, 8.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 201.8, 
191.8, 177.6, 141.5, 139.0, 130.0, 129.0, 52.5, 38.7, 38.6, 32.8, 31.6, 25.0; HRMS calcd for 
C15H16O4 [M + Na]
+ 283.0941, found 283.0949. 
()-2-(trans-2-(4-(carboxymethyl)benzoyl)cyclopentyl)acetic acid (4.05) 
 
A solution of 4.07 (60 mg, 0.22 mmol) in acetone (3 mL) was treated with Jones reagent 
(0.33 mL of a 2.7 M solution, prepared via standard method) slowly dropwise at 0C for 10 
min. The resulting reaction mixture was stirred at 0C for 1 h and then was quenched with 
isopropanol. The mixture was filtered with a pad of Celite and the pad of Celite was 
washed with EtOAc. The combined organic phase was washed with brine and water, dried 
over anhydrous sodium sulphate, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica eluting with 5% → 10% MeOH in DCM to give 
a white solid (58 mg, 91%). 1H NMR (500 MHz, DMSO-d6) δ 12.22 (br s, 2H), 7.90 (d, J = 
8.2 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 3.67 (s, 2H), 3.56 (dt, J = 9.1, 7.1 Hz, 1H), 2.63 (h, J 
= 7.7 Hz, 1H), 2.30 (dd, J = 15.3, 6.4 Hz, 1H), 2.22 (dd, J = 15.3, 8.2 Hz, 1H), 2.13 – 2.00 
(m, 1H), 1.96 – 1.85 (m, 1H), 1.75 – 1.64 (m, 1H), 1.63 – 1.49 (m, 2H), 1.40 – 1.27 (m, 1H); 
13C NMR (126 MHz, DMSO-d6) δ 201.4, 173.7, 172.1, 140.4, 135.1, 129.8, 128.3, 51.0, 
40.5, 38.8, 38.3, 32.2, 31.0, 24.5; HRMS calcd for C16H18O5 [M + Na]
+ 313.1046, found 
313.1045. 
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To a solution of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (776 mg, 4.4 mmol) in 
DCM (20 mL) was added NMM (0.66 mL, 6.0 mmol) under ice-bath. A white suspension 
was formed after 30 min, and benzoic acid (537 mg, 4.4 mmol) was added, resulting in the 
formation of a pink suspension. After stirring the mixture for 1 h, a solution of 2-
deoxycytidine 5.01 (400 mg, 1.76 mmol) in DMF (12 mL) was added dropwise and stirred 
at ambient temperature for 24 h. The resulting clear solution was concentrated under reduced 
pressure, dissolved in a minimum amount of water, and extracted with EtOAc (40 mL) four 
times. The combined organic phase was dried over anhydrous sodium sulphate and 
concentrated under reduced pressure. The residue was purified by flash chromatography on 
silica eluting with 2.5% → 5% → 10% MeOH in DCM to give a white solid (414 mg, 71%).  
1H NMR (500 MHz, DMSO-d6) δ 11.22 (br s, 1H), 8.39 (d, J = 7.5 Hz, 1H), 8.00 (dd, J = 
8.4, 1.4 Hz, 2H), 7.67 – 7.57 (m, 1H), 7.51 (t, J = 7.8 Hz, 2H), 7.35 (d, J = 7.4 Hz, 1H), 6.13 
(t, J = 6.3 Hz, 1H), 5.27 (d, J = 4.2 Hz, 1H), 5.06 (t, J = 5.2 Hz, 1H), 4.23 (dq, J = 7.5, 4.0 
Hz, 1H), 3.87 (q, J = 3.8 Hz, 1H), 3.70 – 3.52 (m, 2H), 2.31 (ddd, J = 13.3, 6.1, 3.9 Hz, 1H), 
2.05 (dt, J = 13.0, 6.3 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 167.3, 163.0, 154.4, 145.0, 
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To a mixture of 5.11 (5.49 g, 16.6 mmol), Ph3P (4.44 g, 16.9 mmol) and NaN3 (1.83 g, 28.1 
mmol) in anhydrous DMF (55 mL) was added CBr4 (5.61 g, 16.9 mmol) and the reaction 
mixture was stirred for 24 h. The reaction was quenched by the addition of MeOH and 
stirring was continued for 1 h. The solvent was evaporated and the residue was purified by 
flash chromatography on silica eluting with 5% MeOH in DCM to give a white solid (4.53 
g, 77%). 1H NMR (500 MHz, CDCl3) δ 8.93 (br s, 1H), 8.16 (d, J = 7.5 Hz, 1H), 7.95 – 7.89 
(m, 2H), 7.66 – 7.60 (m, 1H), 7.53 (dd, J = 8.3, 7.2 Hz, 2H), 6.32 (t, J = 6.3 Hz, 1H), 4.44 
(dt, J = 6.7, 4.2 Hz, 1H), 4.20 (q, J = 3.9 Hz, 1H), 3.80 (dd, J = 13.2, 3.5 Hz, 1H), 3.67 (dd, 
J = 13.2, 4.0 Hz, 1H), 2.74 (ddd, J = 13.9, 6.2, 4.2 Hz, 1H), 2.21 (dt, J = 13.6, 6.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 162.6, 144.4, 133.4, 133.1, 129.2, 127.8, 97.2, 87.3, 85.2, 




2-Deoxycytidine 5.01 (250 mg, 1.10 mmol) was dissolved in anhydrous pyridine (3 mL) 
and concentrated under reduced pressure three times to remove any traces of water. The 
residue was dissolved in anhydrous pyridine (10 mL) and TsCl (220 mg, 1.16 mmol) was 
added. The mixture was stirred at 5 C for 19 h and TsCl (54 mg, 0.28 mmol) added more. 
After another 4 hr, TLC analysis indicated full conversion and the solvent was removed 
under reduced pressure. The residue was purified by flash chromatography on silica eluting 
with 12% MeOH in DCM to give a white solid (166 mg, 40%). Contains an impurity, looks 
like TsOH. 1H NMR (500 MHz, DMSO-d6) δ 8.23 (br s, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.71 
(br s, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 6.10 (t, J = 6.5 Hz, 1H), 5.84 
(d, J = 7.5 Hz, 1H), 5.45 (br s, 1H), 4.25 (dd, J = 11.0, 3.5 Hz, 1H), 4.17 (dd, J = 11.0, 6.0 
Hz, 1H), 4.12 (d, J = 5.0 Hz, 1H), 3.89 (dt, J = 7.5, 3.5 Hz, 1H), 2.43 (s, 3H), 2.14 (ddd, J 
= 13.5, 6.5, 4.5 Hz, 1H), 2.07 (dt, J = 13.5, 6.5 Hz, 1H); HRMS calcd for C16H20N3O6S [M 
+ H]+ 382.1067, found 382.1061. 
4-amino-1-((2R,4S,5R)-5-(azidomethyl)-4-hydroxytetrahydrofuran-2-yl)pyrimidin-2(1H)-
one (5.09) 
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Tosylate 5.12 (0.15 g, 0.40 mmol) was dissolved in anhydrous DMF (4 ml) and NaN3 (39 
mg, 0.60 mmol) was added. The mixture was heated to 45oC. After 18 hr, more NaN3 (13 
mg, 0.20 mmol) was added. When TLC analysis indicated full conversion of the starting 
material, the solvent was removed under reduced pressure. The residue was purified by flash 
chromatography on silica eluting with 18% MeOH in DCM to give a colourless film (46 mg, 
46%). 1H NMR (500 MHz, DMSO-d6) δ 7.63 (d, J = 7.5 Hz, 1H), 7.35 (br s, 1H), 7.22 (br 
s, 1H), 6.21 (t, J = 7.0 Hz, 1H), 5.77 (d, J = 7.5 Hz, 1H), 5.39 (d, J = 4.0 Hz, 1H), 4.17 – 
4.12 (m, 1H), 3.84 (dt, J = 6.0, 4.0 Hz, 1H), 3.61 – 3.50 (m, 2H), 2.16 – 2.03 (m, 2H); 13C 
NMR (126 MHz, DMSO-d6) δ 165.1, 154.5, 141.2, 94.4, 84.8, 84.5, 70.8, 51.8, 39.2.; HRMS 
calcd for C9H12N6O3 [M + Na]




Method 1 (Table 5.1 entry 1) 
The mixture of 5.08 (200 mg, 0.604 mmol) and 10% Pd/C (20 mg) in MeOH/DMF (1:1; 2 
mL) was stirred under H2 gas balloon for 2 h. The mixture was filtered over a Celite pad, 
washed with MeOH, and concentrated under reduced pressure. The residue was triturated 
with DCM. 1H NMR of crude material confirmed the presence of a complex mixture only. 
Method 2 (Table 5.1 entry 2) 
To the solution of 5.08 (4.33 g, 12.15 mmol) in anhydrous pyridine (60 mL) was added Ph3P 
(3.66 g, 13.97 mmol). After 3 h, water (12 mL) was added and stirring was continued for 3 
h. The mixture was diluted with water and extracted with EtOAc twice. The aqueous phase 
was concentrated under reduced pressure and the residue was purified by flash 
chromatography on silica eluting with 15% → 30% MeOH in DCM to give a white solid 
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(1.72 g, 43%). 1H NMR (500 MHz, DMSO-d6) δ 8.39 (d, J = 7.5 Hz, 1H), 8.03 – 7.97 (m, 
2H), 7.62 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (d, J = 7.4 Hz, 1H), 6.12 (t, J = 
6.4 Hz, 1H), 5.21 (s, 1H), 4.19 (dt, J = 6.9, 3.7 Hz, 1H), 3.78 (td, J = 5.2, 3.4 Hz, 1H), 2.77 
(d, J = 5.3 Hz, 2H), 2.30 (ddd, J = 13.5, 6.3, 3.8 Hz, 1H), 2.05 (dt, J = 13.2, 6.4 Hz, 1H); 
13C NMR (126 MHz, DMSO-d6) δ 167.5, 162.9, 154.3, 145.2, 133.2, 132.7, 128.40, 128.39, 
96.2, 88.6, 85.9, 70.6, 43.4, 40.6. 
()-2-(trans-2-(2-hydroxybenzoyl)cyclopentyl)-N-(prop-2-yn-1-yl)acetamide (5.06) 
 
To a solution of trans-4.01 (38 mg, 0.15 mmol) and propargyl amine (11 µL, 0.17 mmol) in 
DMF (1 mL) were added HATU (87 mg, 0.23 mmol) and DIPEA (80 µL, 0.46 mmol), and 
the mixture was stirred for 2 h. Saturated aqueous NH4Cl was added and extracted with 
EtOAc three times. The combined organic phase was dried over anhydrous sodium sulphate 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica eluting with 30% → 50% EtOAc in hexane to give a white solid (38 mg, 87%). 1H 
NMR (500 MHz, CDCl3) δ 12.44 (s, 1H), 7.79 (dd, J = 8.0, 1.5 Hz, 1H), 7.49 – 7.44 (m, 
1H), 6.98 (dd, J = 8.5, 1.0 Hz, 1H), 6.93 – 6.88 (m, 1H), 5.65 (br s, 1H), 3.97 (dd, J = 5.0, 
2.5 Hz, 2H), 3.59 (dd, J = 16.0, 8.5 Hz, 1H), 2.89 – 2.79 (m, 1H), 2.33 (dd, J = 14.5, 7.0 Hz, 
1H), 2.25 (dd, J = 14.5, 7.5 Hz, 1H), 2.21 – 2.13 (m, 2H), 2.12 – 2.03 (m, 1H), 1.85 – 1.70 
(m, 3H), 1.52 – 1.42 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 208.7, 171.4, 163.1, 136.5, 
130.5, 119.1, 118.7, 79.5, 71.7, 51.6, 41.1, 39.4, 32.7, 32.3, 29.3, 24.9; HRMS calcd for 
C17H23N2O3 [M + NH4]
+ 303.1703, found 303.1706. 
()-2-(trans-2-(2-methoxybenzoyl)cyclopentyl)-N-(prop-2-yn-1-yl)acetamide (5.07) 
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To a solution of 4.09 (220 mg, 0.839 mmol) and propargyl amine (59 µL, 0.923 mmol) in 
DMF (4 mL) were added HATU (479 mg, 1.26 mmol) and DIPEA (439 µL, 2.52 mmol), 
and the mixture was stirred for 2 h. Saturated aqueous NH4Cl was added and extracted with 
EtOAc three times. The combined organic phase was dried over anhydrous sodium sulphate 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica eluting with 30% → 50% EtOAc in hexane to give a white solid (225 mg, 90%). 
1H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 7.7, 1.8 Hz, 1H), 7.45 (ddd, J = 8.1, 7.3, 1.8 
Hz, 1H), 7.01 (td, J = 7.5, 1.0 Hz, 1H), 6.96 (dd, J = 8.4, 1.0 Hz, 1H), 5.84 (br s, 1H), 4.06 
– 3.93 (m, 2H), 3.89 (s, 3H), 3.47 (dt, J = 9.4, 7.4 Hz, 1H), 2.78 – 2.66 (m, 1H), 2.41 (dd, J 
= 14.4, 6.2 Hz, 1H), 2.27 – 2.16 (m, 2H), 2.08 – 1.97 (m, 2H), 1.78 – 1.62 (m, 3H), 1.47 – 
1.34 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 206.3, 171.9, 158.0, 133.1, 130.1, 129.4, 120.9, 





5.07 (53 mg, 0.15 mmol) and 5.08 (45 mg, 0.15 mmol) were dissolved in MeCN/H2O (2:1; 
1 mL) and copper nano powder (4 mg, 0.06 mmol) was added. The mixture was sonicated 
for 30 min and stirred overnight. The mixture was concentrated under reduced pressure and 
the residue was purified by flash chromatography on silica eluting with 10% → 20% MeOH 
in DCM to give 5.13 (white solid) as a mixture of diastereomers (72 mg, 74%). 1H NMR 
(500 MHz, CDCl3) δ 9.07 (br s, 1H), 7.93 (d, J = 7.7 Hz, 2H), 7.80 – 7.57 (m, 3H), 7.55 – 
7.36 (m, 4H), 7.00 – 6.88 (m, 2H), 6.84 – 6.75 (m, 1H), 6.12 (q, J = 5.8 Hz, 1H), 4.81 – 4.70 
(m, 1H), 4.70 – 4.49 (m, 2H), 4.46 (d, J = 5.5 Hz, 1H), 4.43 – 4.33 (m, 2H), 4.33 – 4.23 (m, 
1H), 3.84 (s, 3H), 3.46 (dq, J = 16.3, 8.1 Hz, 1H), 2.80 – 2.61 (m, 1H), 2.56 (dq, J = 12.1, 
6.0 Hz, 1H), 2.34 (ddd, J = 20.9, 13.9, 6.9 Hz, 1H), 2.27 – 2.06 (m, 2H), 2.03 – 1.87 (m, 
2H), 1.69 – 1.52 (m, 3H), 1.41 – 1.21 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 206.51, 
206.35, 172.90, 172.85, 157.88, 157.86, 133.37, 133.33, 133.13, 133.11, 130.10, 130.00, 
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129.31, 129.21, 129.14, 129.12, 127.91, 120.84, 111.70, 111.66, 84.42, 84.18, 71.07, 70.58, 






To a solution of 5.13 (67 mg, 0.10 mmol) in MeOH (2 mL) was added 30% NH4OH (3 mL) 
and the mixture was stirred overnight. The mixture was concentrated under reduced pressure 
and the residue was purified by flash chromatography on silica eluting with 20% MeOH in 
DCM to give 5.14 (white solid) as a mixture of diastereomers (48 mg, 85%). 1H NMR (500 
MHz, MeOH-d4) δ 7.81 (s, 1H), 7.51 – 7.45 (m, 3H), 7.11 – 7.06 (m, 1H), 7.00 (t, J = 7.5 
Hz, 1H), 6.17 (t, J = 6.6 Hz, 1H), 5.90 (dd, J = 7.5, 3.5 Hz, 1H), 4.71 (ddd, J = 14.4, 3.8, 
1.9 Hz, 1H), 4.66 – 4.56 (m, 1H), 4.41 – 4.26 (m, 3H), 4.18 – 4.12 (m, 1H), 3.87 (s, 3H), 
3.52 (dt, J = 9.5, 7.1 Hz, 1H), 2.78 – 2.68 (m, 1H), 2.37 – 2.26 (m, 2H), 2.20 (ddd, J = 13.7, 
8.3, 2.0 Hz, 1H), 2.14 – 1.98 (m, 2H), 1.95 – 1.86 (m, 1H), 1.76 – 1.57 (m, 3H), 1.39 – 1.28 
(m, 1H); 13C NMR (126 MHz, MeOH-d4) δ 208.32, 208.26, 175.03, 175.02, 167.63, 159.43, 
158.03, 146.46, 146.41, 142.65, 142.58, 134.34, 130.79, 125.32, 125.27, 121.65, 112.94, 
112.93, 96.39, 96.37, 87.94, 87.87, 85.66, 72.45, 57.87, 56.12, 52.75, 52.73, 42.31, 42.29, 
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Method 1. To a mixture of 5.14 (39 mg, 0.071 mmol) in DCM (2 mL) was added AlCl3 (47 
mg, 0.35 mmol) and the mixture was stirred overnight. The reaction was quenched with 
water and the solvents were evaporated. The residue was purified by flash chromatography 
on silica eluting with 1% TEA in MeOH/DCM (7:1) to give a mixture of the starting material 
5.14 and desired product 5.03 based on 1H NMR. 
Method 2. 5.06 (15 mg, 0.053 mmol) and 5.09 (13 mg, 0.053 mmol) were dissolved in 
MeCN/H2O (2:1; 1 mL) and copper nano powder (2 mg) was added. The mixture was 
sonicated for 30 min and stirred overnight. The mixture was concentrated under reduced 
pressure and the residue was purified by flash chromatography on silica eluting with 1% 
TEA in MeOH/DCM (7:1) to give 5.03 (white solid) as a mixture of diastereomers (15 mg, 
53%). 1H NMR (500 MHz, MeOH-d4) δ 7.89 (ddd, J = 8.3, 2.7, 1.6 Hz, 1H), 7.79 (d, J = 
2.9 Hz, 1H), 7.52 – 7.46 (m, 2H), 6.97 – 6.90 (m, 2H), 6.18 (t, J = 6.6 Hz, 1H), 5.89 (dd, J 
= 7.5, 3.2 Hz, 1H), 4.73 (dd, J = 14.4, 3.7 Hz, 1H), 4.64 (ddd, J = 14.4, 7.2, 3.7 Hz, 1H), 
4.38 – 4.30 (m, 2H), 4.25 (dd, J = 15.3, 3.0 Hz, 1H), 4.15 (dtd, J = 6.5, 4.0, 2.2 Hz, 1H), 
3.66 (dtd, J = 9.6, 7.0, 2.7 Hz, 1H), 2.84 (dtd, J = 9.9, 7.6, 2.4 Hz, 1H), 2.37 – 2.24 (m, 3H), 
2.22 – 2.07 (m, 2H), 2.03 – 1.93 (m, 1H), 1.84 – 1.64 (m, 3H), 1.49 – 1.39 (m, 1H); 13C 
NMR (126 MHz, MeOH-d4) δ 210.32, 210.31, 174.90, 167.48, 163.78, 142.78, 142.70, 
141.64, 137.33, 137.32, 131.85, 129.79, 126.96, 125.28, 120.68, 120.17, 120.16, 119.07, 
88.03, 87.94, 85.68, 72.46, 52.79, 52.75, 52.70, 41.79, 40.99, 40.95, 40.61, 40.57, 35.50, 
33.78, 33.76, 33.28, 25.73; HRMS calcd for C26H31N7O6 [M + H]
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To a mixture of 5.10 (200 mg, 0.605 mmol) and Z-Asp-OMe (204 mg, 0.727 mmol) in DMF 
(2 mL) were added HATU (276 mg, 0.727 mmol) and DIPEA (0.38 mL, 2.180 mmol), and 
the mixture was stirred for 2 hours. The resulting mixture was poured onto brine and 
extracted with DCM three times. The combined organic phase was dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica eluting with 5% → 10% MeOH in DCM to give a white (305 mg, 
90%).1H NMR (500 MHz, DMSO-d6) δ 11.22 (s, 1H), 8.26 (d, J = 7.5 Hz, 1H), 8.04 – 7.99 
(m, 2H), 7.97 (d, J = 8.0 Hz, 1H), 7.66 – 7.60 (m, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.43 – 7.25 
(m, 5H), 6.11 (t, J = 6.6 Hz, 1H), 5.40 (d, J = 4.1 Hz, 1H), 5.03 (s, 2H), 4.49 (td, J = 8.7, 
5.6 Hz, 1H), 4.25 – 4.18 (m, 1H), 4.10 – 4.02 (m, 1H), 3.80 – 3.59 (m, 2H), 3.04 (dd, J = 
17.6, 9.3 Hz, 1H), 2.60 (dd, J = 17.6, 5.6 Hz, 1H), 2.37 – 2.27 (m, 1H), 2.14 (dt, J = 13.4, 
6.6 Hz, 1H), 1.29 – 1.20 (m, 1H); ); 13C NMR (126 MHz, DMSO-d6) δ 176.5, 175.0, 167.3, 
163.1, 155.7, 145.3, 136.5, 133.1, 132.7, 128.4, 128.3, 127.91, 127.86, 127.7, 96.1, 86.7, 




5.10 (100 mg, 0.303 mmol) was added to the mixture of Z-Asp-OMe (85 mg, 0.303 mmol), 
EDC (64 mg, 0.333 mmol), and HOBt (49 mg, 0.363 mmol) in DMF (1 mL), and the mixture 
was stirred overnight. Water was added to the mixture and extracted with EtOAc/MeOH 
(9:1) four times - a lot of organic solvent was added to extract the formed solid because of 
solubility issue. The organic phase was dried over anhydrous sodium sulphate and 
concentrated under reduced pressure. The residue turned into a gel after adding DCM. After 
concentrating it again, the solid was filtered using water and ether to give a white 
solid (145mg, 81%). 1H NMR (500 MHz, DMSO-d6) δ 11.22 (s, 1H), 8.25 – 8.13 (m, 2H), 
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8.00 (d, J = 7.4 Hz, 2H), 7.62 (dd, J = 8.0, 5.7 Hz, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.42 – 7.26 
(m, 5H), 6.11 (t, J = 6.7 Hz, 1H), 5.31 (d, J = 4.2 Hz, 1H), 5.02 (s, 2H), 4.48 (q, J = 7.2 Hz, 
1H), 4.17 – 4.11 (m, 1H), 3.91 – 3.85 (m, 1H), 3.61 (s, 2H), 3.38 – 3.32 (m, 1H), 2.66 (dd, 
J = 15.3, 6.2 Hz, 1H), 2.58 – 2.50 (m, 1H), 2.34 – 2.27 (m, 1H), 2.05 (dt, J = 13.4, 6.6 Hz, 
1H); 13C NMR (126 MHz, DMSO-d6) δ 172.0, 169.1, 167.3, 163.0, 155.7, 154.4, 145.3, 
136.8, 132.7, 128.4, 128.34, 128.30, 127.86, 127.78, 127.65, 96.2, 86.5, 85.8, 71.2, 65.5, 




The mixture of 5.16 (135 mg, 0.227 mmol) and 10% Pd/C (14 mg) in MeOH/DMF (2:1) (9 
mL) was stirred under H2 gas balloon overnight. The mixture was filtered through Celite 
pad and washed with MeOH. The filtrate was concentrated under reduced pressure and the 
residue was purified by flash chromatography on silica eluting with 10% → 20% MeOH in 
DCM to give a white solid (21 mg, 22%). 1H NMR (500 MHz, DMSO-d6) δ 8.28 (d, J = 7.5 
Hz, 1H), 8.01 (dd, J = 8.1, 1.4 Hz, 2H), 7.62 (td, J = 7.3, 1.5 Hz, 1H), 7.51 (t, J = 7.8 Hz, 
2H), 7.36 (d, J = 7.5 Hz, 1H), 6.11 (t, J = 6.6 Hz, 1H), 5.41 (d, J = 4.2 Hz, 1H), 4.22 – 4.16 
(m, 1H), 4.05 – 3.98 (m, 1H), 3.77 (dd, J = 8.7, 5.1 Hz, 1H), 3.72 – 3.58 (m, 2H), 3.16 (t, J 




5.10 (100 mg, 0.303 mmol) was added to the mixture of Boc-Glu-OBzl (102 mg, 0.303 
mmol), EDC (64 mg, 0.333 mmol), and HOBt (49 mg, 0.363 mmol) in DMF (1 mL), and 
the mixture was stirred overnight. Water was added to the mixture and extracted with EtOAc 
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twice. The combined organic phase was washed with brine, saturated aqueous NaHCO3, and 
water. The organic phase was dried over anhydrous sodium sulphate and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica eluting with 
5% → 10% MeOH in DCM to give a white solid (182 mg, 92%). 1H NMR (500 MHz, 
DMSO-d6) δ 11.21 (s, 1H), 8.22 (d, J = 7.5 Hz, 1H), 8.05 (t, J = 5.8 Hz, 1H), 8.00 (dd, J = 
8.3, 1.3 Hz, 2H), 7.66 – 7.59 (m, 1H), 7.51 (t, J = 7.8 Hz, 2H), 7.40 – 7.27 (m, 6H), 6.10 (t, 
J = 6.6 Hz, 1H), 5.31 (d, J = 4.2 Hz, 1H), 5.11 (q, J = 12.6 Hz, 2H), 4.13 (dq, J = 6.8, 3.5 
Hz, 1H), 4.04 – 3.97 (m, 1H), 3.89 – 3.84 (m, 1H), 3.40 – 3.25 (m, 2H), 2.30 (ddd, J = 13.4, 
5.8, 3.2 Hz, 1H), 2.25 – 2.18 (m, 2H), 2.08 – 1.93 (m, 2H), 1.78 (dq, J = 15.1, 8.0 Hz, 1H), 
1.36 (s, 9H); 13C NMR (126 MHz, DMSO-d6) δ 172.3, 171.6, 167.3, 163.0, 155.5, 154.4, 
145.2, 136.0, 133.1, 132.7, 128.4, 128.3, 127.9, 127.7, 96.2, 86.5, 85.9, 78.2, 71.2, 65.8, 
53.3, 41.0, 31.6, 28.1, 26.5. 
benzyl N5-(((2R,3S,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methyl)-L-glutaminate hydrogen chloride salt (5.20) 
 
To a stirred solution of 5.19 (176 mg, 0.271 mmol) in dioxane (3 mL) under nitrogen gas 
was added 4N HCl in dioxane (1 mL) dropwise. The reaction mixture was stirred for 4 h, 
after which time the mixture was concentrated to give a white solid as the HCl salt. This 
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5.20 (0.253 mmol) and TEA (124 µL, 0.887 mmol) were added to the mixture of 4.07 (70 
mg, 0.253 mmol), EDC (53 mg, 0.279 mmol), and HOBt (45 mg, 0.334 mmol) in DMF (2 
mL), and the mixture was stirred overnight. Water and EtOAc were added to the mixture to 
form a solid. The mixture was filtered and washed with water and EtOAc to give 5.21 (white 
solid) as a mixture of diastereomers (169 mg, 82%). 1H NMR (500 MHz, DMSO-d6) δ 11.24 
(br s, 1H), 8.27 (dd, J = 9.9, 7.4 Hz, 1H), 8.18 (d, J = 7.5 Hz, 1H), 8.09 – 8.03 (m, 1H), 8.00 
(d, J = 7.7 Hz, 2H), 7.85 (dd, J = 8.3, 3.5 Hz, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.6 
Hz, 2H), 7.33 (h, J = 5.2, 4.2 Hz, 8H), 6.11 (t, J = 6.6 Hz, 1H), 5.31 (s, 1H), 5.13 – 5.03 (m, 
2H), 4.66 (s, 1H), 4.22 (dq, J = 14.4, 7.6 Hz, 1H), 4.12 (s, 1H), 3.85 (s, 1H), 3.67 – 3.59 (m, 
2H), 3.59 – 3.51 (m, 1H), 3.30 (s, 2H), 2.77 (t, J = 6.8 Hz, 2H), 2.63 – 2.53 (m, 1H), 2.29 
(ddd, J = 13.5, 6.0, 3.3 Hz, 1H), 2.24 – 2.08 (m, 4H), 2.08 – 1.90 (m, 3H), 1.86 – 1.71 (m, 
2H), 1.69 – 1.48 (m, 3H), 1.33 (dq, J = 14.8, 7.7 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) 
δ 201.56, 201.50, 171.82, 171.77, 171.60, 171.50, 171.47, 145.32, 145.30, 135.91, 134.59, 
134.56, 132.53, 129.17, 129.14, 128.45, 128.42, 128.34, 128.22, 128.21, 127.99, 127.93, 
127.73, 127.67, 126.57, 126.37, 96.51, 86.42, 85.82, 71.23, 65.80, 61.58, 51.75, 51.67, 
50.83, 50.73, 41.00, 38.84, 31.58, 31.50, 30.44, 30.28, 26.67, 26.61, 24.28, 24.20. 
Attempted synthesis of 2-(4-(trans-2-(2-(((S)-5-((((2R,3S,5R)-5-(4-benzamido-2-
oxopyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)amino)-1-(benzyloxy)-1,5-
dioxopentan-2-yl)amino)-2-oxoethyl)cyclopentane-1-carbonyl)phenyl)acetic acid (5.22) 
 
To the mixture of 5.21 (100 mg, 0.124 mmol) in MeCN/H2O (1:1) (10 mL) were added 
TEMPO (3 mg, 0.022 mmol) and PhI(OAc)2 (88 mg, 0.272 mmol) and the resulting white 
suspension was stirred for 2 days. Solvent was evaporated to give a white solid. 1H NMR 
indicated a mixture of starting material 5.21 and reagents. 
benzyl N5-(((2R,3S,5R)-3-acetoxy-5-(4-benzamido-2-oxopyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl)-N2-(tert-butoxycarbonyl)-L-glutaminate (5.23) 
Chapter Six   185 
_________________________________________________________________________ 
 
To a suspension of 5.19 (200 mg, 0.308 mmol), DMAP (2 mg, 0.018 mmol) and TEA (102 
µL, 0.730 mmol) in MeCN (5 mL) was added acetic anhydride (30 µL, 0.320 mmol). The 
suspension was stirred at ambient temperature overnight. Since TLC indicated starting 
material 5.19 left, acetic anhydride (30 µL, 0.320 mmol) was added more. After 2 h, the 
mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give a white solid (206 mg, 
97%). 1H NMR (500 MHz, DMSO-d6) δ 11.27 (br s, 1H), 8.23 (d, J = 7.5 Hz, 1H), 8.09 (t, 
J = 6.0 Hz, 1H), 8.03 – 7.98 (m, 2H), 7.65 – 7.60 (m, 1H), 7.51 (t, J = 7.8 Hz, 2H), 7.41 – 
7.25 (m, 5H), 6.08 (dd, J = 8.0, 5.8 Hz, 1H), 5.18 – 5.05 (m, 3H), 4.08 (td, J = 5.9, 2.4 Hz, 
1H), 4.04 – 3.97 (m, 1H), 3.45 – 3.34 (m, 2H), 2.46 (ddd, J = 14.3, 5.8, 2.1 Hz, 1H), 2.33 – 
2.17 (m, 3H), 2.06 (s, 3H), 2.01 – 1.92 (m, 1H), 1.84 – 1.73 (m, 1H), 1.35 (s, 9H); 13C NMR 
(126 MHz, DMSO-d6) δ 172.2, 171.8, 169.9, 163.1, 155.5, 145.2, 136.0, 133.1, 132.7, 
128.43, 128.41, 128.34, 128.32, 128.0, 127.9, 127.6, 96.4, 86.6, 83.2, 78.2, 74.9, 65.8, 53.3, 
40.6, 36.9, 31.5, 28.1, 26.4, 20.8. 
benzyl N5-(((2R,3S,5R)-3-acetoxy-5-(4-benzamido-2-oxopyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)methyl)-L-glutaminate trifluoroacetic acid salt (5.24) 
 
A solution of 5.23 (1.50 g, 2.24 mmol) in DCM (3.3 mL) was cooled with ice-bath and TFA 
(0.33 mL) was added. The reaction proceeded without bath for 4 h, then was quenched by 
evaporation of the organic solvent and by removing the excess of TFA under high vacuum. 
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To a solution of 4.07 (88 mg, 0.318 mmol) and HOBt (47 mg, 0.347 mmol) in DMF (2 
mL) were added EDC (61 mg, 0.318 mmol) and a solution of 5.24 (199 mg, 0.289 mmol) in 
DMF (2 mL) and TEA (155 µL, 1.113 mmol). The reaction mixture was stirred at ambient 
temperature overnight, then diluted with EtOAc. The organic phase was washed with water 
once and saturated aqueous NaHCO3 twice. The organic phase was dried over anhydrous 
sodium sulphate and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica eluting with 5% MeOH in DCM to give 5.25 (white solid) as a 
mixture of diastereomers (161 mg, 65 %). 1H NMR (500 MHz, DMSO-d6) δ 11.25 (br s, 
1H), 8.30 – 8.20 (m, 2H), 8.09 (td, J = 6.1, 2.8 Hz, 1H), 8.03 – 7.98 (m, 2H), 7.88 – 7.83 
(m, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.42 – 7.26 (m, 7H), 6.08 (t, J = 6.9 
Hz, 1H), 5.15 (td, J = 4.7, 2.1 Hz, 1H), 5.11 – 5.02 (m, 2H), 4.66 (t, J = 5.2 Hz, 1H), 4.27 – 
4.17 (m, 1H), 4.12 – 4.04 (m, 1H), 3.66 – 3.59 (m, 2H), 3.59 – 3.51 (m, 1H), 3.43 – 3.34 (m, 
2H), 2.77 (t, J = 6.8 Hz, 2H), 2.63 – 2.54 (m, 1H), 2.49 – 2.42 (m, 1H), 2.29 (dt, J = 14.3, 
7.0 Hz, 1H), 2.24 – 2.09 (m, 3H), 2.06 (d, J = 1.4 Hz, 3H), 2.03 – 1.90 (m, 2H), 1.86 – 1.71 
(m, 1H), 1.70 – 1.48 (m, 3H), 1.33 (dq, J = 11.8, 7.6 Hz, 1H); 13C NMR (126 MHz, DMSO-
d6) δ 201.55, 201.50, 171.82, 171.76, 171.71, 171.69, 171.58, 169.87, 145.33, 145.31, 
135.91, 134.59, 134.57, 133.08, 132.73, 129.16, 128.41, 128.33, 128.24, 128.19, 127.94, 
127.73, 127.66, 96.36, 86.72, 86.63, 83.21, 83.17, 74.97, 74.87, 65.82, 65.81, 61.59, 51.73, 
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A solution of 5.25 (94 mg, 0.11 mmol) in acetone (2 mL) was treated with Jones reagent 
(0.16 mL of a 2.7 M solution, prepared via standard method) slowly dropwise at 0C for 10 
min. The resulting reaction mixture was stirred at 0C for 1 h and then was quenched with 
isopropanol. The mixture was filtered with a pad of Celite and the pad of Celite was 
washed with EtOAc. The combined organic phase was washed with brine and water, dried 
over anhydrous sodium sulphate, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica eluting with 10% MeOH in DCM to give 5.26 
(white solid) as a mixture of diastereomers (64 mg, 67%). 1H NMR (500 MHz, DMSO-d6) 
δ 11.28 (br s, 1H), 8.30 – 8.20 (m, 2H), 8.09 (td, J = 6.0, 2.6 Hz, 1H), 8.03 – 7.97 (m, 2H), 
7.88 (dd, J = 8.1, 4.7 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.42 – 7.26 (m, 
7H), 6.08 (dd, J = 8.0, 5.8 Hz, 1H), 5.15 (dq, J = 5.0, 2.3 Hz, 1H), 5.12 – 5.01 (m, 2H), 4.27 
– 4.17 (m, 1H), 4.10 – 4.05 (m, 1H), 3.65 (s, 2H), 3.60 – 3.52 (m, 1H), 3.44 – 3.35 (m, 2H), 
2.65 – 2.54 (m, 1H), 2.48 – 2.42 (m, 1H), 2.29 (ddd, J = 14.3, 8.2, 6.2 Hz, 1H), 2.24 – 2.09 
(m, 4H), 2.05 (d, J = 1.5 Hz, 3H), 2.03 – 1.89 (m, 2H), 1.86 – 1.71 (m, 2H), 1.69 – 1.48 (m, 
3H), 1.33 (dq, J = 12.0, 7.6 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 201.58, 201.53, 
172.10, 171.82, 171.77, 171.72, 171.70, 171.58, 169.88, 163.12, 154.20, 145.21, 140.39, 
135.92, 135.12, 135.09, 133.14, 132.73, 129.73, 129.70, 128.43, 128.42, 128.33, 128.26, 
128.25, 127.94, 127.73, 127.67, 96.40, 86.65, 83.19, 74.92, 65.82, 51.72, 51.64, 50.92, 
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To a mixture of 5.26 (60 mg, 0.069 mmol) in THF:MeOH:H2O (3:1:1) (2 mL) was added 
LiOH (7 mg, 0.3 mmol) and the mixture was stirred for 17 hours. The resulting mixture was 
acidified with 1 M HCl to pH = 4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography on C18-reversed phase silica gel eluting with 15% water 
in MeCN to give 5.05 (white solid) as a mixture of diastereomers (14 mg, 32%). 1H NMR 
(500 MHz, DMSO-d6) δ 12.44 (br s, 2H), 8.16 – 7.97 (m, 2H), 7.96 – 7.85 (m, 2H), 7.61 
(dd, J = 7.5, 1.5 Hz, 1H), 7.40 (dd, J = 8.3, 2.7 Hz, 2H), 6.11 (t, J = 6.8 Hz, 1H), 5.72 (d, J 
= 7.5 Hz, 1H), 4.15 – 3.94 (m, 3H), 3.80 – 3.70 (m, 2H), 3.67 (s, 2H), 3.64 – 3.55 (m, 1H), 
3.24 – 3.15 (m, 2H), 2.68 – 2.56 (m, 1H), 2.30 – 1.99 (m, 5H), 1.98 – 1.50 (m, 5H), 1.44 – 
1.29 (m, 1H); 13C NMR (126 MHz, DMSO-d6) δ 201.68, 201.64, 173.42, 173.38, 172.09, 
171.62, 171.59, 171.45, 165.20, 154.66, 141.32, 140.29, 140.26, 135.17, 135.13, 129.74, 
128.32, 128.30, 94.15, 85.16, 84.99, 71.34, 51.57, 51.49, 50.88, 50.82, 41.11, 40.99, 40.51, 
39.26, 31.84, 31.75, 31.65, 31.61, 30.50, 30.32, 30.18, 27.00, 26.94, 24.35, 24.25; HRMS 
calcd for C30H37N5O10 [M + H]
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